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Abstract 
The chemotherapy of solid tumours is hampered by two major obstacles: 1) the lack of 
selectivity of the current drugs and 2) the reduced sensitivity to tumour drugs. Recent 
advances in cancer biology have led to the identification of novel molecular targets 
responsible for aggressive proliferation, drug resistance and invasiveness. Targeting one 
such factor, epidermal growth factor receptor (EGFR), has proven an effective strategy 
to block the progression of solid tumours. However, the potency of the current clinical 
drugs directed at EGFR is mitigated by their reversible cytostatic activity and reduced 
cytotoxicity. Here we de scribe the design and synthesis of a new class of agents termed 
"cascade release combi-molecule" (1-TZ), "prograrnmed" to harnmer the receptor by 
releasing multiple bioactive metabolites (1-TZ', 1-TZ") in a step-wise fashion and a 
reactive DNA damaging species (TZ), with the purpose of promoting sustained 
inhibition of EGFR tyrosine kinase (TK) and drug-induced cytotoxicity. This thesis 
de scribes the synthesis of one such molecule, RB24 (1-TZ), and demonstrates that it was 
capable ofbeing hydrolyzed to its various sub-components with an overall half-life of 42 
min under physiological conditions. The I-TZ induced sustained inhibition of the EGFR 
TK and strong antiproliferative activity in human solid tumour cells. It also inflicted 
higher levels of DNA damage to cancer cells transfected with the EGFR or HER2 gene. 
This selectivity was based on a novel mechanism of targeting described as a bystander 
effect, whereby following distribution of the 1-TZ in the perinuclear region, the 
alkylating species (TZ) was subsequently released towards the nucleus. The 1-TZ was 
significantly more potent than its clinical counterpart, Temodal™. Further investigation 
of the mechanism underlying its superior potency show that blockade of EGFR-
11 
mediated signaling led to down-regulation of: 1) MAPK mitogenic signaling, 2) the 
BER protein, XRCCI and 3) anti-apoptotic signaling mediated by Bad. Further down-
regulation of XRCC1, with a MEKI inhibitor, led to the discovery of a significant 
synergistic antiproliferative effect and a novel formula to further enhance the potency of 
the 1-TZ in refractory tumours. Furthermore, the in vivo activity of the cascade release 
principle was proven in a prostate cancer xenograft study using a more water-soluble 
analogue of RB24. Thus, we have developed a novel model for the therapy of growth 
factor receptor-expressing tumours from the design and synthesis of the probe drugs, to 
the elucidation of their mechanism of action and the demonstration of the in vivo 
efficacy of the proposed strategy. 
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Résumé 
La chimiothérapie des tumeurs solides se heurte à deux obstacles majeures: 1) un 
manque de sélectivité et 2) une chimiorésistance contre les médicaments anticancéreux. 
Les récentes découvertes en oncogénèse ont permis d'identifier de nouvelles cibles 
moléculaires responsables de la prolifération non contrôlée, de la chimiorésistance et de 
la formation des tumeurs métastasiques. L'inhibition du récepteur de facteur de 
croissance (EGFR) s'est avérée être une stratégie efficace pour ralentir la progression 
des tumeurs solides. Cependant, l'efficacité des médicaments actuels ciblant ce 
récepteur est compromise par une activité cytostatique réversible et un manque de 
cytotoxicité. 
Dans ce travail, nous présentons la conception et la synthèse d'une nouvelle classe 
d'agents anticancéreux, dénommée 'combi-molécules à décomposition en chaîne' (I-
TZ). Ces molécules sont conçues pour se fragmenter progressivement en multiples 
métabolites bioactifs (I-TZ', 1-TZ") aboutissant, au final, à la libération d'une espèce 
alkylante (TZ). Cela a pour effet d'induire l'inhibition soutenue de l'activité tyrosine 
kinase du récepteur et de promouvoir la cytotoxicité. Ce manuscrit traite de la synthèse 
et de l'hydrolyse dans les conditions physiologiques d'une molécule type RB24 (I-TZ), 
caractérisée par un temps de demi-vie global de 42 min. De ce fait, elle possède une 
activité antiproliférative envers des tumeurs solides grâce, d'une part, à l'inhibition 
soutenue du récepteur de facteur de croissance et, d'autre part, à l'endommagement de 
l'ADN. Nous avons noté que les cellules tumorales transfectées par des gènes codant 
pour l'EGFR ou HER2 montrent des lésions de l'ADN plus importantes. Ce résultat peut 
être expliqué par la concentration des molécules dans la région péri-nucléaire 
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rapprochant ainsi l'entité alkylante (TZ) du noyau. Le composé RB24 a montré une 
activité supérieure à celle du médicament de référence Temodal™. L'étude approfondie 
du mécanisme d'action a démontré que l'inhibition du récepteur de facteur de croissance 
conduit à la suppression: 1) du signal mitogène transmis via MAP Kinase, 2) de 
l'expression des protéines BER, XRCCI et 3) du signal anti-apoptotique régulé par Bad. 
La co-administration d'un inhibiteur de MEKI capable de bloquer l'expression de 
XRCCI a permis de découvrir une étonnante synergie antiproliférative, et d'établir une 
nouvelle formule pour l'optimisation de l'effet de 1-TZ envers les tumeurs réfractaires. 
De plus, nous avons également démontré l'efficacité in vivo d'un analogue plus 
hydrosoluble de RB24, dans un modèle de xénogreffes de la prostate. 
En conclusion, nous avons réalisé un cycle complet de découverte d'une nouvelle 
méthode de traitement des tumeurs exprimant le récepteur de facteur de croissance: de la 
conception et la synthèse des molécules sondes, l'élucidation de leur mécanisme 
d'action, à la démonstration d'une efficacité de cette stratégie in vivo. 
v 
Science knows no country, because knowledge belongs to humanity, and is the torch 
which illuminates the world. 
-Louis Pasteur (1822-1895) 
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INTRODUCTION 
1.1. Preface 
Cancer originates from the development of numerous mutations that lead to uncontrolled 
cellular proliferation. Certain mutations lead to abnormal or aberrant expression of 
signaling proteins and transcription factors. Despite the importance of the aforementioned 
proteins in cancer progression, traditional chemotherapeutic treatment regimens are 
primarily directed at damaging DNA or blocking proteins required for DNA replication. 
The lack of tumour selectivity and toxicity associated with these regimens are considered 
major deterrents for their use as therapeutic agents. Recently, therapies targeting the 
receptor tyrosine kinases (RTK) or cytoplasmic RTKs, that control the activation of 
numerous signaling cascades (e.g. cell cycle progression, anti-apoptotic signaling, 
cellular proliferation) have proven highly efficacious. These cellular receptors include 
~. , . 
the insulin-like growth factor receptor (IGFR), vascular endothelial growth factor 
receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), epidermal growth 
factor receptors (EGFR), as well as its closely related homologue, c-ErbB2 (HER2). AlI 
these receptors are implicated in tumour progression, aggressiveness and invasiveness of 
various carcinomas. Since the purpose of this thesis was to develop a novel approach for 
tandem targeting of EGFR and DNA, a brief review of CUITent knowledge acquired on 
this class of receptors is presented herein. 
1.2 EGF Receptor and its signaling pathways 
1.2.1. EGFR family 
The epidermal growth factor receptor subfamily consists of EGFR (ErbB 1), HER2 
(ErbB2/neu) an orphan receptor, HER3 (ErbB3) lacking kinase function and HER4 
2 
(ErbB4) (Hackel et al., 1999; Christensen et al., 2001). HER2 is the preferential 
dimerization partner for aU the members of the ErbB receptor family (Christensen et al., 
2001; Roskoski, 2004). The HER3 receptor lacks a tyrosine kinase domain and therefore, 
can only activate downstream signaling cascades when it dimerizes with another ErbB 
receptor (Roskoski, 2004). High levels or overexpression of EGFR and HER2 have been 
correlated with aggressiveness and poor prognosis, making EGFR a promising target for 
effective chemotherapy of tumours that express this class of RTK (Alaoui-Jamali et al., 
1997; Harari and Yarden, 2000). Similarly, the EGFRvIII is a truncated form ofEGFR 
caused by an in-frame deletion of exons 2-7. The resulting prote in lacks 267 amino acids 
(aa 6-273) in the extracellular domain resulting in a 145 kDa truncated structure, the 
activation of which is ligand-independent. Thus, EGFRvIII is constitutively activated 
/~~ (Alaoui-Jamali et al., 1997; Harari and Yarden, 2000). It has been shown that cells 
expressing EGFRvIII have a greatly enhanced capacity for unregulated growth due to the 
ability of the EGFRvIII to promote tumour cell survival and proliferation. This aberrant 
receptor is expressed in many different types of cancer, including breast carcinomas, non-
small ceIllung carcinomas and glioblastoma multiforme (Okamoto et al., 2003; Rae et 
al., 2004; Heimberger et al., 2005). 
1.2.2. EGFR structure and activation 
EGFR is a 170-kDa glycoprotein that contains three functional domains: a 
transmembrane domain, a carboxy terminal and an extracellular domain (ectodomain) to 
which its cognate ligand can bind (Roskoski, 2004; Normano et al., 2006). The 
extracelluar domain consists of the following four subdomains: LI and L2, the ligand 
3 
(-., binding domains, CRI and CR2, the cysteine rich regions that participate in receptor 
dimerization (Fig. 1.1) (Burgess et al., 2003). The 11 different ligands determined for 
the ErbB c1ass of receptors are EGF, transforming growth factor (TGF)-a, heparin-
binding (HB)-EGF, betacellulin, amphiregulin, epiregulin, epigen and the neuregulins 1-4 
which are also known as heregulins (HRG) (Hackel et al., 1999; Normano et al., 2006). 
In the absence of ligand, EGFR is found on the cell surface in both monomer and dimer 
form. Following ligand binding to the L2 region, which is situated in the extracellullar 
domain of EGFR, the receptor undergoes receptor dimerization (Normano et al., 2006). 
Once the receptor is ligand-bound (e.g. EGF, TGF-a), a loop from the CRI domain of 
one receptor, known as the 'dimerisation loop', interacts with the CRlloop in the partner 
(Roskoski, 2004; Normano et al., 2006). Mutations or deletions in the dimerization loop 
region have been shown to completely block EGFR activation (Burgess et al., 2003). 
The transmembrane domain has also been found to play an important role in receptor 
association through either van der Waals interactions or hydrogen bonding (Lemmon et 
al., 1997). In order to promote receptor dimerization, it is believed that a significant 
portion of EGFR molecules are distributed in c1usters throughout the membrane (Maione 
et al., 1999; Jorissen et al., 2003). This proximal distribution permits rapid interaction 
between receptors upon ligand binding. The C-terminal consists of several important 
residues that are required for both initiation of signaling cascades and receptor 
endocytosis (Jorissen et al., 2003). Once activated, the ATP binding site for EGFR, 
which is located between the N- and C-terminal domains, catalyses the transfer of 
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the gamma-phosphate of bound ATP to tyrosine residues found on both intracellular 
targets and the C-terminal domain of the EGFR TK (Bishayee et al., 1999). There are 
five tyrosine residues in the C-terminal domain that are considered important substrates 
for EGFR signal transduction (Y1068, Y1148, Yl173, Y992, Y1086) (Bishayee et al., 
1999). These tyrosine residues can either be autophosphorylated (a process by which the 
receptor phosphorylates its own amino acid residues or residues of a partnering receptor) 
or transphosphorylated by other kinases in the cell and function as docking sites for 
various adaptor proteins or signaling proteins (Koch et al., 1991; Normano et al., 2006). 
The strength and duration of the signal from EGFR depends upon how quickly the 
activated protein is intemalized and recyeled. The naturally occurring EGFR mutant 
(- known as EGFR vIII (version III) is constitutively activated and, therefore, not 
intemalized (Pedersen et al., 2001). Cells that express this mutant have been shown to 
harbour elevated levels of phosphotidylinositol-3-kinase (PI3K) and c-jun-N-terminal 
kinase (JNK) activation, as well as upregulation of the antiapoptotic protein Bel-xL, a 
member of the Bel-2 elass of proteins (Nagane et al., 1996; Antonyak et al., 1998; 
Pedersen et al., 2001). 
1.2.3. Recruitment of adaptor proteins and activation of signal transduction 
Numerous pathways are initialized following receptor dimerization and 
autophosphorylation, and two such pathways, the Ras/Raf/MAPK and the PI3K1 Akt are 
the most extensively studied. The phosphorylated tyrosine residues found in the C-
r- terminal of activated EGFR can recruit various adaptor proteins, such as Grb2 which is 
6 
r constitutively bound to the guanine nuc1eotide exchange factor, Sos, through its two SR3 
(src homology-3) domains (Koch et al., 1991; Mayer, 2001; Vidal et al., 2001). The 
latter domain interacts with proline-rich sequences. Following EGFR activation, Grb2 
interacts with the phosphorylated residues on EGFR through its SR2 (src homology-2) 
domain or indirectly through another adaptor protein Shc (Fig. 1.2.1) (McInnes and 
Sykes, 1997). The latter can subsequently recruit Grb2 or other signaling proteins. Once 
Grb2 is relocated to the cell surface via receptor interaction, it can interact with Sos and 
the membrane-bound Ras, a serine-threonine kinase, that facilitates the exchange of 
GDP-bound Ras for a GTP-bound state (Macias et al., 2002). As depicted in figure 1.2, 
activation of Ras triggers the RaslRaf/MAPK signaling cascade and this ultimately 
culminates into the expression of early response genes such as c-fos and other genes that 
(~' control proliferation (Tari et al., 1999; Rowinsky et al., 1999). 
1.2.4. The RaslRaflMAPK signaling pathway 
The RaflMEKIERK cascade generally controls cellular growth and differentiation 
(Rowinsky et al., 1999). When EGFR is activated upon EGF -binding, adaptor proteins, 
such as Grb2, are recruited to assist in the activation of Ras (Alessi et al., 1994; Sebolt-
Leopold, 2000; Chang et al., 2003). GTP-bound Ras activates Raf, which can 
subsequently phosphorylate MEK1I2 on Ser 217 and Ser 221 residues. Further, 
phosphorylation of ERK 1 and 2 on threonine (e.g. T185, T202) and tyrosine (e.g. 
Y204, Y187) residues by MEK1/2 lead to the activation of various cytoplasmic targets 
proteins, including the intracellular domain of EGFR and the p90 ribosomal S6 kinase 
/" (RSK) (Alessi et al., 1994; Chang et al., 2003). 
7 
~ .. 
/-
~. 
Cell growth 
and proliferation 
Figure 1.2.1. Activation of the Ras-Raf-MAPK signaling cascade following EGFR 
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The ERK kinases translocate into the nucleus, where they can phosphorylate numerous 
transcription factors that initiate cell cycle progression from the GO (quiescent phase )/G 1 
(GAPI ) phase to the S (Synthesis) phase of the cell cycle (Murray and Hunt, 1993). 
Growth factor induced signaling cascades, such as the Ras/Raf/MAPK pathway, 
culminate into the transcription of both "early-response" and "delayed-response genes" 
(Murray and Hunt, 1993). Early-response genes encode transcription factors such as c-
fos and c-jun, that heterodimerize to form the AP-1 transcription factor complex and 
subsequently stimulate the transcription of "delayed response" genes required for cell 
cycle progression (e.g. cyclin Dl) (Murray and Hunt, 1993). Accumulation of cyclin Dl 
following growth factor stimulation results in the formation of cyclin D1/Cdk4,6 
complexes (Cheng et al., 1998) that phosphorylate the retinoblastoma protein (pRb). pRb 
is a tumour suppressor that exerts its growth-suppressing effects by trapping various 
proteins, including the E2F family of transcription factors (see Fig. 1.2.2) (Murray and 
Hunt, 1993; Zhu, 2005). Unbound (free) E2F transcription factors induce the expression 
of genes that regulate the Gl-S phase transition that precedes DNA replication. 
Following initial phosphorylation by the cyclin DlICDK4 complex, pRb releases E2F, 
permitting transcription and accumulation of a second cyclin, cyclin E (Boonstra, 2003). 
The cyclin E forms a complex with cdk2 that further phosphorylates pRb. 
Hyperphosphorylation of pRb leads to the full activation of the E2F transcription factors 
(Fig. 1.2.2) (Murray and Hunt, 1993). 
When growth factors are removed from cell culture medium, transcription of G1-phase 
cdks and cyclins is halted (Moyer et al., 1998). As a result, the cells cannot enter the S 
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Figure 1.2.2. Cell cycle progression from the G 1 to the S phase mediated by pRb 
phosphory lation. 
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(' phase and remain in G 1. Inversely, when growth factors (e.g. EGF) are added, the 
activation of RTKs such as EGFR, allow the cell to progress through the cell cycle and 
proliferate and is referred to as growth-stimulation. This is a procedure used in this thesis 
to study the inhibition of EGFR. Briefly, the cells are placed in serum-free media for 24 
h to deprive them of growth factors and subsequently exposed to either EGF or TGF-u. 
Phosphorylated tyrosine residues found on the activated EGF receptor following addition 
of growth factors are then detected using an anti-phosphotyrosine antibody. 
1.2.5. The PI3K/ Akt pathway and anti-apoptotic signaling 
Cancer cells are endowed with the unique property to not only escape controlled growth 
/~, and proliferation, but also to evade apoptosis, or "programmed cell death". Apoptosis is 
a process that entails several morphological changes such as chromatin condensation, 
DNA fragmentation and plasma membrane blebbing (or budding) (Vermeulen et al., 
2005). The apoptotic process can be activated by several factors such as the activation of 
death receptors (e.g. Tumour Necrosis Factor Receptor), DNA damage in the absence of 
DNA repair or exposure of cells to cytotoxic drugs and irradiation (Fumarola and 
Guidotti, 2004; de Thonel and Eriksson, 2005). 
Extrinsic apoptotic signaling is mediated by the activation of "death receptors" which are 
cell surface receptors that include the tumor necrosis factor receptor (TNFR) gene 
superfamily. This family encompasses TNFR-1, Fas, and the TRAIL receptors (de 
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(' Thonel and Eriksson, 2005; Hail et al., 2006). As depicted in Fig. 1.3.1, activation of Fas 
recruits adaptor proteins such as Fas-associating protein with death domain (F ADD), 
which subsequently activate proteins termed caspases (Houston and O'Connell, 2004; de 
Thonel and Eriksson, 2005). Caspases are cysteine proteases that are originally 
synthesized as inactive zymogens called procaspases. In order to be activated, the latter 
proteins require eleavage at their N-terminus between the large and small subunit. This 
scission forms an active heterotetramer consisting of two small and two large subunits 
(Thornberry and Lazebnik, 1998; Debatin, 2004). Activation of death receptors (e.g. Fas) 
initiates the apoptotic process via eleavage of procaspase-8 that belongs to the initiator 
elass of caspases. The latter ineludes procaspase-2, -9 and -10 (Thornberry and 
Lazebnik, 1998; Ho and Hawkins, 2005). Caspase-8 can subsequently induce a cascade 
~ of effector caspases (e.g. procaspase-3, -6, -7) that eleave critical substrates such as DNA 
repair proteins (e.g. P ARP), focal adhesion kinase (F AK) and the nuelear lamina 
(Thornberry and Lazebnik, 1998). 
In sorne cells, apoptotic signaIs can also be mediated via intrinsic (intracellular) signaling 
pathways that culminate into a mitochondria-dependent apoptotic process (de Thonel and 
Eriksson, 2005). Mitochondrial permeability is generally regulated via members 
belonging to the Bel-2 family of proteins that consists of both pro-survival (e.g. Bel-2, 
Bel-XL) and pro-apoptotic (e.g. Bax, Bak, Bid) members (Heiser et al., 2004; de Thonel 
and Eriksson, 2005; Armstrang, 2006). Protein-protein interactions between anti-
apoptotic and pro-apoptotic Bel-2 members prevent the oligomerization of Bax, an event 
required for mitochondrial pore formation (see Fig. 1.3.2). Activation of Bax allows for 
13 
the release of mitochondrial proteins, such as cytochrome c, into the cyctoplasm (de 
Thonel and Eriksson, 2005; Armstrang, 2006). Once cytochrome c is released, it can 
form a complex with the cytoplasmic prote in Apaf-l, termed the apoptosome. This 
apoptosome can then bind and cleave procaspase-9, releasing its activated form and 
subsequently initiating the caspase cascade through caspase-3 (Thomberry and Lazebnik, 
1998; Heiser et al., 2004). 
Intrinsic apoptotic signaling is not only regulated by downstream signaling cascades 
induced by death receptors, but can also be triggered by growth factor receptors, such as 
EGFR. One of the major pathways by which EGFR can regulate anti-apoptotic signaling 
is by the phosphatidylinositol-3-kinase (PI3K)1 Akt pathway (Fig. 1.3.2) (Grant et al., 
! 2002; Martelli et al., 2006). Since the central theme ofthis thesis is EGFR targeting, we 
will focus herein on the activation of this pathway by growth factor stimulation. PI3K is 
composed of a catalytic plI 0 domain and a p85 regulatory subunit that can directly 
interact with activated members of the ErbB family through an SH2 domain (Grant et al., 
2002; Kim et al., 2005). As shown in Fig. 1.3.2., PI3K catalyses the phosphorylation of 
the 3' position of phophatidylinositols (Ptdlns), that bind to their downstream target, the 
serine/threonine kinase, AktlPKB (Datta et al., 1999). This kinase is extremely important 
in the cellular response to anti-tumour drugs. Therefore, a brief description of its 
properties is provided below. 
The Akt family is composed of three members: 1 )Aktl/PKBa, 2) Akt2/PKB~ and 3) 
(' Akt3/PKBy (Songyang et al., 1997; Datta et al., 1999). This class of serine/threonine 
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Figure 1.3.2. Activation of the PI3K1Akt pathway by EGFR. 
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r' kinase is activated by vanous stimuli in a PI3K-dependent manner, ineluding the 
activation ofEGFR following EGF binding (Fig. 1.3.2). PI3K converts phosphoinositide, 
Ptdlns-3,4-P2 (PIP2) into Ptdlns3,4,5-P3 (PIP3) that can bind directly to the pleckstrin 
homology (PH) domain of Akt, a process that mediates membrane translocation and a 
conformational change (Datta et al., 1999). This interaction permits the phosphorylation 
of the activation loop of Akt at Thr 308 by the phosphoinositide-dependent protein kinase 
1 (PDK1) (Grant et al., 2002; Martelli et al., 2006). Anti-apoptotic properties of the 
PI3K1Akt signaling cascade are mediated by the ability of Akt to negatively regulate the 
pro-apoptotic protein Bad by phosphorylating the Ser136 residue, inhibiting Bad from 
interacting and sequestering Bel-2 and Bel-xL (Martelli et al., 2006). Bel-2 and Bel-xL 
exert their anti-apoptotic activity by binding to Bax, thereby preventing mitochondrial 
!~' pore formation (Thomberry and Lazebnik, 1998; Martelli et al., 2006). 
While activation of the PI3K1 Akt plays an important role in anti-apoptotic signaling, its 
deactivation is also considered an important regulatory function in apoptotic signaling 
and is carried out by the dual-specificity protein and lipid phosphatase, PTEN (Pommery 
and Henichart, 2005; Cully et al., 2006). One of the central roles for PTEN is to remove 
the D3 phosphate group of PIP3 thereby depleting levels of PIP3 and inactivating Akt 
(see Fig. 1.3.2) (Pommery and Henichart, 2005; Cully et al., 2006). Once cells mutate or 
delete PTEN, the regulatory function of this protein is lost and this allows for the 
constitutive activation of the anti-apoptotic prote in, Akt (Cully et al., 2006; Dong, 2006). 
Mutations or deletions of PTEN are found in numerous cancers, ineluding glioblastomas 
and prostate carcinomas. These cells have demonstrated chemoresistance to various 
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agents, such as cisplatin and 5-fluorouracil (Oki et al., 2005). A number of studies have 
also demonstrated that tumour cells lacking PTEN activity are rendered insensitive to 
clinical EGFR targeted agents (Bianco et al., 2003; She et al., 2003; Kokubo et al., 
2005). 
1.3. Small molecule approach: Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors (TKIs) bind to the ATP-binding site of the receptor TK and 
block its ability to phosphorylate tyrosine residues located in its own kinase do main or on 
downstream effectors (Fry et al., 1994; Bridges et al., 1996). By inhibiting receptor 
activation, the TKI can be used to control unregulated cell growth and proliferation. One 
class of TKI currently being used in the clinic is the quinazoline, the structures of which 
/- straddle that of adenine in ATP (Fry et al., 1994; Levitzki, 1999). As depicted in Figure 
1.4.1., the structures of aIl the EGFR TK inhibitors exemplified therein retain the 
aminopyrimidine backbone of adenine. Once bound to the receptor, quinazolines can 
stabilize the receptor and create inactive EGFR dimers (Arteaga et al., 1997). 
Examination of structure activity relationship (SAR) studies of quinazoline derivatives 
led to the determination of three critical regions required for quinazoline binding to the 
ATP binding pocket of the receptor. As exemplified in Figure 1.4.1., the binding of the 
clinical EGFR TKI, erlotinib, in the ATP binding pocket is primarily sustained by 2 
nitrogen (N) atoms and a hydrophobic substituent on the anilino ring: 1) the NI-position 
of the agent interacts with Met769 through hydrogen bonding, 2) the N3 position is 
bridged by a water molecule present within the binding pocket, to H-bond with Thr766 
and 3) a hydrophobic group is favoured at the 3' position of the anilino ring (Assefa et 
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(\ al., 2003). Initial modeling studies of the binding of reversible anilinoquinazoline and 
anilinopyridopyrimidine inhibitors suggested the 6- and 7-positions point out of the ATP 
binding pocket, at the entrance of the binding cleft. Therefore, both positions can tolerate 
steric bulk without losing binding affinity (Smaill et al., 1999; Smaill et al., 2004; Palmer 
et al., 1997; Vincent et al., 2000; Herbst et al., 2002). As an example, Smaill et al. 
(1999) appended bulky acrylamido side chains at the 6- and 7-position and the resulting 
molecule did not lose EGFR TK inhibitory activity. It was the purpose of the CUITent 
work to modify the 6-position of the purine ring for the design ofreceptor affine "combi-
molecules." 
1.3.1. Clinical activity 
Gefitinib (Iressa™, ZD1839) (see Fig. 1.4.2a) is a specific, orally active synthetic 
quinazoline known to block EGFR-activated induction of downstream signaling cascades 
(Herbst et al., 2002). Although studies have demonstrated the ability of gefitinib to 
induce apoptosis in various tumour cell lines, the inhibitory activity of the TKI is 
generally cytostatic. In corroboration, clinical trials have shown that the drug must be 
given in a once daily schedule to induce sustained inhibition of EGFR TK activity 
(Blackledge and Averbuch, 2004). Results from two clinical studies, Iressa Dose 
Evaluation in Advanced Lung Cancer (IDEAL)-l and IDEAL-2, demonstrated that 
gefitinib was weIl tolerated and generated overall response rates ranging from 100/0-20% 
in patients with non-small ceIllung carcinoma (NSCLC) given 250 and 500 mg/day (EI-
Rayes and LoRusso, 2004). A recent study has also demonstrated that inhibitory activity 
~, induced by gefitinib translated into significant clinical antitumour activity in a particular 
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subset of NSCLC patients whose tumours harboured mutations in the intracellular region 
of EGFR. These mutations influence the rate at which the receptor was intemalized 
following ligand-binding, thereby affecting the duration of the signal generated by the 
activated receptor (Paez et al., 2004; Hsieh et al., 2006). Similarly, mutations 
surrounding the A TP-binding site of the EGFR TK domain were detected in tumours 
from NSCLC patients with no prior gefitinib therapy that conferred enhanced sensitivity 
to gefitinib inhibition (Lynch et al., 2004) 
Another quinazoline derivative directed towards EGFR that has currently entered clinical 
trials is the orally active compound, erlotinib (Tarceva, OSI-774) (Fig. 1.4.2b). Erlotinib 
is currently being used as a second-line or third-line drug in the therapy of advanced 
/' NSCLC, in patients who fail on platinum-based treatment regimens (Kumar and 
Wakelee, 2006). Phase III clinical trials of erlotinib in NSCLC patients following first or 
second line chemotherapy, demonstrated the ability of erlotinib to generate prolonged 
survival and an 8.9% response rate (Maione et al., 2006). 
Although clinical EGFR TK inhibitors like gefitinib and erlotinib are well tolerated 
agents that have demonstrated antitumour activity in numerous cancers, such as breast, 
ovarian and lung cancer, the potency and efficacy of these drugs are limited by their 
virtually reversible EGFR inhibitory activity (Lynch and Kim, 2005; Kwak et al., 2005). 
Patients have been known to relapse after an initial response to these EGFR inhibitors 
due to mutations, such as the T790M mutation, that causes steric hindrance in the ATP-
/-, binding pocket of EGFR, blocking the ability of the TKI to bind to the receptor (Thomas 
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r-'. et al., 2005). 
Several inhibitors of EGFR have already demonstrated significant inhibitory activity. 
However, the potency of reversible TKIs are hampered by high intracellular 
concentrations of ATP. In order to ameliorate the activity of quinazolines, a class of 
EGFR inhibitors was designed that target and irreversibly inactivate the EGFR TK. The 
first class of irreversible inhibitors were designed to posses an acrylamide side-chain on 
the 6- or 7- position of the molecule that covalently modify the Cysteine 773 residue, 
located within the ATP binding pocket, upon binding (Bridges, 1999; Smaill et al., 2004). 
These irreversible inhibitors demonstrated in vivo antitumour activity superior to their 
reversible counterparts (Denny, 2002). CI-1033 (Fig. 1.4.2c) is an orally administered 
irreversible inhibitor of aIl the members of the ErbB family that exhibited antitumour 
activity in preclinical studies against various cancers such as breast and ovarian 
carcinomas (Allen et al., 2003). Phase II clinical studies for CI-1033 demonstrated 
approximately one third of patients achieving stable disease in numerous tumours, such 
as ovarian cancer (Campos et al., 2005). Although thrombocytopenia was observed in 
patients at high doses, CI-1033 demonstrated substantial activity in dose regimens that 
ranged from once daily to once weekly (Calvo et al., 2004). 
In summary, studies have demonstrated that targeted therapies that block activation of 
EGFR are promising. However, cross-talk between a multitude of intracellular pathways 
can diminish the potency of EGFR-targeted therapies. These observations support the 
argument that inhibition of the receptor alone does not generate enhanced and sustained 
therapeutic response. In order to augment the clinical potency of these targeted agents, 
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(\ combination studies with other traditional chemotherapeutic agents have emerged as a 
promising avenue (Gasparini et al., 2005; Shimoyama et al., 2006; Reckamp et al., 
2006). Within the same line of thinking, the purpose of this thesis was to introduce the 
concept oftargeting EGFR TK with single drugs that not only possess the ability to bind 
to the ATP pocket, but also to damage DNA. The c1ass of DNA damaging agent used 
belong to the triazene c1ass and we summarize herein previous results obtained on their 
structure, mechanism of action and c1inical efficacy. 
1.4. 3-Methyltriazenes 
Aromatic triazenes are simple molecules often containing an N=N-N linkage that upon 
hydrolysis release an arylamine and a methyldiazonium (Vaughan et al., 1984; Manning 
~ et al., 1985). Methylating agents are the most common c1ass of alkylators used in the 
therapy of solid tumors and leukemias (Newlands et al., 1992). One such agent, 
Temodal® (TEM), is an oraUy available methylating agent used in the therapy of 
malignant melanomas and gliomas (Stevens et al., 1987; Nagasubramanian and Dolan, 
2003). As depicted in Figure 1.5.1, hydrolytic c1eavage of TEM gives rise to the 5-
aminoimidazole-6-carboxamide (Ale) and DNA damaging methyldiazonium species. 
This species reacts with several nuc1eophilic sites in DNA to give rise to various DNA 
adducts inc1uding N7-methylguanine (N7meG), N3-methyladenine (N3meA) and 06-
methylguanine (06meG) (Fig. 1.5.2) (Tentori et al., 1999). The most prevalent lesion 
induced by 3-methyltriazenes is the N7meG (~70% of aU lesions) foUowed by N3meA 
(~10%) and 06meG (~5%) (Tentori et al., 1999). Although the 06meG is the least 
r-' abundant adduct formed upon treatment with methylating agents, it is by far the most 
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Figure 1.5.3. Base pairing observed between guanine and cytosine and 0 6 -methylguanine 
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~ cytotoxic lesion induced by these drugs (Middleton and Margison, 2003). As shown in 
Figure 1.5.3, methylation at the 06-position of guanine (G) disrupts hydrogen bonding of 
G with cytosine (C) and if the methyl is not removed, it will mispair with thymine (T) in 
the following round of DNA replication (Middleton and Margison, 2003). The presence 
of 0 6 -alkyguanine transferase (AGT), a DNA repair enzyme that can remove the methyl 
group from the 06-position of G, conf ers resistance to tumour cells exposed to 
methylating agents such as TEM (Pegg and Byers, 1992). Further details on the 
mechanism of action of AGT in chemoresistance will be presented in the DNA repair 
section 1.5.2. 
1.5. Cellular response to triazenes 
r' Cellular responses to DNA damaging agents play an important role in regulating the 
response of tumours to chemotherapy and radiation. As previously mentioned, the three 
most common DNA lesions induced by methylating agents such as TEM and 
dacarbazine, are the 06meG, the N7meG and the N3meA adducts (Tentori et al., 1999). 
N7meG and N3meA lesions, which are the most prevalent adducts observed, are repaired 
efficiently and handled by the repair mechanism termed Base Excision Repair (BER). 
~, 
1.5.1. Base excision repair (BER) 
Despite its abundance, N7meG adducts cause very little distortion of the DNA double 
helix. However, they are readily recognized by a class of enzymes termed damage-
specific DNA glycosylases (Krokan et al., 1997, Fromme et al., 2004). As depicted in 
Figure 1.6.1, DNA glycosylases are generally small, monomeric proteins that cleave the 
N-C l' glycosydic bond between the base and the deoxyribose ring. This cleavage leads 
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to the release of the damaged base, thereby generating a gap termed abasic site (Krokan 
et al., 1997). Abasic sites can also be formed by simple non-enzymatic hydrolysis of the 
glycosidic bond (Fig. 1.6.2). 
The human DNA glycosylase that repalrs alkylation damage is known as the 3-
methyladenine DNA glycosylase or alkyladenine glycosylase (AAG) (Scharer and 
Jiricny, 2001). The AAG protein removes N3meA, N7meG and various forms of DNA 
adducts induced by alkylating agents used in chemotherapy (Krokan et al., 1997; Scharer 
and Jiricny, 2001). Although N7meG and N3meA do not cause distortion in the DNA 
structure, binding of AAG to DNA causes nuc1eotide unstacking from the DNA helix and 
exposure of the alkylated base (Krokan et al., 1997; Scharer and Jiricny, 2001). The 
~ active site of AAG has high affinity for the e1ectron-deficient methylated base and a 
water molecule within the site is positioned to attack the flipped-out nuc1eotide, allowing 
the displacement of the damaged base from DNA (Krokan et al., 1997; Hollis et al., 
2001). 
F ollowing base removal, mammalian cells have two pathways that replace the formation 
of the abasic site: 1) short-patch repair or 2) the minor long-patch repair pathway. 
1.5.1.1. Short-patch repair 
The short patch repair pathway involves single nuc1eotide gap replacement. As 
shown in Figure 1.6.1, following removal of the damaged base by the DNA glycosylase, 
5'AP endonuc1ease creates a single nuc1eotide gap (Scharer and Jiricny, 2001) that is 
subsequently filled by the DNA polymerase J3. The latter attaches a single nuc1eotide to 
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Figure 1.6.1. Repair ofN7meG and N3meA lesions by the BER pathway. 
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o the newly generated 3'OH and dislodges the baseless sugar-phosphate backbone. The 
scaffold protein, X-ray cross-complementation protein 1 (XRCC1) interacts with DNA 
polymerase P through its N-terminal domain, whereas the C-terminal region of XRCC1 
interacts with DNA ligase III (Krokan et al., 1997). Through interactions with XRCC1, 
DNA ligase III is brought to the site of the nick in the DNA backbone where it connects 
the broken strand by catalysing a covalent phosphodiester bond formation (Krokan et al., 
1997). Substantial evidence indicates an important role for XRCC 1 in single strand 
break repair (SSBR) and BER. Mutant Chinese hamster ovary (CHO) cells with no 
functional XRCC 1 prote in are hypersensitive to a broad range of DNA damage induced 
by methylating agents, reactive oxygen species or ionizing radiation (Zdzienicka et al., 
1992). This is probably due to a greater number of unrepaired SSBs encountered by the 
replication fork. 
1.5.1.2. Long-patch repair 
In the alternative long patch repair pathway, gap filling of several nucleotides (2-
10 nucleotides) is performed. As depicted in Figure 1.6.1, the AP endonuclease performs 
the 5'-incision followed by DNA synthesis assisted by DNA polymerase ô or E in 
conjunction with the proliferating cell nuclear antigen (PCNA) (Scharer and Jiricny, 
2001; Gary et al., 1999). The flap produced by the displaced DNA strand is removed by 
the flap endonuc1ease/exonuclease termed FEN-1 and the nick is sealed by DNA ligase l 
(Scharer and Jiricny, 2001). 
/~ The protective effect of BER in tumour cells has been demonstrated in numerous studies 
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r usmg inhibitors of proteins involved in BER such as methoxylamine (MX). 
Methoxylamine, by reacting with the aldehyde group formed at AP sites on the sugar-
phosphate backbone of DNA, can generate a DNA-MX adduct that interrupts the BER, 
leaving high levels ofunrepaired single strand breaks in the DNA (Liu and Gerson, 2004) 
(Fig. 1.6.3). Studies performed by Liu et al. (1999) demonstrated that this translated into 
MX potentiation of cytotoxicity induced by TEM in cells regardless of mismatch repair 
(MMR) status. 
Although N7meG is produced at a significantly higher frequency (>70% of alliesions) 
than the 06meG lesion (approximately 5%), studies have demonstrated that it is the 
06meG adduct that plays a major role in the cytotoxicity of triazenes (Tentori et al., 
~, 1999). As previously mentioned, tumours that express the DNA repair enzyme 06-
alkylguanine transferase (AGT) are resistant to the methylating class of chemotherapeutic 
agents. 
1.5.2. 06- alkylguanine transferase (AGT) repair mechanism 
1.5.2.1. Structure 
The 06meG residues in DNA are the primary cytotoxic lesions induced by 
antitumour agents such as TEM and dacarbazine (Tentori et al., 1999). Conversely, the 
most critical factor in the resistance of tumours to methylating agents of the triazene class 
is the expression of the 21kDa DNA repair enzyme, 06-alkylguanine transferase (AGT), 
that binds to the lesion and removes the methyl group (Pegg and Byers, 1992; Middleton 
/~, and Margison, 2003). 
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~. The overall structure of AGT is generally conserved. However, the C-terminal domain is 
well conserved, with two overlapping and tight turns stabilized by an asparagine (the 
Asn-hinge), and a helix-tum-helix (HTH) DNA-binding motif (Daniels and Tainer, 
2000). Crystallographic studies by Daniels and Tainer (2000) demonstrated that AGT 
binds through the minor groove via a DNA binding sequence that anchors deep into the 
mmor groove. 
1.5.2.2. Function 
As depicted in Figure 1.7.1, following binding of the 0 6 -alkylguanine substrate, 
AGT transfers the alkyl group to its active-site cysteine (Cys145) in an irreversible and 
stoichiometric reaction (Pegg and Byers, 1992; Daniels and Tainer, 2000). The presence 
of a water molecule in the active site forms two hydrogen bonds, one with the SH group 
of Cys145 in the active site and another with the His146 located within a hydrophobic 
region. Vpon activation, the histidine N abstracts the H proton leading to a highly 
nuc1eophilic thiolate that undergoes an SN2 attack on the methyl group. This gives rise to 
an S-methylated enzyme that is ubiquitinated and degraded by proteosomes. Due to this 
mechanism, AGT is commonly referred to as a "suicide" enzyme. 
1.5.2.3. Strategies to down-regulate AGT activity 
There is a great deal of variablility in the expression of AGT between cells, 
tissues and individuals (Lee et al., 1996; Wani et al., 1997). Resistance against DNA-
alkylating agents based on increased AGT production is observed during chemotherapy 
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Figure 1.7.1. The stoichiometric reaction involving the removal of a methyl group from the 06-position of guanine by 0 6_ 
alkylguanine transferase (AGT). 
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r, with alkylators. There have been numerous strategies on improving sensitivity to DNA 
alkylating agents by depleting AGT levels. 
One approach to deplete the levels of AGT was to alter the dosing schedule of the 
methylating agent, TEM. Patients resistant to TEM were given a bolus dose to deplete 
levels of the DNA repair enzyme and a second dose was administered when AGT levels 
were substantially depleted. Although this approach resulted in significant AGT 
depletion, its efficacy was compromised by increased myelotoxicity in clinical trial 
(Brandes et al., 2001). 
1.5.2.4. AGT inhibitors 
r'· Depletion of AGT levels in cells that are resistant to methylating agents by 
exposure to free 0 6 -alkylguanine derivatives has been extensively studied. The first 
AGT inhibitor synthesized was free 06-methylguanine. However, due to the poor AGT 
affinity and limited cellular uptake of the latter agent, other inhibitors were developed 
(Dolan et al., 1985). Studies on a series of 0 6 -alkylgunaine analogs by Pegg et al. 
(1998) demonstrated that 06-benzylguanine (06_BG, see Fig. 1.7.2) to be the favoured 
substrate over 06meG adducts. The two guanine derivatives currently being studied in 
clinical trials are 0 6 -BG and 0 6 -4-bromothenylguanine (06 -BTG), an AGT inhibitor 
found to be 10 times more potent than 06-BG (Kaina et al., 2004). 
Mutational screens were used to isolate the key regions in the binding pocket of 
,"--'. the enzyme that would render AGT resistant to 06_BG. The results showed that specifie 
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point mutations ofPro138, Pro140 and Thr158 were the most effective in producing 0 6_ 
BG resistance without hindering AGT activity (Xu-Welliver et al. 1998). 
1.5.2.5. Clinical response 
Results from preclinical studies in human tumour xenografts demonstrated 
that combining clinical alkylating agents, TEM or carmustine (BCNU), with 0 6 -BG 
sensitized cells to the alkylators (Kokkinakis et al., 2001; Kokkinakis et al., 2003). 
BCNU belongs to the class of bi-functional nitrosoureas used in the therapy of many 
solid tumours including melanomas and gliomas (Ewend et al., 2005). As shown with 
methylating agents of the triazene class, BCNU is capable of inducing cytotoxic 0 6 -alkyl 
lesions that are readily repaired by AGT (Chen et al., 1993). Although the 2-drug 
("--, combination sensitized cells, pronounced blockade by 06-BG in cells with basallevels of 
the enzyme induced myelotoxicity. 
Phase 1 clinical trial with patients with malignant glioma treated with a combination of 
06_BG + the clinical alkylator BCNU demonstrated 06_BG to be well-tolerated and 
capable of depleting AGT activity. However, partial or complete responses were not 
observed in any of the patients treated with the BCNU/06-BG combination. It is believed 
that this is due to the MTD of the two drug combination being far below the therapeutic 
dose of BCNU alone. As expected, patients treated with the combination experienced 
severe myelotoxicity at higher doses (Schilsky et al., 2000; Quinn et al., 2002). 
/~ Although AGT was proven an effective target to sensitize cells to methylating agents in 
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.r, vitro, clinical outcomes of therapies involving depletion of AGT levels are hindered by 
the following obstacles: 1) the possibility of patients developing single point mutations 
that produce 06_BG resistant forms of AGT, thereby generating tumours that remain 
resistant to the alkylator, and 2) enhanced myelotoxicity when used in combination with 
DNA alkylators. Therefore, there is an urgent need to develop other drugs that can 
enhance the activity of methylating agents in resistant tumours that do not significantly 
enhance the toxicity associated with DNA damaging agents. It is the purpose of this 
thesis to develop alternative strategies to sensitize cells resistant to methylating agents by 
synthesizing unimolecular agents that not only damage DNA, but also target various 
intracellular proteins such as EGFR, thereby potentiating the cytotoxic activity of the 
DNA methylating moiety. 
1.5.3. Mismatch Repair (MMR) 
In the absence of AGT, upon formation of 06meG, a mispairing occurs with thymine (T) 
during DNA replication and generates a G:T mismatch (Fig. 1.5.3) (Tentori et al., 1995; 
Peponni et al., 2003). The presence of G:T mismatches activates the DNA mismatch 
repair (MMR) system that consists of at least five homologs of the bacterial protein MutS 
(hMSH) and at least four homologs of the bacterial MutL protein (hMLH) (Stojic et al., 
2004a). The central elements of the system are the multimeric MutSlMutL complexes 
that are endowed with the mechanism to recognize base-base mismatches (e.g. G-T) and 
insertions-deletion loops (Stojic et al., 2004a). One of the proposed mechanisms or 
models for the recognition of base mismatches by MMR is the thermodynamic 
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!~ destabilization of the DNA double helix by the 06meG-T mispair (Isaacs and Speilmann, 
2004). 
As depicted in Figure 1.8, the hMSH2/6 heterodimer (MutSa) binds to the base-base 
mismatch through an amino-terminal mismatch-recognition domain and exchanges ADP 
for ATP (Lamers et al., 2000; Stojic et al., 2004a). A conformational change occurs 
upon ATP binding and the complex acts as a sliding clamp (Iaccarino et al., 2000; Stojic 
et al., 2004a). The lateral movement allows the complex to differentiate between the 
template and newly synthesized strand by the presence of 3' -hydroxy terminaIs. The 
DNA:MutS:ATP complex then recruits the MutL complex (a heterodimer composed of 
hMLHI and hPMS2) and the exonuclease termed Exo1 (Stojic et al., 2004a). Exol 
/~ excises the newly synthesized DNA fragement containing the mismatch and the resulting 
single-stranded DNA is stabilised by replication protein A (RP A) (Stojic et al., 2004a; 
Guo et al., 2006). The latter protein also facilitates DNA resynthesis by permitting DNA 
polymerases to perform DNA synthe sis (Stojic et al., 2004a). Interestingly, as shown in 
Figure 1.8, the newly synthesized DNA strand will still contain the mispaired T and the 
entire process will be triggered by the MutSa complex. This series of "futile" cycles of 
DNA repair initiate multiple pathways ultimately leading to cell cycle arrest or apoptosis 
(Tentori et al., 2002; Stojic et al., 2004a; Stojic et al., 2004b). Cells that lack a functional 
MMR system do not recognize the G:T mispair, thereby by-passing MMR-induced DNA 
strand breaks. It has been reported that MMR-deficient cells are relatively resistant to 
methylating agents, whereas cells with a functioning MMR system enter either G2/M 
~~, arrest or apoptosis (Hawn et al., 1995). Recently, Tentori et al. (2002) demonstrated that 
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f"". AGT -null glioma cells with MMR-deficiency were resistant to TEM treatment. Studies 
carried out by D' Atri et al. (1998) showed that TEM induced apoptosis and G2/M cell 
cycle arrest in MMR-proficient cells and that these responses were absent in MMR-
deficient cells. 
1.5.4. Activation of DNA damage checkpoints 
As previously mentioned, the proliferation of dividing cells is characterized by several 
transitions in the cell cycle known as checkpoints (Hoglund, 2006; O'Brien and Brown, 
2006). At these checkpoints, genomic integrity is probed by two major players, the 
PI3K-related kinases ATM (ataxia telangiectasia, mutated) and ATR (ATM and Rad3-
related) (Hiom, 2005). ATM and ATR are phosphorylated upon DNA damage through 
yet an unknown mechanism. 
While cellular response to methylating agents is highly dependent on DNA repair 
processes such as BER and MMR, it has been shown to be influenced by the G2/M 
checkpoint (D' Atri et al., 1998). The G2/M cell cycle checkpoint is an important control 
measure that inhibits cell cycle progression and the ability of the cell to enter mitosis 
(Stark and Taylor, 2006). As illustrated in Figure 1.9, the activation of ATR and ATM is 
followed by phosphorylation of the two checkpoint kinases, Chkl and Chk2, as well as 
the tumour suppressor, p53 (Niida et al., 2006). The dual specificity phosphatase 
Cdc25C is phosphorylated upon Chkl and Chk2 activation, inhibiting its ability to release 
the cyclin-dependent kinase, cdc2, from cyclinB 1 complex, thereby generating a 
blockade between the G2 to M transition (Niida et al., 2006; Stark and Taylor, 2006). 
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(" Studies with the methylating agent, TEM, showed that this drug that can induce N7meO, 
N3meA and 06meO lesions in cells, blocks the cell cycle in 02/M (D'Atri et al., 1998; 
Stojic et al., 2004b). However, Hirose et al. (2001) demonstrated that MMR-proficient 
cells, in which Chk1 is deactivated by the inhibitor, VCN-01, were unable to 
arrest in 02/M, thereby enhancing the cytotoxic activity of TEM. The results indicated 
that Chk1 is critical for the cytoprotective role of 021M arrest in these cells. 
1.5.5. The stress response pathway (MAPK family) 
In addition to cell cycle perturbation, in response to DNA damage, other signaling 
cascades known as stress response pathways, are activated to promote cell survival or cell 
death (Herr and Debatin, 2001; Fang and Richardson, 2005). The stress-activated protein 
/'--~ kinases (SAPK) are a family of serine/threonine kinases that include c-jun N-terminal 
kinase (JNK) and p38 MAP kinase (MAPK14) (Herr and Debatin, 2001; Fang and 
Richardson, 2005). The SAPKs are activated predominantly by cellular stress signaIs, 
but have also been shown to be activated by mitogens (Dent et al., 2003). These cellular 
responses are mediated by the induction of various signaling cascades and the 
transcriptional activity of the AP-1 complex, a dimer consisting of various combinations 
of the transcription factors, c-jun, c-fos and ATF-2 (Herr and Debatin, 2001). 
The JNK family of kinases are activated following phosphorylation by the upstream 
kinase JNKKlMKK4 and/or MKK7 (see Fig. 1.10). JNK-mediated phosphorylation can 
either increase the stability or transcriptional activity of AP-1 components, c-jun and 
ATF-2, thereby promoting cell survival (Vasilevskaya and O'Dwyer, 2003). Among the 
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r\ pro-apoptotic targets of c-jun is the promoter for the death inducing ligand TNF-a, which 
contains binding site for AP-l (Mikami et al., 2006). Another method by which JNK can 
regulate apoptosis is by phosphorylating members of the anti-apoptotic Bcl-2 class of 
proteins (e.g. Bcl2, Bcl-xL), thereby promoting mitochondrial-dependent apoptosis 
(Yamamoto et al., 1999; Xiao et al., 2004; Zu et al., 2005). Studies by Tournier et al. 
(2000), revealed defective cellular responses in JNK null prim~ fibroblasts following 
exposure to UV irradiation and the methylating agent, methyl methane-sulfonate (MMS). 
The impaired activation of mitochondrial-dependent apoptosis was caused by defective 
initiation of the effector caspases (e.g. caspase-3). 
As shown in Figure 1.10, the p38 family of SAPKs are regulated by the upstream kinases, 
f~ MKK3 and/or MKK6, in response to external stresses (Ono and Han, 2000). Like JNK, 
p38MAPK can also target a variety of transcription factors including, p53 and ATF-2 
(Ono and Han, 2000; Hayakawa et al., 2003). Similar to JNK activation, studies have 
also shown p38 to play a role in apoptosis. Interestingly, activation of p38MAPK has 
been linked to cell cycle arrest at various checkpoints (e.g. G liS, G2/M) following cell 
exposure to external stress signaIs (Ono and Han, 2000; Zhu and Zhang, 2003; Kurosu et 
al., 2005). One such pathway, known for the response to the methylating agent, N-
methyl-N'-nitro-nitrosoguanidine (MNNG), involves activation of ATM/ATR kinases 
and the subsequent phosphorylation of p38MAPK following DNA damage that resulted 
in GIIS arrest (Zhu and Zhang, 2003). Studies by Hirose et al. (2003) also demonstrated 
a role for p38MAPK in G2/M arrest following exposure to the clinical agent, TEM, in 
~.. MMR-proficient cells. The results showed that activation of the G2/M checkpoint 
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~. initiated following TEM treatment was in parallel with p38MAPK phosphorylation and 
could be attenuated by the p38 inhibitors, SB203580 and SB202590. This p38-mediated 
G2/M arrest was also suggested to be critical in mediating chemoresistance since 
inhibition of the latter prote in in MMR-proficient cells resulted in increased sensitivity to 
the methylating agent (Hirose et al., 2003). 
Although a significant body of work has accumulated to demonstrate the pro-apoptotic 
role of the stress activated kinases, JNK and p38. Recent studies indicate a pro-survival 
role for SAPKs during cancer progression (Dent et al., 2003; Uzgare et al., 2003; Maroni 
et al., 2004). Results obtained by Harper et al. (2002) demonstrate that activation ofboth 
p38 and JNK in the prostate carcinoma cell line, DU145, produced a distinct growth 
advantage that was mitigated when the cells were exposed to an EGFR TKI. This drug 
downregulated both p38 and JNK activation. Other studies suggest a role for p38MAPK 
activation in the development of breast cancer. Breast epithelial cells stimulated with 
EGF induce EGFR-mediated activation ofboth ERK and p38 via Ras, and are associated 
with cellular proliferation and invasive growth (Kim et al., 2003). 
1.6. The Combi-Targeting Concept 
Traditional chemotherapeutic approaches to cancer treatment are primarily based on 
multi-drug combinations. The therapeutic activities of these regimens are frequently 
hampered by severe toxicity and the lack of chemosensitivity of solid tumours at the 
advanced stages. To circumvent these problems, drugs with more targeted effects are 
urgently needed. Furthermore, due to tumour target heterogeneity in advanced diseases, 
combinations of single agents with pleiotropic effects would be more effective than 
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(' single targeted agents. It is within this context that our laboratory recently developed a 
novel approach termed "combi-targeting." The main thrust of this novel targeting 
concept is to synthesize drugs known as "combi-molecules," that are designed to generate 
a variety of fragments with multiple antitumour targets under hydrolytic conditions 
(Matheson et al., 2001). As illustrated in Figure 1.11, the combi-molecule represented by 
1-TZ, wherein 1 represents the TK recognition moiety and TZ the DNA damaging tail, 
was designed to penetrate the cell by passive diffusion and bind to the A TP binding 
pocket to give rise to an EGFR-I-TZ complex or to be converted to another EGFR TK 
inhibitory molecule + a DNA damaging species that diffuses towards the nucleus. It was 
also assumed that the combi-molecule I-TZ could de grade within the active site and react 
with a Cys773 residue of the receptor, thereby inducing irreversible inhibitory activity. 
l"~ In contrast, in cells that do not express the EGFR, the I-TZ will not have any target and 
will simply behave as a classical DNA damaging agent. Thus, we surmised that the I-TZ, 
due to its combination of effects, would be more potent in the receptor expressing cells 
than the nuIl ones. 
Previous studies by Matheson et al. (2001; 2003a; 2004a; 2004b) have provided 
significant data to propose a model that confirmed the primary postulates of the combi-
targeting concept. Radiolabeled combi-molecule, SMA41 (I-TZ, see Fig. 1.12), was used 
to study the subcellular distribution of the DNA alkylating species and was found to react 
with aIl three macromolecules including protein, RNA and DNA (Mathes on et al., 2003b; 
Matheson et al., 2004a; Matheson et al., 2004b). However, fluorescence microscopy 
showed that the inhibitor 1 (SMA52) was specifically localized in the 
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) 
perinuclear region (Matheson et al., 2004a). Moreover, the 1-TZ was found to be 
intemalized at a faster rate than its corresponding 1 administered alone. More 
importantly, flow cytometric analysis demonstrated that the half-life of SMA41 was 
considerably shorter (tl/2=15min) inside the cell than in exogenous medium (tl/2=40min) 
(Matheson et al., 2004a). Thus, the proposed model was the following: a rapid diffusion 
of 1-TZ into the cell, followed by its rapid intracellular decomposition into an inhibitor l, 
concentrated in the perinuclear region, and a methyldiazonium species TZ, that reacted 
with all three major macromolecules in the cell (e.g. RNA, DNA, protein) (Matheson et 
al., 2004a). As it will be discussed later, new discoveries in the context of this thesis 
have urged a revis ion ofthe model. 
(' A significant body of work has accumulated to demonstrate that the combi-molecules are 
not only agents programmed to release multiple fragments, but also to block intracellular 
signaling pathways. Brahimi et al. (2002), demonstrated that BJ2000, an 1-TZ of the 
same class as SMA41 , was capable ofblocking EGF-induced EGFR phosphorylation in a 
partially irreversible fashion in the carcinoma of the vulva cell line, A431. This 
inhibitory activity translated into a dose-dependent blockade of MAPK activation and c-
fos transcription. Using a different type of combi-molecule of the nitrosourea class 
(FDI37), Qiu et al. (2003; 2004) obtained similar results showing that the I-TZ was 
capable inducing a tandem blockade of EGFR phosphorylation and DNA damage in 
prostate cancer cells. These events also translated into blockade of the early response 
gene, c-fos. In all cases, the combined EGFRIDNA targeting properties of the combi-
r molecules translated into superior antiproliferative activity when compared with a 
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classieal two-drug eombination. Other types of eombi-moleeules designed to bloek 
another tyrosine kinase, ber-abl, were shown to inhibit TK phosphorylation in eells and to 
damage DNA in a similar manner (Rachid et al., 2003b; Katsoulas et al., 2005). 
It is important to note that eombi-moleeules tested thus far demonstrated significant 
antiproliferative activity in cens that are resistant to their parent alkylating agents. For 
instance, previously synthesized combi-moleeules (e.g. BJ2000, SMA41, FD137) were 
an more potent than the classical clinical agents TEM and BCNU in eens that express 
AGT (Brahimi et al., 2002; Matheson et al., 2003a; Qiu et al., 2003; Qiu et al., 2004). 
The two major objectives of the combi-targeting principle being to exert increased 
r-" poteney in advanced refraetory tumours and to achieve target selectivity, receptor 
specificity studies were performed to confirm the selectivity of the combi-molecules for 
EGFR or Her2. These studies were performed aceording to two major strategies: 1) using 
selective inhibition of growth factor stimulation and 2) analyzing effeets of the combi-
moleeules on isogenie pairs of cens transfeeted with the EGFR or HER2 genes. Brahimi 
et al. (2002) demonstrated that in contrast to TEM, the I-TZ BJ2000 preferentiany 
blocked EGF- or TGF-a-induced growth stimulation over PDGF- or serum-stimulation of 
cens. In the Same study, it was shown that the combi-molecule preferentially inhibited 
EGFR TK over src kinase and IGFR. On the other hand, studies by Rachid et al. (2003a), 
using an extended series of combi-molecules of the triazene class demonstrated that the 1-
TZs selectively block NIH3T3 cells transfected with neu (ErbB2) and interestingly the 
( levels of antiproliferative activity linearly correlated with their IC50 values for 
52 
competitive binding of EGFR TK, indicating that these compounds may target both 
EGFR and the ErbB2 receptor. More importantly, Rachid et al. (Rachid et al., 2003a) 
showed that compounds designed to solely block EGFR TK or to damage DNA were 
significantly less potent than the combi-targeted agents. 
The translation of the in vitro activity of the combi-molecules into in vivo potency was 
extensively studied in xenograft models. The primary purpose of these studies was to 
investigate whether the binary EGFR/DNA targeting properties of these molecules was a 
toxic event and to demonstrate their potency in refractory tumours (i.e. expressing AGT) 
known to be resistant to methylating agents. While Brahimi et al. (Brahimi et al., 2005) 
showed that ZRBAI was more potent than SMA41 in MDA-MB-468 (AGT+) breast 
cancer model, toxic side effects were observed. In addition, comparisons of combi-
molecules with their corresponding classical combination were hampered by the 
difference in plasma concentrations achieved at equi-doses. The major obstacle 
encountered in the in vivo translation with combi-molecule was the reduced water 
solubility of quinazoline-based molecules. Matheson et al. (2004b) showed that SMA41 
was weIl tolerated. However, significant antiproliferative activity for SMA41 could only 
be observed at a dose as high as 200mglkg in an aqueous suspension. Thus, 
demonstration of in vivo potency of combi-molecules with water-soluble probes remains 
to be achieved. 
Knowledge on combi-molecules pnor to this thesis can be summarized by a) 
(' demonstration of the binary EGFR/DNA targeting properties of the combi-molecule, b) 
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demonstration of selective antiproliferative activity and c) evidence for the supenor 
activity of combi-molecules over classical two-drug combinations in vitro. However, 
strategies to induce sustained potency of the combi-molecules and to elucidate cross-talk 
between various signaling pathways awakened by mixed EGFRIDNA targeting activities 
remain elusive. Further, in vivo demonstration of activity with a well-tolerated, water-
soluble combi-molecular probe still remained to be achieved. 
In light of progress on the combi-molecular strategy, my work has brought the following 
innovations summarized herein as the plan of this thesis: a) Chapter 2: design and 
synthesis of a novel combi-molecule termed "cascade release" combi-molecule 
"programmed" to hammer the EGFR TK with several inhibitors released in a stepwise 
fashion + a DNA damaging species, with the purpose of inducing sustained inhibition of 
phosphorylation, b) Chapter 3: analysis of the sustained antiproliferative mechanisms by 
the complex cascade release combi-molecule and demonstration of its ability to behave as 
a targeted precursor of multiple inhibitors and an alkylating species in the resistant AGT-
expressing A431 carcinoma of the vulva cell line, c) Chapter 4: elucidation of the 
selective mechanism of target-mediated DNA damage by the cascade release combi-
molecule and description of a novel model for the combi-targeting postulate, d) Chapter 
5: analysis and discovery of a novel cross-talk mechanism between the stress response 
and EGFR-MAPK pathways in response to the multi-targeting effect of the cascade 
release combi-molecule and, e) Chapter 6: in vivo translation of the efficacy of the 
cascade release combi-molecule in a prostate cancer xenograft model. 
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r\ 1.7. Summary 
A detailed description of aIl the intracellular mechanisms discussed in this thesis was 
described. These various aspects are presented in detail since the thesis deals with 
molecules that are not only cell signaling inhibitors but also DNA damaging agents that 
trigger complex stress response pathways. Thus, in summary we described: 
1. The EGF receptor family and its signaling pathways 
2. The small molecule inhibitors that target the A TP-binding site of EGFR TK 
3. The 3-methyltriazenes and their mechanism of action 
4. The DNA repair pathways induced by the triazene class of agents (e.g. BER, AGT, 
MMR) 
(- 5. The stress response pathways in response to methylating agents 
6. Previous knowledge acquired from the "combi-targeting" concept 
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r\ 1.8. Research objectives 
The objective of this thesis was to synthesize a novel class of combi-molecule termed 
"cascade release" combi-molecule capable of inducing sustained inhibition of EGFR TK 
while damaging DNA throughout its degradation cascade and to elucidate its mechanism 
of action in EGFR- or Her2-expressing cells. 
1.8.1 Project outline 
The following research objectives were pursued in order to realize the goals ofthis thesis: 
Objective 1: to synthesize a novel combi-molecule capable of degrading into multiple 
inhibitors of EGFR TK + a methyldiazonium species and confirm its binary EGFRIDNA 
.~ targeting properties 
Objective 2: to characterize the sustained and irreversible antiproliferative activity of the 
complex combi-molecule 
Objective 3: to elucidate which intracellular pathways can be targeted to enhance the 
potency of the combi-molecule, inducing synergistic antiproliferative activity 
Objective 4: to demonstrate the in vivo potency of a new generation of water-soluble 
complex combi-molecules 
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~. 1.8.2. Contribution of Authors 
CHAPTER 2: This paper has been published in the Journal of Medicinal Chemistry 
46(25):5546-51 (2003). My contribution was the synthe sis of the novel combi-molecules 
with the exception of ZR08, which was synthesized by Dr. Zakaria Rachid. AlI of the in 
vitro analyses were performed by myself, and preparation of the first draft of the 
manuscript. While 1 performed the single-cell microelectrophoresis, the imaging and 
quantitation of the samples was done by Dr. James P. McNamee at Health Canada. My 
supervisor (Dr. Bertrand J. Jean-Claude) made comments and revisions. 
CHAPTER 3: This paper has been published in the British Journal of Cancer 
91(6):1066-73 (2004). My contribution was the majority of the experimental work and 
preparation of the first draft of the manuscript. Dr. Zakaria Rachid synthesized the combi-
molecule, ZR08. Dr. Qiyu Qiu provided one set of RT-PCR data and 1 performed the 
following RT-PCR experiments. Dr. Ana Tari at the M.D. Anderson Cancer Center in 
Houston provided the Western blot for Erkl,2 activation on the samples 1 prepared. In 
addition, 1 ran the single-cell microelectrophoresis and the imaging of the samples was 
performed by Dr. James McNamee at Health Canada. My supervisor assisted in the 
revision of the manuscript. 
CHAPTER 4: This manuscript will be submitted to Oncogene. My contribution was aIl 
of the experimental work and preparation of the manuscript. The imaging of the single 
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cell microelectrophoresis samples was performed by Dr. James McNamee. Dr. Jean-
Claude made suggestions and the necessary revisions to the manuscript. 
CHAPTER 5: This manuscript is under submission to Cancer Research. 1 performed the 
majority of the in vitro experiments and the first draft the manuscript. Dr. Qiu performed 
the antiproliferative SRB assay for one of the control compounds (TEM). All the 
imaging of the single-cell microe1ectrophoresis samples that 1 prepared were performed 
by Dr. James McNamee. My supervisor provided suggestions and comments on the 
manuscript. 
CHAPTER 6: This manuscript will be submitted to the Journal of Experimental 
/~, Pharmacology and Therapeutics. 1 carried out aIl the in vitro experiments and the imaging 
of the single cell microeletrophoresis was prepared by Dr. James McNamee. 1 also 
synthesized the water-soluble combi-molecule required for the in vivo xenograft studies. 
Although 1 received training for animal handling from the Mc Gill Animal Resources 
Centre, all the technical work was carried out by the Centre. 1 also prepared the first draft 
ofthe manuscript that was further revised by my supervisor, Dr. Jean-Claude. 
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2.1. Abstract 
The synthesis of a novel acetoxymethyltriazene designed to be a prodrug of multiple 
inhibitors of the epidermal growth factor receptor (EGFR) and a methyldiazonium 
species is described. Studies with each of the expected metabolites demonstrated 
significant EGFR tyrosine kinase inhibitory activities and the released methyldiazonium 
was trapped with p-nitrobenzylpyridine. Their ability to damage genomic DNA in whole 
cells was demonstrated by using the single-cell microelectrophoresis (cornet) assay. The 
results suggest that this approach may weIl represent a novel drug combination strategy 
involving single molecules masking multiple bioactive agents. 
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2.2. Introduction 
The altered protein expreSSIOn and activity of receptor tyrosine kinases (TK) are 
implicated in the progression of various types of cancers. One such dysfunction is the 
overexpression of the epidermal growth factor receptor (EGFR) and its closest 
homologues HER2 (erbB2) that correlates with aggressive tumor progression and po or 
prognosis (Modjtahedi and Dean, 1994). Recently, we developed a novel strategy that 
seeks to combine DNA damaging properties and EGFR TK inhibitory activities into 
single molecules termed "combi-molecules" designed to kill EGFR-expressing tumour 
cells (Matheson et al., 2001; Brahimi et al., 2002; Qiu et al., 2003; Matheson et al., 
2003a). In order to enhance the EGFR inhibitory potency and stability of these 
compounds, we designed a novel strategy termed "cascade release" (CR) that seeks to 
mask the combi-molecule into a prodrug "programmed" to release the antitumour 
species by hydrolytic activation. Since these molecules henceforth referred to as 
"cascade release molecules" (CRM) are also designed to retain significant EGFR affinity 
on their own, this principle leads to conditions under which three generations of 
inhibitors can be derived from the parent CRM. 
Scheme 2.1 
To test the CRM principle, we initially designed structure 2 (Scheme 2.1) with the hope 
that it would not only retain affinity for EGFR but also hydrolyze to generate 
monoalkyltriazene 1 which, as previously demonstrated, heterolyzes into the 
89 
corresponding 6-amino-4-anilinoquinazoline (an inhibitor of EGFR) + a 
methyldiazonium species (Matheson et al., 2001; Brahimi et al., 2002). Thus, CRM 2 
was designed to be the prodrug of two known inhibitors of EGFR. Its synthesis 
proceeded according to Scheme 2.1. Structure 1, obtained as described earlier was 
treated with acetyl chloride in methylene chloride at O°C to give 2 in an 18% yield 
(Matheson et al., 2003b). Studies of the hydrolysis of 2 under physiological conditions 
(Le. incubation in serum containing media at 37°C) demonstrated little degradation after 
24 h. Further exposure for an additional 24 h led to minor degradation. Therefore, it 
was concluded that this molecule was not a suitable probe for the demonstration of the 
CRM principle. 
4 
~ b,< 
-0 )-Me -0 
HN Br ,CHtO d HN Br ,CHtOH 
ND-"'::: N:N·N'CH3 III( N~N"N,N'CH3 Il '" A 1l~1~ N N 
6 5 
Scheme 2.2. Synthesis of 6-(3-Acetoxymethyl-3-methyl-triazenyl)-4-(3' -bromophenyl-
We subsequently designed structure 6 (Scheme 2.2), which would not only offer the 
opportunity to further mask the CRM, but also to degrade according to known kinetics 
and mechanisms (Manning et al., 1985; Cameron et al., 1985). It has already been 
demonstrated that acetoxymethyltriazenes rapidly degrade to the corresponding 
hydroxymethyl triazene, which in turn is converted to a monoalkyltriazene of type 1 
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(Matheson et al., 2003b). Further, heterolysis of triazene is known to generate an 
aromatic amine and an alkylating agent (Cameron et al., 1985). Thus, we surmised that 
these mechanisms of degradation might lend themselves to the demonstration of the 
CRM principle. 
2.3. Experimental Section 
2.3.1. Chemistry 
IH NMR spectra and 13C NMR spectra were recorded on a Varian 400 or 300 
spectrometer. Mass spectroscopy was performed by the McGill University Mass 
spectroscopy Center. ESI and APCI spectra were performed on a Finnigan LC QDUO 
spectrometer. Data are reported as mlz (intensity relative to base peak = 100). Melting 
points were determined in open capillary tubes on a Meltemp melting point apparatus 
and were uncorrected. 
2.3.2. Synthesis of 6-(3-Acetyl-3-methyl-triazenyl)-4-(m-toluidyl)quinazoline (2) 
To a solution of 6-(3-methyltriazenyl) -4 anilinoquinazoline 1 (100 mg, 00400 mmol) in 
methylene chloride (5 mL) was added triethylamine (0.1 mL). The mixture was stirred 
for 15min at O°C and acetyl chloride (0.05 mL, 0.920 mmol) was added dropwise. 
Thereafter, the solution was evaporated under vacuum and the resulting brown residue 
purified on a silica gel column (40% ethyl acetate in hexane) to give 2 as a brown 
powder (18 mg, 16%) : mp 188°C; FABS m/z 335.2 (MH+), 235 (M-3-acetyl-3-
methyltriazene) m/z 335.162034 (MW), C18H18N601 requires 335.16190; IH NMR 
(300MHz, DMSO-d6) 8 8.84 (s, IH, NH), 8.58 (s, IH), 8.14 (d, IH, J=2.1Hz), 8.12 (d, 
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1H, J=2.1Hz), 7.83 (d, 1H, J=8.7Hz), 7.68 (s, 1H), 7.66 (s, 1H), 7.26 (t, 1H, J=7.8Hz), 
6.95 (d, 1H, J=8.1Hz), 3.39 (s, 3H, CH3), 2.57 (s, 3H, CH3), 2.34 (s, 3H, CH3); l3C 
NMR (75MHz, DMSO-d6) Ù 173.3, 158.6, 155.7, 150.7, 146.6, 139.5, 138.2, 130.0, 
128.9, 125.3, 124.5, 123.6, 120.6, 120.4, 116.0,28.4,22.8,22.0. 
2.3.3. Synthesis of 6-(3-Hydroxymethyl-3-methyl-triazenyl)-4-(3'-bromophenyl-
amino)quinazoline (5) 
To a solution of 4-(3' -bromophenyl-amino )-6-aminoquinazoline 3 (100 mg, 0.318 
mmol) in acetonitrile (20 mL) kept at O°C on an ice bath, nitrosonium tetrafluoroborate 
(74.3 mg, 0.637 mmol) was added dropwise. The solution was stirred for 20 min and 0.9 
mL of a mixture of methylamine 40% (0.075 mL, 0.954 mmol), formaldehyde 37% 
(0.75 mL, 9.54 mmol) , concentrated HCI (0.1 mL) was added aIl at once. The 
diazonium solution was subsequently alkalinized with potassium carbonate (400 mg, 
2.86 mmol) and the precipitate was filtered to give a white solid contaminated with 
excess potassium carbonate. The precipitate was therefore re-suspended in THF and the 
resulting solution filtered. The organic solvent was further evaporated ta give 4 as a pure 
brown solid (90 mg, 73%) : mp 150°C; FABS m/z 387 (MH+ with 79Br), 389 (MH+ with 
81Br), 359 (M-N2) m/z 387.056895 (MH+), C16HlSN601Br requires 387.05670; IH NMR 
(400MHz, DMSO-d6) Ù 9.91 (s, 1H, NH), 8.57 (s, 1H), 8.50 (s, 1H), 8.25 (s, 1H), 7.99 
(d, 1H, J=8.8Hz), 7.92 (d, 1H, J=7.6Hz), 7.76 (d, 1H, J=8.8Hz), 7.34-7.25 (m, 2H), 6.37 
(s, 1H, OH), 5.17 (s, 2H, CH2), 3.19 (s, 3H, CH3); l3C NMR (75MHz, DMSO-d6) Ù 
164.3, 158.0, 154.0, 148.9, 149.8, 130.9, 129.5, 126.3, 125.2, 124.7, 121.8, 121.2, 116.4, 
116.1, 78.8, 34.0. 
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2.3.4. Synthesis of 6-(3-Acetoxymethyl-3-methyl-triazenyl)-4-(3'-bromophenyl-
amino)quinazoline (6) 
6-(3-Hydroxymethyl-3-methyl-triazenyl)-4-(3' -bromophenyl-amino )quinazoline 5 (100 
mg, 0.258 mmol) was dissolved in pyridine (2 mL) after which acetic anhydride (0.055 
mL, 0.516 mmol) was slowly added. The solution was further kept on ice for 1.5 h and 
the pyridine evaporated as an azeotrope with toluene to give 6 as a pure brown residue 
(105 mg, 95%) : mp 140°C; FABS m/z 429 (MW with 79Br), 431 (MH+ with 8IBr), 298 
[M-(3-acetoxymethyl-3-methyltriazene)], 401 (M-N2) mlz 429.067460 (MH+), 
C18H17N602Br requires 429.06728; IH NMR (400MHz, DMSO-d6) ô 10.02 (s, IH, NH), 
8.61 (s, 2H), 8.25 (s, IH), 7.99 (d, IH, J=8.4Hz), 7.93 (d, IH, J=7.6Hz), 7.79 (d, IH, 
J=9.2Hz), 7.35-7.26 (m, 2H), 5.86 (s, 2H, CH2), 3.26 (s, 3H, CH3), 2.07 (s, 3H, CH3); 
13C NMR (100MHz, DMSO-d6) ô 170.8, 158.1, 154.4 149.5, 147.7, 141.8, 130.9, 129.7, 
126.5, 125.1, 124.8, 121.8, 121.3, 117.3, 116.2, 79.4, 35.5, 21.6. 
2.3.5. Drug Treatment 
Compounds 1,2,3,5,6 and 8 were synthesized in our laboratories according to known 
procedures. Temozolomide (TEM) was provided by Shering-Plough Inc. (Kenilworth, 
NJ, USA). In aIl assays, drugs were dissolved in DMSO and subsequently diluted in 
RPMI-1640 containing 10% fetal bovine serum (FBS) (Wisent Inc. St-Bruno, Canada) 
or in DMEM containing 10% bovine calf serum (GIBCO BRL, Burlington, Canada) 
immediately before the treatment of ceIl cultures. In ail assays, the concentration of 
DMSO never exceeded 0.2% (v/v). 
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2.3.6. Purity of Compounds 
Purity analyses were performed by high performance liquid chromatography (HPLC) 
using a Spectrasystem (Thermoquest) and a Waters C4 15-llm 300x3.9-mm column 
(reverse phase). The operating mode was isocratic and two different systems of solvents 
were used: the first one was 100% acetonitrile with a 0.35mL/min flow rate at 254nm; 
and the second system was 80% isopropanol and 20% dioxane with a 0.5 mL/min flow 
rate at 254 nm. 
2.3.7. Cell Culture 
The celllines used in this study, the mouse fibroblasts NIH3T3, NIH3T3/HERI4 
(NIH3T3 celIs stably transfected with the EGFR gene) and NIH3T3/neu (NIH3T3 celIs 
stably transfected with HER2) were generous gifts from Dr. Moulay Aloui-Jamali of the 
Montreal Jewish General Hospital. NIH3T3, NIH3T3/HERI4 and NIH3T3/neu celIs 
were maintained in DMEM supplemented with 10% FBS and antibiotics. AlI celIs were 
maintained in an atmosphere of 5% COz. 
2.3.8. Degradation 
The half-lives of 6, 5 and 8 under physiological conditions were studied by a UV-
spectrophotometer. The compounds were dissolved in a minimum volume of DMSO, 
diluted with RPMI-1640 supplemented with 10% FBS, and absorbances were read at 
240 nm in a UV cell maintained at 37°C with a circulating water bath. The half-life was 
estimated by a one-phase exponential decay curve-fit method using the GraphPad 
software package (GraphPad software, Inc., San Diego, CA, USA). 
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The study of the conversion of the eompounds (6, 5 and 8) to their eorresponding free 
inhibitor (3) was performed by speetrofluorometer as the latter amine is fluorescent 
(absorption 290 nm, emission 450 nm). Briefly, 125 J.lM of the drug eonjugates were 
added to RPMI-1640 with 10% FBS and ineubated for 4 h at 37°C in a mieroplate 
speetrofluorometer (SpeetraMax Gemini floureseenee reader, Moleeular Deviee, CA). 
The data are aequired and analyzed by SoftMax®Pro (Moleeular Deviee, CA). 
HPLC analysis was performed to study the degradation of eompounds 2, 5, and 6. The 
eompounds were dissolved in a minimum volume ofDMSO, diluted with RPMI-1640 
supplemented with 10% FBS, using a Spectrasystem (Thermoquest) and a Waters C4 
15-J.lm 300x3.9-mm column (reverse phase). The operating mode was isoeratic using a 
60% acetonitrile and 40 % water solvent system with a 0.5 mL/min flow rate at 254 nm. 
2.3.9. EGFR Kinase Assay 
Nunc Maxisorp 96-well plates were incubated ovemight at 37°C with 100 J.lL/weIl of25 
ng/mL PGT in PBS. Excess PGT was removed and the plate was washed three times 
with wash buffer (Tween 20 (0.1%) in PBS). The kinase reaction was performed by 
using 4.5 ng/well EGFR affinity-purified from A431 cells. The compounds were added 
and phosphorylation was initiated by the addition of A TP (20 J.lM). After 8 min at room 
temperature with constant shaking, the reaction was terminated by aspiration mixture 
and by rinsing the plate four times with wash buffer. Phosphorylated PGT was detected 
following a 25 min incubation with 50 ilL/weIl of HRP-conjugated PY20 anti-
phosphotyrosine antibody (Santa Cruz Biotechnology, CA) diluted to 0.2 mg/mL in 
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blocking buffer (3% bovine serum albumin; 0.05% Tween 20 in PBS). Antibody was 
removed by aspiration, and the plate washed four times with wash buffer. The signaIs 
were developed by the addition of 50 llL/well of 3,3',5,5'-tetrarnethylbenzidine 
peroxidase substrate (Kirkegaard and Perry Laboratories, Gaithersberg, MD, USA) and 
following blue color development, 50 ilL of H2S04 (0.09 M) was added per weIl, and 
plates were read at 450 nm using a Bio-Rad ELISA reader (model 2550). 
2.3.10. In vitro Growth Inhibition Assay 
To study the effect of our compounds on serum-stimulated proliferation, cells were 
grown to 70 % of confluence in 96-well plates and washed twice with PBS after which 
they were exposed to serum-free media for 24 h. Cells were exposed to each drug + 
serum for 72 h and cell growth measured using the sulforhodarnine B (SRB) assay. 
Briefly, following drug treatment, cells were fixed using 50 ilL of co Id trichloroacetic 
acid (50%) for 60 min at 4°C, washed five times with tap water, and stained for 30 min 
at room temperature with SRB (0.4%) dissolved in acetic acid (0.5%). The plates were 
rinsed five times with 1 % acetic acid and allowed to air dry. The resulting colored 
residue was dissolved in 200 ilL of Tris base (10 mM), and optical density read for each 
well at 492 nrn using a Bio-Rad microplate reader (model 2550). Each point represents 
the average of at least two independent experiments run in triplicate. 
2.3.11. Alkylating Activity Assay 
For each time point, 10 III of compound (20 IlM) were added to a 2% p-
nitrobenzylpyridine (NBP): ethyleneglycol (100 ilL) mixed with Tris pH 7.5 (27% 
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ethanol) (70 ilL) and incubated at 37°C. The color was developed with a solution of 
acetone:triethylamine (50/50, v/v). Optical density was read for each weIl at 540 nm 
using a Bio-Rad microplate reader (model 2550). 
2.3.12. Cornet Assay for Quantitative Analysis of DNA Damage 
A modified alkaline cornet assay technique was used to quantitate DNA damage induced 
by 6 and 5 in MDA-MB-435 cells. The cells were exposed to drugs for 24 h and 
harvested with trypsin-EDTA. They were subsequently collected by centrifugation and 
re-suspended in PBS. The resulting cell suspensions were diluted to 3xl05 ceIl/mL, and 
mixed with 0.75% agarose in PBS at 37°C in a 1:9 dilution. The gels were cast on 
Gelband strips (Mandel Scientific, Guelph, ON, Canada) using gel casting chambers, as 
previously described, then immediately placed into a lysis buffer (2.5 M NaCI, 0.1 M 
tetrasodium EDTA, 10 mM Tris-base, 1% w/v N-Iauryl sarcosine, 10% v/v DMSO and 
1% v/v Triton X-I00). After being kept on ice for 30 min, the gels were gently rinsed 
with distilled water and immersed in a second lysis buffer (2.5 M NaCI, 0.1 M 
tetrasodium EDTA, 10 mM Tris-base) containing 1 mg/mL proteinase K for 60 min at 
37°C. Thereafter, they were rinsed with distilled water, incubated in alkaline 
electrophoresis buffer for 30 min at 37°C, and electrophoresed at 300 mA for 60 min. 
The gels were subsequently rinsed with distilled water and placed into 1 M ammonium 
acetate for 30 min. They were further soaked in 100% ethanol for 2 h, dried ovemight 
and subsequently stained with SYBR Gold (l: 1 0,000 dilution of stock supplied by 
Molecular Probes, Eugene, Ore.) for 20 min. For evaluation of cornets, DNA damage 
was assessed using the tail moment parameter (i.e. the product of the distance between 
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the barycenters of the head and the tail of the cornet multiplied by the percentage DNA 
in the tail region). A minimum of 50 cells/comet were analyzed for each sample, using 
ALKOMET v3.1 software, and the values presented are average tail moments for the 
entire cell population. 
2.4. Results and Discussion 
2.4.1. Chemistry 
The synthesis of 6 proceeded according to Scheme 2.2. Briefly, compound 3 was treated 
in acetonitrile with NOBF4 to generate intermediate 4, which was treated in situ with a 
10: 1 mixture of formaldehyde/methylamine. Alkalinization with aqueous K2C03 led to 
precipitation of compound 5, in high yield. However, this compound co-precipitated 
with solid K2C03, which was removed by re-suspension in THF followed by collection 
and evaporation of the filtrate. Hydroxymethyltriazene 5, was obtained in a pure state 
(yield: 70%) without requirement for further purification. Treatment of 5 with acetic 
anhydride in pyridine gave 6 as a pure solid. We have already reported the synthesis of 
8 (Rachid et al., 2003). 
n HN ~ Br 
N»~ NH2 
l!.. /. A 
N 
3 
Scheme 2.3. 
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The stability of 6 and that of each of its putative metabolites were studied by allowing 
them to degrade in both phosphate buffered saline (PBS) and serum-containing media 
using UV spectrophotometric analysis. Compound 6 was much less stable than 2, with a 
half-life of 42 min in serum-containing media (Table 2.1). Interestingly, its putative 
metabolite 5 (Scheme 2.3) showed a half-life of 40 min suggesting that conversion of 6 
to 5 may be a rapid event. Indeed, it has already been reported that 
acetoxymethyltriazenes are rapidly converted to the corresponding 
hydroxymethyltriazene in PBS (Remens et al., 1984; Remens and Vaughan, 1986; Reid 
et al., 1999). 
Attempts to monitor the formation of 5 by RPLC failed due to its instability under the 
separation conditions. Rowever, when 6 was allowed to de grade ovemight under 
physiological conditions, we could successfully detect amine 3 (Schemes 2.2 and 2.3) as 
the sole product, suggesting that the putative intermediary metabolites may have been 
formed according to the mechanism outlined in Scheme 2.3. This mechanism has 
already been proposed for similar triazenes (Remens et al., 1984; Remens and Vaughan, 
1986). Addition of water to iminium ion 7 may generate the methylol 5 which may self-
deformylate to give the monoalkyltriazene 8. To circumvent problems associated with 
on-column degradation of 6 and that of its metabolite 5, we designed a fluorescence 
detection assay in order to monitor the formation of 3, the ultimately generated stable 
metabolite. Absorption-emission spectra of the latter showed absorption at 290 nm and 
emission at 450 nm. Thus we could unambiguously analyze the kinetics of formation of 
3 by spectrofluorimetry. Interestingly, the rate of conversion of 5 to 3 was slower than 
that of 8 to 3. These data support a stepwise degradation of the CRM in the sequence 
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proposed in Scheme 2.3. More importantly, the symmetrically inversed relationship 
between the degradation of the diverse metabolites and the formation of 3 suggest a near 
stoichiometric conversion of 6 to 3 (Fig. 2.1). A similar result was reported for 
triazenoquinazolines oftypes 1 and 8 (Brahimi et al., 2002). 
2.4.2. Biology 
Our objective being to generate multiple inhibitors from a parent one, we tested the 
EGFR TK inhibitory activity of each of the putative metabolites alone in a short 8-min 
exposure ELISA. The as say was based on the inhibition of phosphorylation of poly(L-
glutamic acid-L-tyrosine, 4:1) (PGT) by EGFR tyrosine kinase. Structure-activity 
relationships (SAR) in the quinazoline series have already demonstrated tolerance of 
bulky substituents at the 6- and 7-positions (Rewcastle et al., 1995; Rewcastle et al., 
1997; Rewcastle et al., 1998). Indeed the triazene appendage to the 6-position of this 
series did not significantly alter the EGFR binding affinities when compared with 3. 
As an example, the ICso values for 3 and 8 were in the same range [e.g. 8 (lCso= 0.07 
J..tM); 3 (lCso= 0.04 J..tM)] (Table 2.1). More importantly, previous studies have 
demonstrated the strong dependence of the SAR of quinazolines on the electronic 
character of the substituents at the 6-position (Rewcastle et al., 1995; Rewcastle et al., 
1998). Electron-donating groups at the 6-position enhance activity, whereas electron-
withdrawing ones are deleterious to affinity. In this study, it was found that acylation of 
1 decreased the affinity of the resulting compound 2 by threefold (Table 2.1). This may 
be due to the decrease in the electron-donating character of the triazene, that may deplete 
the partial charges on the nitrogens in the quinazoline ring. Indeed, when acylation was 
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Table 2.1. EGFR TK inhibition, alkylating activity, and half-lives of compounds 1-3, 5-
6 and 8. 
Compounds Inhibition of EGFR Alkylating Half-life Half-life 
ICso, IlMa Activity (RPMI) (PBS) (l0-3min- l i (t1/2),min.c (t 112) ,min.d 
1 0.2 9.1 35 69 
2 0.578 1.5 >200 >200 
3 0.04 0.05 NIA NIA 
5 0.11 6.6 40 70 
6 0.13 5.8 42 84 
8 0.07 8.9 38 68 
TEM NIA 11.3 NIA NIA 
a EGFR TK values are means of two experiments, alkylating activity and half-lives values 
were obtained from single experiments. b Measured as a rate of alkylation of NBP at pH 
~ 7. 5. c,dMeasured by UVabsorbance at 290nm. 
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Table 2.2. Inhibition of serum-stimulated growth in NIH3T3, NIH3T3/HER14 and 
NIH3T3/neu celllines by compounds 1-3,5-6,8, TEM, AG1478 and combination of 
TEM + AG1478. 
Compounds 
1 
2 
3 
5 
6 
8 
TEM 
AG1478 
TEM+AGI478 
NIH3T3 
ICso, gMa 
125 ± 1.7 
200 ± 6.3 
14.5 ± 1.9 
12.8 ± 0.45 
15.4 ± 0.55 
15 .5 ± 1.9 
214.0 ± 11.1 
28.6 ± 3.6 
39.4 + 5.4 
NIH3T3/HER14 
ICso, gMa 
28.9 ± 5.5 
149 ± 14.2 
10.4 ± 0.5 
2.1 ± 0.3 
3.4 ± 1.2 
8.8 ± 0.6 
207.2 ± 12.7 
9.8 ± 0.3 
6.2 + 0.5 
a Values are means ofIC5o values and SEMsfrom three experiments. 
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NIH3T3/neu 
ICso, gMa 
16.5 ± 2.3 
60.6 ± 6.9 
0.42 ± 0.03 
0.09 ± 0.03 
0.21 ± 0.05 
0.09 ± 0.03 
210.0 ± 16 
4.0 ± 0.2 
1.1 + 0.06 
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Figure 2.1. Formation (-) of 3 during the degradation (Â) of a) 6, b) 5 and c) 8 in 
RPMI supplemented with FBS 10 % at 37°C. Degradation experiments were carried out 
by UV spectrophotometric analysis. The analyses were performed at 25/-lM. Drugs 
were added to RPMI-1640 with 10% FBS (2 ml) and incubated at 37°C. 
103 
performed in a manner that did not affect the p-extended system of 1,2,3-triazene (as in 
6), there was little change in binding affinity when compared with the parental 
monomethyl triazene 8. A significant decrease in the electron density at NI was already 
demonstrated by 15N spectroscopy when N3 in cyclic and acyclic triazenes are acylated 
(Wilman, 1990; Jean-Claude and Williams, 1998). 
Previous studies demonstrated that serum stimulation of isogenic cells transfected with 
EGFR or the HER2 gene product represent good models for the determination of tumour 
selectivity of combi-molecules since they offer the advantage of growth-stimulating the 
two ceIllines with a common growth factor (Matheson et al., 2003a). When this model 
was used, aIl compounds possessing EGFR TK inhibitory activities selectively blocked 
serum-stimulated growth ofNIH 3T3 ceIls transfected with EGFR (NIH3T3/HERI4) or 
HER2 (NIH3T3/neu), indicating translation of the EGFR TK inhibition into blockade of 
growth factor-mediated proliferation (Table 2.2). A typical NIH3T3/NIH3T3neu 
differential growth response profile is shown in Figure 2.2. Moreover, it is noteworthy 
that the cascade release molecule 6 is significantly more potent than its metabolite 8 
(p<0.001) in the EGFR transfected cell line, NIH3T3/Her14. However, the order of 
potency ofthese two molecules was inverted in the NIH3T3/neu ceIlline, indicating that 
perhaps 6 is less selective for HER2/neu than 8 and therefore may not serve as an 
efficiently targeted prodrug of 8 in these ceIls. 
In order to further demonstrate the efficacy of the cascade combi-molecular approach, 
the effects of 6 were compared with those of classical combination of Temozolomide 
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Figure 2.2. Effect of 6 on serum stimulated-proliferation in NIH3T3 (-) and 
NIH3T3/neu ( .... ) cells_ Cells were starved for 24 h and exposed to each drug + serum 
for 72 h and growth inhibition was measured using SRB assay. Each point represents at 
least two independent experiments run in triplicate. 
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(TEM) and AG1478, a known in vivo active EGFR-TK inhibitor (Nagane et al., 2001). 
The combinations were performed at ICso(TEM)/IC50(AGI478) molar ratios. 
OMe 
OMe 
AG1478 
Structures of the clinical agents Temozolomide and AG1478 
The results showed that 6 was 2.5- and 5-fold more potent than equi-effective doses of 
TEM+AGI478 in NIH3T3/Her14 and NIH3T3/neu cells respectively. Superior activity 
(e.g lO-fold) when compared with the TEM+AG478 combinations was observed for 8 
only in the NIH3T3/neu cells, which is in agreement with its strong activity in the latter 
cell line. These results support the significant antiproliferative potency of our combi-
targeting and combi-molecular CRM approaches. 
The hydrolysis of our CRM is expected to generate multiple inhibitors of EGFR and at 
the final stage of degradation the methyldiazonium species. Since the latter is known to 
be the cytotoxic DNA alkylating metabolite of triazenes, we studied the alkylating 
potency of the different agents using the 4-(p-nitrobenzyl)pyridine (NBP) test (Nelis et 
al., 1982; Brahimi et al., 2002; Jean-Claude et al., 2002; Qiu et al., 2003; Matheson et 
al., 2003a). In this colorimetrie assay, the alkylating species is trapped by NBP and a 
106 
-------
( (A) 
400 ---.- 6 
-.-3 
-c QI 
~ 
QI 300 r:l._ 
.0 
-... c-QI C 
E 0 
OU 200 E 
CIl 
t-
100 
0 10 20 30 40 50 60 
Conee ntration (J.1M) 
(B) 
---.- 6 
-.-3 
500 
-
C 
QI 
~ 400 
QI 
r:l._ 
~ .0 
-... ; ë 300 
E 0 
OU 
E 
200 
~ 
100 
0 10 20 30 40 50 60 
Conee ntration (J.1M) 
Figure 2.3. Quantitation of DNA damage using the alkaline cornet assay. DNA damage 
induced by RB24 and RBlO in a) NIH 3T3 and b) NIH 3T3/neu celllines. Tail moment 
was used as a parameter for the detection ofDNA damage in NIH 3T3 and NIH 3T3/neu 
cells exposed to RB24 or RBIO for 30 min. 
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purple color is developed following addition of base. As a control, we compared the 
alkylating capacity of our compounds with that of a clinical DNA methylating cyclic 
triazene, Temozolomide (TEM). The NBP assay indicated that the parent compound 6 
had a slower rate of alkylation when compared with the putative metabolite 5, 8 and 
TEM (Table 2.1). As expected, the naked inhibitor 3 demonstrated no alkylating activity 
and the stable acylated compound 2 was found to have the slowest rate of alkylation in 
the entire triazene series. 
The translation of the alkylating activity of 5 and 6 into DNA damage in human tumour 
cells was tested using the single cell microelectrophoresis (cornet) assay in mouse 
fibroblast isogenic cell lines NIH 3T3 and NIH3T3/neu. In contrast to the naked 
inhibitor 3, the acetoxymethyltriazene 6 was found to induce a dose-dependent increase 
in DNA strand breaks in both NIH 3T3 and its transfected counterpart, NIH 3T3/neu 
(Figure 2.3) confirming the binary targeting properties of the CRM. 
This study conclusively demonstrates the feasibility of a molecule that may de grade in a 
stepwise mechanism into intermediary structures which when tested independently 
showed EGFR TK inhibitory activities. Although it was not possible to monitor the 
kinetics of formation ofall the degradation products (e.g. the methylol intermediate 5, or 
the monoalkyltriazene 8), their ultimate conversion to the stable metabolite 3 suggests 
that they may have been formed according to the mechanism outlined in Scheme 2.3. 
Further, in addition to the ability of the CRMs to release inhibitors of EGFR, their 
alkylating activity and their DNA damaging potential suggest the formation of the 
putative methyldiazonium species. Thus, the combi-targeting and CRM principles mimic 
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the effects of complex multi-drug combinations involving modem inhibitors of EGFR 
TK and a classical DNA damaging agent. More importantly, the results presented herein 
suggest that these effects may be selectively targeted to cells expressing the HER2 or 
EGFR oncogenes. 
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2.7. Connecting text 
In the preceding chapter (Chapter 2), a detailed synthe sis of the first ever "cascade 
release" combi-molecule,. RB24 (Structure 6), was described. This novel class of combi-
molecule is a masked form of monomethyltriazene that degrades to release several 
daughter inhibitors of EGFR TK and at the last step of the cascade, a methyldiazonium 
species. Independent synthesis of each of the putative degradation products of RB24 
[e.g. RB14 (Structure 5), ZR08 (Structure 8), RBI0 (Structure 3)] permitted the 
determination of their individual in vitro activity. Since aH of them retained significant 
EGFR TK inhibitory activity, we surmised that RB24 would not be deactivated through 
degradation. These results stimulated us to examine whether this property would 
translate into sustained EGFR TK inhibition. Furthermore, we sought to determine 
whether this sustained EGFR inhibitory activity + DNA damage would translate into 
irreversible antiproliferative activity. Thus, the next chapter investigates the reversible 
mechanism of action of RB24 and its effect on downstream signalling cascades. This 
paper was published in the British Journal of Cancer 91: 1 066-73 (2004) (see Appendix). 
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CHAPTER3 
SUSTAINED ANTIPROLIFERATIVE MECHANISMS BY RB24, A 
TARGETED PRECURSOR OF MULTIPLE INHIBITORS OF 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND A 
DNA ALKYLATING AGENT IN THE A431 EPIDERMAL 
CARCINOMA OF THE VULV A CELL LINE 
Ranjita BanerjeeI, Zakaria Rachidl, Qiyu Qiu" James P. McNamee2, Ana M. Tari3 
and Bertrand J. Jean-Claudel 
(ICancer Drug Research Laboratory, Department of Medicine, Division of Medical 
Oncology, Mc Gill University Health CenterlRoyal Victoria Hospital, 687 Pine Avenue 
West, Rm. M 7.15, Montreal, Quebec, H3A lAI, Canada; 2Consumer and Clinical 
Radiation Protection Bureau, Health Canada, Ottawa, Ontario, KIA ICI, Canada; 3The 
University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, U.S.A) 
3.1. Abstract 
Recent results on clinical trials of epidermal growth factor receptor (EGFR) inhibitors 
showed a rather moderate potency for the reversible inhibitors, a debility that might be 
due to their lack of sustained antiproliferative activity in human tumours. With the 
purpose of enhancing the potency of EGFR-based therapies, we designed a novel 
strategy termed "Cascade-release targeting" that seeks to develop molecules capable of 
degrading to multiple tyrosine kinase inhibitors and highly reactive electrophiles, in a 
stepwise fashion. Here we report on the tirst prototype of this model, RB24, a masked 
methyltriazene, that in addition to being an inhibitor on its own, was designed to degrade 
to RB 14, ZR08, RB 1 0 + a DNA alkylating methyldiazonium species. The cascade 
degradation ofRB24 requires the generation oftwo reactive electrophiles: a) an iminium 
ion and b) a methyldiazonium ion. Thus, we surmise that these species could alkylate 
the active site of EGFR, thereby irreversibly blocking its action and that DNA damage 
could be induced by the methyldiazonium. Using the EGFR-overexpressing human 
epidermoid carcinoma of the vulva cellline, A43l, we demonstrate herein that: a) RB24 
and its derived specles (e.g. RB14, ZR08), irreversibly inhibit EGFR 
autophosphorylation, b) RB24 induced signiticant levels of DNA strand breaks, c) its 
sustained inhibition of EGFR was associated with blockade of MAPK activation and c-
fos gene expression, d) it induced irreversible cell growth inhibition with a lOO-fold 
greater potency than Temodal™, a clinical methyltriazene. The pronounced growth 
inhibitory potency of RB24 was attributed to its ability to simultaneously damage DNA 
and to irreversibly block EGFR TK activity. 
Keywords: EGFR, triazene, DNA, quinazoline 
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3.2. Introduction 
Overexpression of the epidermal growth factor receptor (EGFR) family and its cognate 
ligand has been correlated with aggressiveness and po or prognosis in various tumours 
such as breast, ovarian and prostate cancer (Modjtahedi et al., 1994; Xie et al., 1995; 
Turner et al., 1996; Meden et al., 1997; Chen et al., 2000). The implication of these 
receptors in cancer progression has garnered significant attention and agents capable of 
blocking disordered growth signaling mediated by these proteins are now in a significant 
number of clinical trials against many cancers. One such agent, Iressa®, a trademark of 
the AstraZeneca group of Companies exhibits a broad spectrum of anti-tumour activity 
against many human solid tumour xenografts of various origins including breast, lung, 
colorectal and head and neck (Ciardiello et al., 2001a; Moulder et al., 2001;Heimberger 
et al., 2002; Magné et al., 2002; Ranson et al., 2002). However, despite the significant 
activity of this compound in pre-clinical models, in Phase II clinical trial, it only induced 
a response rate of approximately 10% in a cohort of patients with non-small cell lung 
cancer (NSCLC) (Magné et al., 2002; Dancey et al., 2003). Several possible 
explanations have been put forth to explain the failure to demonstrate a benefit: 
inadequate dosing, reduced drug delivery to tumour, lack of sustained potency and 
failure to select patients on the basis of having tumours in which EGFR presents a 
growth advantage (Dancey et al., 2003). 
The lack of sustainability of the antitumour action of reversible inhibitors has stimulated 
the design of new irreversible inhibitors of EGFR tyrosine kinase (TK). One such 
compound, PD183805, bearing a 6-acrylamido group designed to alkylate cysteine 773 
in the active site of the ATP binding pocket irreversibly blocks EGFR TK and is now in 
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Phase 1 development in patients with head and neck, breast and non-small cell lung 
carcinoma (Ciardiello et al., 2001b). Other approaches to enhance the potency of 
EGFR inhibitor-based therapy include combinations of inhibitors with several cytotoxic 
agents including taxol, cytoxan and adriamycin (Ciardiello et al., 1999; Ciardiello et al., 
2001a; Magné et al., 2002; Dancey et al., 2003). Within the same line of idea, with the 
purpose of developing more potent and targeted therapies, we developed a novel strategy 
termed "Combi-targeting" that seeks to synthesize single molecules capable of both 
blocking EGFR tyrosine kinase (TK) and inducing cytotoxicity by damaging DNA 
(Matheson et al., 2001; Brahimi et al., 2002; Matheson et al., 2003b; Matheson et al., 
2003c; Qiu et al., 2003a; Qiu et al., 2003b; Rachid et al., 2003). Two such compounds, 
SMA41 (Matheson et al., 2003a; Matheson et al., 2003b) and BJ2000 (Brahimi et al., 
2002), the first models designed to demonstrate the feasibility of this principle showed 
significant DNA damage ability and irreversible blockade of EGFR autophosphorylation 
in A431 cells. More importantly, these agents induced a more sustained antiproliferative 
activity when compared with a reversible inhibitor of EGFR (Matheson et al., 2001; 
Brahimi et al., 2002; Matheson et al., 2003a). In addition, the se molecules, also termed 
"Combi-molecules," selectively induced antiproliferative activity against EGFR-
transfectants in isogenic models (Brahimi et al., 2002; Matheson et al., 2003b). 
ln order to further augment the potency of the Combi-targeting approach, we recently 
designed RB24 (an acetoxymethyltriazene) to generate three inhibitors of EGFR and at 
the final stage of degradation a methyldiazonium species capable of damaging DNA 
(Banerjee et al., 2003). This masked cluster of molecules was expected to produce 
more sustained anti-tumour effects with the prospect of inducing activities similar or 
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superior to that of c1assical combinations involving a reversible EGFR inhibitor + a 
cytotoxic drug. Here we study the mechanism of action of RB24, the first prototype of 
this strategy termed "cascade release", and demonstrated the sustainability of its 
antitumour activity in A431 cells which overexpress EGFR and its cognate ligand, TGF-
a (Lanzi et al., 1997). The ability ofthis cellline to aggressively proliferate by a TGF-a 
mediated autocrine induction has made it an ideal model for studying the mechanism of 
action of EGFR TK inhibitors. In addition, these cells express 06-alkylguanine 
transferase (06-AGT), a DNA repair enzyme that by repairing the 06-alkylguanine 
DNA adduct conf ers significant resistance to AGT+ cells (Lee et al., 1991; Mitchel et 
al., 1993; Pegg et al., 1995; Cai et al., 2000; Yingna et al., 2000; Matheson et al., 
2003b). 
3.3. Materials and Methods 
3.3.1. Drug Treatment 
RB24, RB14, ZR08 and RBlO were reported elsewhere (Banerjee et al., 2003). 
Temodal™ was provided by Shering-Plough Inc. (Kenilworth, NJ, USA). In all assays, 
drug was dissolved in DMSO and subsequently diluted in RPMI-1640 containing 10% 
fetal bovine serum (FBS) (Wisent Inc. St-Bruno, Canada) immediately before the 
treatment of cell cultures. In all assays, the concentration of DMSO never exceeded 
0.2% (v/v). 
3.3.2. Cell Culture 
The cellline used in this study, the human epidermoid carcinoma of the vulva, A431, 
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was obtained from the American Type Culture Collection (Manassas, V A, USA). The 
A431 cell line was maintained in RPMI-1640 supplemented with 10% FBS and 
antibiotics as described previously (Matheson et al., 2001). AlI cells were maintained in 
an atmosphere of 5% CO2• 
3.3.3. In vitro Cytokinetic Growth Inhibition Assay 
To study the irreversible effects of our compounds on cell proliferation, 200 cells/well 
were plated in 96-well plates with serum-containing media. Cells were exposed to each 
drug + serum for either 2h, 8h, 12h, 24h or 48h. After each time point the drug was 
removed and cells were washed 2x with PBS and allowed to recover with fresh serum-
containing media for a total of 96 hrs. Cell growth was measured using the 
sulforhodamine B (SRB) assay. Briefly, following drug treatment and recovery, cells 
were fixed using 50 J.1L of cold trichloroacetic acid (50%) for 60 min at 4°C, washed 
five times with tap water, and stained for 30 min at room temperature with SRB (0.4%) 
dissolved in acetic acid (0.5%). The plates were rinsed five times with 1% acetic acid 
and allowed to air dry. The resulting colored residue was dissolved in 200 J.1L of Tris 
base (10 mM), and optical density read for each weIl at 492 nm using a Bio-Rad 
microplate reader (model 2550). Each point represents the average of at least two 
independent experiments run in triplicate. 
3.3.4. Autophosphorylation Assay 
A431 cells (1 xi 06) were preincubated in a six-weIl plate with 10% serum at 37°C for 48 
h and starved ovemight for 24 h, after which they were exposed to a dose range of each 
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drug for 2 h and subsequently treated with 50 ng/ml EGF for 15 min at 37°C. Cells were 
washed with PBS and resuspended in cold lysis buffer [50 mM Tris-HCI pH 7.5; 150 
mM NaCI; 1 % Nonidet P-40, ImM EDTA; 5 mM NaF; 1 mM Na3 VÛ4; protease 
inhibitor tablet (Roche Biochemicals, Laval, Canada)]. The lysates were kept on ice for 
30 min and collected by centrifugation at 10,000 rpm for 20 min at 4°C. The 
concentrations of protein were determined using the Bio-Rad protein assay kit (Bio-Rad 
Laboratories, Hercules, CA). Equal amounts of prote in were added to a 10% SDS-
polyacrylamide gel electrophoresis (SDS-P AGE) and transferred to a polyvinylidene 
difluoride membrane (Millipore, Bedford, MA). Non-specific binding on the membrane 
was minimized with a blocking buffer containing nonfat dry milk (5%) in PBST. 
Thereafter, the membranes were incubated with primary antibodies [either anti-
phosphotyrosine antibody (Upstate Biotechnology, Lake Placid, NY) for the detection of 
phosphotyrosine, or anti-EGFR (Neomarkers, Fremont, CA)] for determination of 
corresponding receptor levels. Blots were incubated with HRP-goat anti-mouse antibody 
(Bio Rad Laboratories) and the bands visualized with an enhanced chemiluminescence 
system (Amersham Pharmacia Biotech, Buckinghamshire, UK). Band intensities were 
measured using the SynGene GeneTools software package. 
To study the effects of RB24 on the activation of extraceullular signaIs regulated kinases 
1,2 (Erkl,2), prote in lysates were obtained as described above and Western blot was 
performed as previously reported (Tari et al., 2000). The membrane was incubated with 
anti-phosphorylated Erkl,2 antibodies or antibodies specific for Erkl,2 (Cell Signaling, 
Beverly, MA, USA). 
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3.3.5. Reverse EGFR Autophosphorylation 
This assay was performed as previously described (Fry et al., 1998). A431 cells were 
grown to confluence in 6-well plates and then incubated in serum-free medium for 24 h. 
Duplicate sets of cells were then treated with 30 ~M of each compound for 90 min. One 
set of cells was then stimulated with EGF (50 ng/ml) for 15 min and extracts were made 
as described under the Western blotting procedure above. The other set of cells was 
washed free of the compound with warmed serum-free media and incubated for 2 h. 
Thereafter, the ceUs were washed, incubated for another 2 h, washed again, and then 
incubated for a further 4 h. This set of cells was then stimulated with EGF and extracts 
were prepared as for the first set. 
3.3.6. RT -PCR for c-fos Expression 
A431 ceUs were grown to confluence in 6-well plates and then incubated in serum-free 
medium for 24 h. Cells were exposed to the indicated concentrations of drug prior to 
stimulation with EGF (50 ng/ml) for 30 min. Total RNA was isolated using the High Pure 
RNA Isolation Kit of Roche Molecular Bochemicals (Germany), following the 
manufacturer's instructions. Quantitative analysis of c-fos mRNA and G3PDH mRNA (2 ~g 
of RNA for each sample) was preformed by Titan One Tube RT-PCR Kit (Roche Molecular 
Bochemica1s), following the manufacturer' s instructions and using the following primers: 
5' ATGATGTTCTCGGGCTTC3' (sense), 5' CTCCTGCCAA TGCT CTGC3' (antisense) for 
c-fos and 5'CCATGGAGAAGGCTGGGG3'(sense), 5'CAAA GTTGTCATGGATGACC3' 
(antisense) for G3PDH. 
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3.3.7. Alkaline Comet Assay for Quantitation of DNA Damage 
The alkaline comet assay was performed as previously described (Matheson et al., 2001). 
The cells were exposed to drugs (RB24, RB 14 or RB 1 0) for 30 min, harvested with trypsin-
EDT A, subsequently collected by centrifugation and resuspended in PBS. Cell suspensions 
were diluted to approximately 106 cells, and mixed with agarose (1 %) in PBS at 37°C in a 
1: 1 0 dilution. The gels were cast on Gelbond strips (Mandel Scientific, Guelph, Canada) 
using gel casting chambers, as previously described (McNamee et al., 2000), and then 
immediately placed into a lysis buffer [2.5 M NaCl, 0.1 M tetra-sodium EDTA, 10 mM Tris-
base, 1% (w/v) N-lauryl sarcosine, 10% (v/v) DMSO, and 1 % (v/v) Triton X-lOO, pH 10.0]. 
After being kept on ice for 30 min, the gels were gently rinsed with distilled water and 
immersed in a second lysis buffer (2.5 M NaCI, 0.1 M tetrasodium EDTA, 10 mM Tris-base) 
containing 1mg/ml proteinase K for 60 min at 37°C. Thereafter, they were rinsed with 
distilled water, incubated in alkaline electrophoresis buffer for 30 min at 37°C, and 
electrophoresed at 300 mA for 20 min. The gels were subsequently rinsed with distilled 
water and placed in 1 M ammonium acetate for 30 min. Thereafter, they were soaked in 
100% ethanol for 2 h, dried ovemight, and stained with SYBR Gold (1/10, 000 dilution of 
stock supplied from Molecular Probes, Eugene, OR) for 20 min. Comets were visualized at 
330x magnification and DNA damage was quantitated using the Tail Moment parameter 
(i.e., the distance between the barycenter of the head and the tail of the comet multiplied by 
the percentage of DNA within the tail of the comet). A minimum of 50 cell comets was 
analyzed for each sample, using ALKOMET version 3.1 image analysis software. 
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3.4. Results 
3.4.1. Inhibition of EGFR autophosphorylation 
Western blot analysis demonstrated that RB24 blocked EGF -induced EGFR 
autophosphorylation in A431 cens in a dose-dependent manner with an IC50 :::; 2 f.lM 
without affecting the levels of EGFR (Figure 3.1). RB24 is a degradable molecule 
capable of generating an extremely reactive iminium ion intermediate that may alkylate 
the receptor and irreversibly inhibit EGFR activity. To test this hypothesis, we used the 
reversibility assay previously described (Fry et al., 1998; Smaill et al., 2000) according 
to which the cens were treated with drug for 90 min and the culture medium repeatedly 
removed and replaced 3 times after treatment, after which EGFR autophosphorylation 
was measured. As expected, RB24 at 30 f.lM completely suppressed EGF-dependent 
EGFR autophosphorylation in A431 cens immediately after drug exposure (Figure 3.2a). 
However, at 8 h post-treatment fonowing repeated washouts in drug-free medium, 
EGFR autophosphorylation activity was completely inhibited in cens treated with RB24, 
indicating that the latter is capable of inducing irreversible inhibition of EGFR 
autophosphorylation. Similarly, irreversible inhibition was observed in cens exposed to 
the daughter molecules, RB 14 and ZR08, however with a 20% recovery of the total 
activity (Figure 3.2b). In contrast, the naked inhibitor, RBlO was shown to have 
completely reversible inhibition ofEGFR autophosphorylation (Figure 3.2a). 
3.4.2. Inhibition of EGFR-mediated signaling 
Antiproliferative activity induced by RB24 requires the translation of inhibition of 
EGFR autophosphorylation into inhibition of downstream signaling. To determine 
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Figure 3.1. Selective inhibition of EGFR autophosphorylation in intact cells by RB24. 
Serum starved A431 cells were pre-incubated for 2 h with the indicated concentrations 
of RB24 prior to stimulation with EGF for 15 min. Equal amount of cell lysates was 
analyzed by western blotting using anti-phosphotyrosine antibodies. Membranes were 
stripped of anti-phosphotyrosine and reprobed with anti-EGFR antibodies as a loading 
controL Band intensities were measured using the SynGene GeneTools software 
package. 
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Figure 3.2. Reverse EGFR autophosphorylation in the presence of RB24, RB 14, ZR08 
and RB lOin A431 cens. (A) Duplicate sets of cens were treated with 30 J..lM of 
designated compound to be tested as a reversible EGFR inhibitor for 90 min. One set of 
cens were then stimulated with EGF for 15 min, and extracts were made as described 
under the Western blotting procedure above. The other set of cens were washed free of 
the compound with serum-free media, incubated for 2 h, and further washed twice and 
incubated for 4 h. This set of cens was then stimulated with EGF, and extracts were 
made similar to the first set. (B) Comparison between the inhibition of 
autophosphorylation activity induced by RB24, RB14, ZR08 and RBI0. The film was 
scanned and band intensities were quantified using Syngene GeneTools software. 
Values are percentage of control of phosphotyrosine/EGFR. 
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Figure 3.3. Effect ofRB24 on Erk1,2 activation in A431 cells. Serum-starved cells were 
preincubated for 2 h with the indicated concentrations of RB24 prior to stimulation with 
EGF for 15 min. Protein lysates were obtained and Western blot was performed as 
described by Tari and Lopez-Berestein (2000). 
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whether blockade of EGFR autophosphorylation translates into inhibition of downstream 
signaling, we analyzed the effect of the parent compound, RB24, on EGF-induced 
phosphorylation of Erk1,2 and c-fos expression in A431 cells. The results showed that RB24 
induced complete inhibition of Erk1,2 phosphorylation at concentrations as low as 5 /lM 
without affecting the levels of Erk1,2 (Figure 3.3). Similarly, RT-PCR analysis showed that 
RB24 induced nearly 100% inhibition of EGF-mediated c-fos gene expression at low 
concentrations (l/lM) (Figure 3.4), indicating that inhibition of EGFR phosphorylation by 
RB24 is accompanied by a significant blockade ofEGFR-dependent downstream signaling. 
3.4.3. Quantitation of DNA damage 
Using the alkaline cornet assay, we demonstrated that like TEM (Matheson et al., 2001), 
RB24 and RB14 induced a dose-dependent DNA damage in A431 cells after a 30 min 
drug exposure (Figure 3.5). Interestingly, RB24 and RB14 induced identicallevels of 
DNA damage, which is in agreement with the fact that the former is a prodrug of the 
latter. As expected, the reversible inhibitor RB 1 0, did not demonstrate any DNA 
damaging activity. 
3.4.4. Irreversible growth inhibitory activity 
SRB assays demonstrated that RB24 and RB 14 retained significant antiproliferative 
activity after a short 2 h exposure and a 4 day recovery (Figure 3.6a,b). In contrast, the 
free inhibitor, RB 1 0, lost at least 95% of its activity under the same conditions (Figure 
3.6d). The monoalkyltriazene, ZR08, showed partially reversible activity with an 85% 
retention of activity following 2 h drug exposure (Figure 3.6c). In contrast to the 
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Figure 3.4. Effect of RB24 on c-fos gene expression in A431 cells. Serum-starved cells 
were preincubated for 2 h with the indicated concentrations of RB24 prior to stimulation 
with EGF for 30 min. Quantitative analysis of c-fos and GAPDH was preformed by RT-
PCR as described in "Materials and Methods". 
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Figure 3.5. Quantitation of DNA damage using the alkaline cornet assay. Tail moment 
was used as a parameter for the detection of DNA damage in A431 cells exposed to 
RB24, RBIO and RB14 for 30 min. Each point represents at least two independent 
experiments. 
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Figure 3.6. Irreversible growth inhibition for RB24, RB 14, ZR08, RB 1 0 and TEM in 
A431 cells. Cells were exposed to A) RB24, B) RB14 or C) ZR08 for 2,8, 12,24 or 48 
h following recovery for a total of 96 h. Cell growth was measured using SRB assay. 
Each point represents at least two independent experiments run in triplicate. 
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Figure 3.6. Irreversible growth inhibition for RB24, RB 14, ZR08, RB 1 0 and TEM in 
A431 cells. Cells were exposed to D) RBI0 or E) TEM for 2, 8, 12, 24 or 48 h 
following recovery for a total of 96 h. Cell growth was measured using SRB assay. Each 
point represents at least two independent experiments run in triplicate. 
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antiproliferative effects of RB24, increasing exposure time was associated with 
significant increase in potency for all other molecules of the degradation cascade (RB 14, 
ZR08, RBI0). Despite being a potent alkylating agent, the clinical triazene, TemodaITM, 
demonstrated no significant activity at any of the exposure times in the A431 cells 
(Figure 3.6e). In summary, the strength of the retention ofpotency was in the following 
order: RB24>RBI4>ZR08»RBI0. 
3.5. Discussion 
3.5.1. Mechanisms of EGFR TK inhibition 
The design of our combi-molecule, RB24, was based on the premlse that 
acetoxymethyltriazenes are known to be hydrolyzed to a hydroxymethyltriazene 
intermediate that rapidly degrades into the corresponding monoalkyltriazene (Hemens et 
al., 1984; Cameron et al., 1985; Hemens et al., 1986). The latter further heterolyzes to 
an aromatic amine + a DNA damaging species. In a recent publication (Banerjee et al., 
2003), we demonstrated that indeed RB24 was capable of generating the ultimate amino 
compound RBlO, in a symmetrically inversed relationship. As depicted in Scheme 3.1, 
decomposition through the intermediates, RB 14 and ZR08, is the sole mechanism by 
which RB24 can be converted to RBlO. Thus, the significant EGFR inhibitory potency 
of the putative intermediates RB 14, ZR08 and RB 1 0, indicates that RB24 would 
maintain its TK inhibitory potency throughout the multistep degradation cascade. More 
importantly, RB24 and its two progenitors (RB14, ZR08) induced irreversible inhibition 
of EGFR TK when tested alone, a protracted inhibition that may be rationalized in light 
of recent data on the mechanism of irreversible acrylamide-based inhibitors. It is now 
known that 4-anilinoquinazolines bearing a 6-acrylamido group react with the cysteine 
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773 of EGFR, thereby irreversibly blocking the receptor (Fry et al., 1998; Smaill et al., 
1999; Smaill et al., 2000). Based upon the mechanism of decomposition of RB24 
(Banerjee et al., 2003), we did not expect a direct reaction between the cysteine thiol 
group and the acetoxy moiety. Perhaps, if the iminium ion is formed in the active site of 
EGFR, it may react with the cysteine as depicted in Scheme 3.2. Addition of thiols 
group to the iminium ions of acetoxymethyltriazene have already been reported by Iley 
et al. (1991) who developed this type of triazenes as lyase inhibitors. Moreover, the 
ultimate triazene metabolite of RB24, ZR08, may also directly alkylate the cysteine 
residue. Quinazolinotriazenes of the same class, BJ2000 and SMA41 , have already been 
demonstrated to induce irreversible inhibition (Brahimi et al., 2002; Matheson et al., 
2003a; Matheson et al., 2003d). 
Although it was not the focus of this study to identify the site of alkylation of the 
receptor, the irreversible nature of TK inhibition by RB24, indicates that it may have 
inflicted covalent damage at a site of EGFR that is critical for its TK activity. In 
corroboration, RB 1 0 that does not possess a reactive triazene tail induced reversible 
EGFR TK inhibitory activity. 
3.5.2. DNA damage 
The iminium ion is a stable cation that may not be reactive enough to account for the 
strong DNA damaging potential of RB24. Despite the significant body of results that 
confirm its formation in the mechanism of hydrolysis of acetoxymethyltriazenes 
(Hemens et al., 1984; Hemens et al., 1986; Iley, 1987; Vaughan et al., 1988; Merrin et 
al., 1992), its implication in the DNA damaging properties of the latter class of 
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compounds is yet to be demonstrated. In contrast, it is now common knowledge that the 
methyldiazonium is capable of inducing significantly high levels of DNA alkylation 
particularly at N7 and 06 positions of guanine, thereby inducing DNA damage and 
lethal mutations in tumour cells (Bodell et al., 1985; Tisdale, 1987; Baer et al., 1993). 
The promutagenic 06-alkylguanine adduct is considered to be the primary cytotoxic 
lesion induced by triazenes. Cells like A431 that express high levels of AGT, a DNA 
, 
repair enzyme that repairs the 06-alkylguanine adduct, are known to be resistant to 
alkyltriazenes. In corroboration, the A431 cells used in the study were markedly 
insensitive to TemodaFM, a cyclic triazene known to release the methyldiazonium 
species upon hydrolysis (Cameron et al., 1985; Gibson et al., 1986; Baig et al., 1987). 
3.5.3. Irreversible growth inhibition 
The ability of RB24 to degrade into several species with significant EGFR inhibitory 
activities and to damage DNA, may perhaps be responsible for its sustained potency in 
A431 cells. More importantly, while its antiproliferative effect was maintained even 4 
days after a 2-h drug exposure, under the same conditions, ZR08 induced a partially 
reversible growth inhibitory activity. We have already reported similar results in A431 
cells for analogous quinazolinotriazenes (e.g SMA41 and BJ2000). Thus, the marked 
irreversibility of the action of RB24 may be partially imputed to additive 
antiproliferative contribution of species generated during the degradation steps that 
precede the formation of ZR08. This antiproliferative contribution may result from their 
ability to block EGFR-mediated growth signaling, since as previously mentioned, the 
transient iminium ion species generated during these degradation steps may not damage 
DNA. The partially reversible growth inhibitory potency of ZR08 (third step of the 
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(---. cascade) may perhaps be due to the dependence of its antiproliferative activity on the 
ultimately released reversible inhibitor RB 1 0, the concentrations of which might have 
been drastically depleted by multiple washouts. This indicates that the ultimate 
antiproliferative effect of ZR08 is mediated by a combination of DNA damage inflicted 
by the methyldiazonium species and EGFR-TK inhibitory activity induced by RB 1 O. 
A synergistic interaction between the strong EGFR TK inhibitory potency and the 
marked DNA damaging potential of RB24 may also partly account for its remarkable 
potency against the A43l cells. Indeed, blockade of EGFR in these cells was 
accompanied by potent inactivation of Erkl,2 kinase and inhibition of c-fos gene 
expression. We now know, based upon previous experiments, that blockade of EGFR-
mediated signaling may not affect the levels or function of the AGT enzymes. However, 
Yacoub et al. (2003) recently demonstrated that EGF up-regulates the DNA repair genes 
XRCCl and ERCCl in prostate ceIllines through Erkl,2 signaling. Thus, blockade of 
EGFR-mediated signaling may downregulate these DNA repair enzymes that are 
involved in the repair of DNA strand breaks, thereby exacerbating the cytotoxic effect of 
the latter lesions. 
ln conclusion, we have demonstrated that a molecule engineered to possess complex 
EGFR inhibitory properties and capable of further releasing DNA damaging species 
could induce significantly more sustained antiproliferative activity than a reversible 
inhibitor of the same class (e.g. RBlO). Moreover, its multiple properties have conferred 
antiproliferative activity in a cellline in which a classical methylating agent of the same 
class does not show any detectable activity. Thus this model may weIl represent a new 
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strategy to ameliorate the chemotherapy of EGF-dependent refractory tumours. Further 
studies are ongoing to demonstrate the potency ofthis novel drug in vivo. 
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3.8. Connecting text 
As described in Chapter 3, we have now demonstrated the irreversible mechanism of 
EGFR TK inhibition of the cascade re1ease combi-molecule, RB24. The latter agent was 
also capable of blocking EGFR-mediated activation of: 1) the MAPKs, Erk1,2 and 2) 
transcription of the early-response gene, c-fos. Furthermore, the potent blockade of 
EGFR TK activation and downstream signaling cascades translated into sustained 
antiproliferative activity for RB24 in an EGFR-overexpressing cell line. Having 
demonstrated the pronounced growth inhibitory activity of RB24, we wished to 
determine whether the EGFR recognition moiety of the combi-molecule could 
selectively target the entire molecule and assist in the selective delivery of DNA damage 
to EGFR or Her2-expressing cells. Therefore, in Chapter 4 we will examine the target 
selectivity ofRB24 in an isogenic panel ofbreast celllines transfected with the EGFR or 
Her2 gene. It should be noted that breast cancers are characterized by overexpression of 
the EGFR or Her2 gene and this is a negative prognostic factor. 
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CHAPTER4 
THE COMBI-TARGETING CONCEPT: SELECTIVE TARGE TING 
OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-
AND HER2-EXPRESSING BREAST CANCER CELLS BY THE 
COMPLEX COMBI-MOLECULE RB24 (NSC 741279) 
Ranjita Banerjeet, James P. McNamee2, and Bertrand J. Jean-Claudel 
eCancer Drug Research Laboratory, Department of Medicine, Division of Medical 
Oncology, McGill University Health CenterlRoyal Victoria Hospital, 687 Pine Avenue 
West, Rm. M 7.15, Montreal, Quebec, H3A lAI, Canada; 2Consumer and Clinical 
Radiation Protection Bureau, Health Canada, Ottawa, Ontario, KIA ICI, Canada) 
4.1. Abstract 
Overexpression of the EGFR and/or Her2 oncogene in breast cancer is associated with 
resistance to drug induced apoptosis and aggressive proliferation. Within the context of a 
new strategy termed "combi-targeting", we designed a novel molecule (RB24, NSC 
74129) to block EGFR and Her2 and to further degrade upon hydrolysis to another 
inhibitor termed RB 1 0 + a cytotoxic methyldiazonium species. Here we show that 
RB24, could block the growth of established celllines (MDA-MB-468, MDA-MB-453, 
MDA-MB-435) and selectively induce apoptosis in the EGFR and ErbB2-transfectants 
in an MDA-MB-435 isogenic panel of celllines. Experiments designed to elucidate the 
targeting mechanism of RB24 revealed that: (a) it was capable of releasing 2-3-fold 
higher levels of the free inhibitor, RB 1 0, in the transfectants than in their wild-type 
counterpart, (b) the released RB 1 0 was concentrated in the perinuc1ear region of the 
cells, and (c) the selective concentration of RB 1 0 in ErbB transfectants was concomitant 
with elevated levels of DNA damage in the latter cells. However, selective induction of 
DNA damage by RB24 was aboli shed by co-incubation of cells with exogenous RB10. 
Conversely, co-incubation with a non-fluorescent inhibitor JDA41 diffused the 
fluorescence from the perinuc1ear region, indicating that the entire combi-molecule may 
bind to its cognate site prior to degradation. These targeting events are accompanied by a 
dose-dependent depletion of EGFR and ErbB2 phosphorylation, down-regulation of the 
anti-apoptotic protein Bad and concomitant activation of JNK: three sets of cooperative 
events that account for selectively high levels of apoptosis induced in the transfectants. 
The results in toto suggest the following targeting model: the combi-molecule penetrate 
~ .. the cells and blocks the tyrosine kinase activity of EGFRlErbB2 and significantly binds 
to perinuc1ear located proteins from which they degrade to generate RBlO and the DNA 
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damaging methyldiazonium that may diffuse away from its cognate site towards the 
nucleus. 
Key words: EGFR, Her2, perinuclear localization, DNA damaging agent, JNK 
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4.2. Introduction 
Members of the Epidermal Growth Factor (EGF) family of receptors, including EGFR, 
Her2 (ErbB2) and EGFRvlII (truncated EGFR) are overexpressed in 20-40% of breast 
cancers (Tang et al., 2000; Koenders et al., 1991) The Her2 receptor, the closest EGFR 
homologue, is overexpressed in 20-25% of overall breast cancers, 60-70% of ductal 
carcinoma in situ (DCIS) and is often associated with highly aggressive tumour 
phenotypes and po or disease-free survival (Slamon et al., 1989; Arteaga, 2001). The 
average survival of breast cancer patients with Her2-positive tumors is 2-3 years when 
compared with 6-7 years of Her2-negative tumors (Slamon et al., 1987; Borg et al., 
1990). More importantly, this dysfunction is also associated with resistance to 
endocrine therapy and chemotherapy (Slamon et al., 1987). The significant implication 
of the ErbB family members in tumour progression has made them important targets for 
breast cancer therapy. lndeed, blockade ofEGFR or Her2 has proven highly effective in 
breast xenograft models and in the clinic (Ciardello et al., 1999; Moulder et al., 2001). 
Although gefitinib that targets the EGFR tyrosine kinase (TK) has shown moderate 
activity in breast cancer models, Herceptin, a monoclonal antibody directed towards 
Her2, has demonstrated significant activity in advanced breast carcinomas (Albain et al., 
2001; von Minckwitz et al., 2005; Tokunaga et al., 2006). Its effectiveness is such that 
it is now being evaluated for adjuvant breast cancer therapy. However, despite its 
significant potency against Her2-positive breast tumours, its efficacy in patients who 
express EGFRvlII with loss of PTEN function remain to be demonstrated. As a 
corollary to the great potency of Herceptin, strategies are now being developed to 
enhance its potency in breast tumours using combinations with cytotoxic DNA 
damaging drugs (Ciardello et al. 2006; Gasparini et al., 2006). Here we de scribe a 
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similar strategy based on the use of a small molecule approach to target Her2 TK-
mediated signaling pathways while damaging DNA. This strategy, termed "combi-
targeting", seeks to design a single molecule targeted to the TK function of Her2 and 
EGFR and programmed to be a latent DNA damaging agent (Matheson et al., 2001; 
Brahimi et al., 2002; Matheson et al., 2003a; Banerjee et al., 2003; Matheson et al., 
2003b; Rachid et al., 2003; Qiu et al., 2003; Matheson et al., 2004a; Matheson et al., 
2004b; Banerjee et al., 2004; Brahimi et al., 2004; Qiu et al., 2004). 
Activation of EGFR and Her2 leads to the recruitment of multiple adaptor proteins such 
as Grb2, followed by activation of the Ras-Raf-MAPK pathway that culminates into the 
expression of genes that regulate cellular growth and proliferation (McCubrey et al., 
2006). More importantly, activation of the latter receptors prevent apoptosis through 
induction of phosphorylation of the Phosphatidylinositol 3-kinase (PI3K) and its 
downstream target Akt, a sequence of events that leads to the inactivation of the pro-
apoptotic protein, Bad, a member of the Bc1-2 family of proteins (McCubrey et al., 
2006; Stauffer et al., 2005). On the other hand, cell exposure to cytotoxic agents is often 
associated with induction of apoptotic signaling through stress activated prote in kinases 
such as c-jun N-terminal kinase (JNK) that is known to interact with members of the 
Bc1-2 family (Ohtsuka et al., 2003; Huang et al., 2006). Based upon these mechanisms 
we surmise that molecules capable of inducing DNA damage while blocking receptor-
mediated signaling should induce significant leve1s of apoptosis and cell kill in breast 
cancer cells expressing these receptors. More importantly, the molecules being designed 
to penetrate the cell intact can bind to the ATP binding site of the TK domain prior to 
releasing their DNA damaging fragments, thereby targeting them to cells that 
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overexpress these receptors. Here we study the mechanism of action of one such 
molecule, RB24, which possesses the foIlowing properties: a) it has a half-life 
comparable with that of a clinical methylating agent, Temodal™ (TEM) (tll2=45 min in 
serum), b) it blocks EGFR TK activity both in enzyme and whole ceIl phosphorylation 
assays, and c) it has been shown to induce significant levels of DNA damage in tumour 
cells. This study sought to demonstrate its ability to selectively induce antiproliferative 
activity in breast cancer ceIls that express the target receptor and analyzes the 
mechanisms by which it selectively targets EGFR- or Her2-transfected ceIls. 
4.3. Materials and Methods 
4.3.1. Drug Treatment 
RB24, RBlO and JDA41 were synthesized in our laboratory according to known 
procedures (Banerjee et al., 2003). Temozolomide was provided by Shering-Plough Inc. 
(Kenilworth, NJ, USA). Gefitinib (ZD1839) was provided by AstraZeneca. In all 
assays, drug was disso1ved in DMSO and subsequently diluted in DMEM containing 
10% fetal bovine serum (FBS) (Wisent Inc. St-Bruno, Canada) immediately before the 
treatment of ceIl cultures. In aIl assays, the concentration of DMSO never exceeded 
0.2% (v/v). 
4.3.2. Cell Culture 
The ceIllines used in this study, the human breast carcinoma MDA-MB-435, MDA-
MB-435/EGFR (MDA-MB-435 ceIls stably transfected with the EGFR gene) and 
MDAMB435/ErbB2 (MDA-MB-435 ceIls stably transfected with the HER2 gene) were 
generous gifts from Dr. Moulay Aloui-Jamali of the Montreal Jewish General Hospital. 
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The human breast cancer cell lines, MDA-MB-468 and MDA-MB-453, were obtained 
from the American Type Culture Collection (Manas sas, V A). AlI MDA-MB-435 cells 
(transfected and non-transfected) were maintained in DMEM supplemented with 10% 
FBS. MDA-MB-468 and MDA-MB-453 cells were maintained in RPMI-1640 
supplemented with 10% FBS and antibiotics as described previously (Matheson et al., 
2001). AlI cells were maintained in an atmosphere of 5% CO2. 
4.3.3. Growth Inhibition Assay 
For non-stimulated cell growth inhibition, approximately 10 x 103 cells/well were plated 
in 96-well plates. After a 24 h incubation at 37°C in a humidified environment of 5% 
C02, cell monolayers were exposed to different concentrations of each drug continuously 
for 6 days and all growth inhibitory activities were evaluated using the sulforhodamine 
B (SRB) assay (Skehan et al., 1990). Briefly, following drug treatment, cells were fixed 
using 50 /lI of co Id trichloroacetic acid (50%) for 60 min at 4°C, washed four times with 
tap water, and stained for 30 min at room temperature with SRB (0.4%) dissolved in 
acetic acid (0.5%). The plates were rinsed five times with 1% acetic acid and allowed to 
air dry. The resulting colored residue was dissolved in 200 /lI of Tris base (10 mM), and 
optical density was read for each well at 540 nm using a Bio-Rad microplate reader 
(mode! 2550). Each point represents the average of at least two independent experiments 
run in triplicate. 
4.3.4. Autophosphorylation Assay 
4.3.4.1. EGFR or ErbB2 activation 
MDA-MB-435/EGFR or MDA-MB-435/ErbB2 cells (1 X 106) were plated in six-
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weIl plates with 10% serum at 37°C for 24 h and starved ovemight for 24 h, after which 
they were exposed to a range of drug for 2 h and subsequently treated for 15 min with 
50 ng/ml EGF or SOng/ml of HRGa, respectively. Cells were washed with PBS and 
resuspended in co Id lysis buffer [50 mM Tris-HCL PH 7.5; 150 mM NaCI; 1 % Nonidet 
P-40, 1mM EDTA; 5 mM NaF; 1mM Na3V04; protease inhibitor tablet (Roche 
Biochemicals, Laval, Canada)]. The lysates were kept on ice for 30 min and collected by 
centrifugation at 10,000 rpm for 20 min at 4°C. The concentrations of protein were 
determined using the Bio-Rad protein assay Kit (Bio-Rad laboratories, Hercules, CA). 
Equal amounts of protein were added to an 10 % SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride membrane 
(Millipore, Bedford, MA). Non-specifie binding on the membranes were minimized with 
a blocking buffer containing nonfat dry milk (5%) in PBST. Thereafter, the membranes 
were incubated with primary anti-phosphotyrosine antibody (Upstate Biotechnology, 
Lake Placid, NY) for the detection of phosphotyrosine. Membranes were stripped and 
re-probed with anti-EGFR (Neomarkers, Fremont, CA) or anti-ErbB2 (Upstate 
Biotechnology, Lake Placid, NY) for determination of corresponding receptor levels. 
Blots were incubated with HRP-goat anti-mouse antibody (1: 1000 dilution; Cell 
signaling research, Beverly, MA) and the bands visualized with an enhanced 
chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, UK) 
(Matheson et al., 2001). 
4.3.4.2. Bad activation 
Inhibition of Bad activation was determined by exposing serum-starved MDA-
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MB-435/EGFR or MDA-MB-435/ErbB2 cens for 2 h with the indicated concentrations 
of RB24 or TEM prior to stimulation with EGF (50ng/ml) or HRGa (50ng/ml), 
respectively. Equal amounts of celllysates were analyzed by Western blot using anti-
phosphoBad (Ser136) antibodies (Cell Signaling Tech., Danvers, MA). Membranes were 
stripped of antibody and reprobed with anti-Bad antibodies (Cell Signaling Tech., 
Danvers, MA). 
4.3.4.3. JNK activation 
Activation of JNK was determined by exposing MDA-MB-435/ErbB2 cens for 4 
h with the indicated concentrations of RB24 or TEM. Equal amounts of cell lysates 
were analyzed by Western blot using anti-phosphoJNK (ThrI83/Tyr185) and anti-JNK 
antibodies (Cell Signaling Tech., Danvers, MA). 
4.3.5. UV Flow Cytometric Analysis of Intracellular Fluorescence 
MDA-MB-435, MDA-MB-435/EGFR and MDA-MB-435/ErbB2 cells were seeded in 
DMEM with 10% FBS for 24 h and grown in six-well plates (1 x 106 /well). cens were 
then treated with varying concentrations of RB24 and 10% FBS at 37°C for 2 h. 
Thereafter, cells were harvested with trypsin-EDTA, subsequently collected by 
centrifugation and resuspended in PBS. Fluorescence levels were measured using the 
BD LSR flow cytometer (Becton Dickinson, Oakville, ON, Canada). 
4.3.6. Fluorescence Microscopy Imaging for Intracellular Release of the Amine 
MDA-MB-435, MDA-MB-435/EGFR and MDA-MB-435/ErbB2 cells were seeded in 
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DMEM with 10% FBS for 24 h and grown in six-weIl plates (1 x 106/weIl). Cells were 
then treated with varying concentrations of RB24 alone or in combination with the non-
fluorescent EGFR TK inhibitor, JDA41 (40f..lM) and 10% FBS at 37°C for 2 h and media 
was replaced for drug-free media in each weIl. Thereafter, plates were analyzed using a 
Zeiss LSM 510 confocal microscope and cells were excited at 405nm and emission was 
at250nm. 
4.3.7. Alkaline Cornet Assay for Quantitation ofDNA Damage 
The alkaline cornet assay was performed as previously described (Matheson et al., 
2001). The cells were exposed to drugs (RB24, RBlO, TEM or RB24+RBlO) for 2 h, 
harvested with trypsin-EDTA, subsequently collected by centrifugation and resuspended 
.~. in PBS. Cell suspensions were diluted to approximately 106 ceIls, and mixed with 
agarose (1%) in PBS at 37°C in a 1:10 dilution. The gels were cast on Gelbond strips 
(Mandel Scientific, Guelph, Canada) using gel casting chambers, as previously 
described (McNamee et al., 2000), and then immediately placed into a lysis buffer [2.5 
M NaCI, 0.1 M tetra-sodium EDTA, 10 mM Tris-base, 1 % (w/v) N-Iauryl sarcosine, 
10% (v/v) DMSO, and 1% (v/v) Triton X-100, pH 10.0]. After being kept on ice for 30 
min, the gels were gently rinsed with distilled water and immersed in a second lysis 
buffer (2.5 M NaCI, 0.1 M tetrasodium EDTA, 10 mM Tris-base) containing 1mglml 
proteinase K for 60 min at 37°C. Thereafter, the gels were rinsed with distilled water, 
incubated in alkaline electrophoresis buffer for 30 min at 37°C, and electrophoresed at 
300 mA for 60 min. The gels were subsequently rinsed with distilled water and placed in 
1 M ammonium acetate for 30 min. Thereafter, they were soaked in 100% ethanol for 2 
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h, dried overnight, and stained with SYBR Gold (1/10, 000 dilution of stock supplied 
from Molecular Probes, Eugene, OR) for 20 min. Cornets were visualized at 330x 
magnification and DNA damage was quantitated using the Tail Moment parameter (i.e., 
the distance between the barycenter of the head and the tail of the cornet multiplied by 
the percentage of DNA within the tail of the cornet). A minimum of 50 cell cornets were 
analyzed for each sample, using ALKOMET version 3.1 image analysis software. 
Statistical significance was determined using the one-tailed Student t-test. 
4.3.8. Annexin V Binding 
Cells were grown in 6-well plates until confluence and then incubated with the 
compounds for 24 h. The cells were then harvested, washed twice with PBS, and 
centrifuged. Cells (105) were treated with annexin V-FITC and propidium iodide (PI) 
using the apoptosis Detection Kit (BD Bioscience Pharmingen, San Jose, CA) and the 
supplier's protocol. Annexin V-FITC and PI binding were analyzed by flow cytometry. 
Data were collected using logarithmic amplification of both the FL1 (FITC) and FL2 
(PI) channels. Quadrant analysis of co-ordinate dot plots was performed with CellQuest 
software. Unstained cells were used to adjust the photomultiplier voltage and for 
compensation setting adjustment in order to eliminate spectral overlap between the FL 1 
and FL2 signaIs. Statistical significance was determined using the Student t-test. 
4.4. Results 
4.4.1. Antiproliferative activity of RB24, RBIO, gefinitib and TEM 
The combi-molecule, RB24, is designed to hydrolyze into various derivatives that inhibit 
EGFR TK activation, the most stable metabolite being RB 1 O. As previously 
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demonstrated, at the last stage of the decomposition pathway, concomitantly with the 
release of RBI0, a methyldiazonium is formed that damages DNA (Banerjee et al., 
2003). In a similar fashion, TEM is also hydrolyzed in a stepwise manner to release the 
latter species that methylates DNA. However, its transient metabolites, 5-(3-
methyltriazen-l-yl)imidazole-4-carboxamide (MTIC) and hydroxymetabolite, do not 
have any biological target and we have already demonstrated that TEM is deprived of 
EGFR inhibitory activity (Matheson et al., 2001). Therefore, TEM represents an 
appropriate comparison for our combi-molecule as it can only damage DNA but not 
block EGFR activation. On the other hand, gefitinib, a clinical EGFR TK inhibitor that 
does not have any DNA damaging potential was used as an appropriate mechanistic 
control for this study. Thus, we first examined the antiproliferative activities of aIl these 
compounds, including the expected degradation product for RB24, RBI0, in a panel of 
breast cancer cells and focused the mechanistic studies in a subset of isogenic breast 
cancer ceIls, MDA-MB-435, and its ErbB transfectants, MDA-MB-435/EGFR, MDA-
MB-435/ErbB2. The results showed that RB24 is selectively more potent in breast 
cancer cells overexpressing EGFR or Her2, with ICso values ranging from 0.8/-lM-
2.5/-lM and 7/-lM for the wild-type (Table 4.1). Evidence of this selectivity was 
strengthened by the response of the isogenic ceIlline panel to the various drugs. Indeed, 
RBI0 and gefitinib selectively targeted the EGFR and Her2 transfectants with ICso 
values ranging from 9-21/-lM (Table 4.1). Interestingly, RB24 was 8-13 fold more 
potent against the transfectants than its EGFR inhibitory counterparts RB 1 0 and 
gefitinib. Inversely, TEM selectivity targeted the non-transfected wild-type breast 
cancer ceIls, MDA-MB-435 (ICso=18/-lM) and was found to be inactive in the ErbB 
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Table 4.1. Antiproliferative effects ofRB24, RBI0, gefitinib and TEM in the isogenic breast carcinoma panel, MDA-MB-435, MDA-
MB-435/EGFR and MDA-MB-435/ErbB2. 
Compounds MDA-MB-435 MDA-MB-435/EGFR Fold selectivity MDA-MB-435/ErbB2 F old -selectivity 
~IC50, J..1M)* ~ICso, J..1M) * forEGFR Q.Cso, J..1M)* for ErbB2 
RB24 7 +2.4 1 + 0.4 7 0.8 ± 0.2 8.8 
RBI0 41 ± 2.1 9±1.4 4.5 14 + 1.3 3 
TEM 18 ± 1.3 >50 > 100 
Gefitinib 48 + 1.9 11 + 2.1 4.4 21 + 1.8 2.4 
* Values are means ofIC5o values and SEMsfrom three experiments. 
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Table 4.2. Antiproliferative effects ofRB24, RB 10, gefitinib and TEM in ErbB-negative cellline, MDA-MB-435, and the ErbB-
expressing celllines, MDA-MB-468 and MDA-MB-453. 
Compounds MDA-MB-435 MDA-MB-468 Fold selectivity MDA-MB-453 Fold-
~IC5o, JlM)* ~IC5o, J.LM} * ~IC5o, J.LM}* selectivity 
RB24 7±2.4 2.5 ± 0.2 2.8 1.3 ± 0.5 4.1 
RBI0 41 ± 2.1 22.2 ± 1.6 1.8 18.3 ± 1.1 2.2 
TEM 18 ± 1.3 >100 >100 
Gefitinib 48 + 1.9 18.4 + 1.8 2.6 ND 
* Values are means ofIC5o values and SEMsfrom three experiments. 
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transfectants (ICso>50J..tM). It was more than 50-fold less potent than RB24 (Table 4.1). 
4.4.2. Mechanism of target selectivity of the combi-molecule 
The combi-molecules being designed to target both EGFR and DNA, various factors 
such as DNA repair enzymes and non-specifie binding, may affect their potency in 
established cell lines. Therefore, we chose to pursue our studies on the mechanism of 
target selectivity of the combi-molecule in the isogenic cellline panel, MDA-MB-435, 
MDA-MB-435/EGFR and MDA-MB-435/ErbB2 that do not express AGT, a DNA 
repair protein known to mitigate cellular response to the DNA lesions induced by TEM 
or the combi-molecules (Fomace et al., 1990; Pegg et al., 1995; Matheson et al., 2003b). 
First, cornet assay analysis was performed to determine the extent of DNA damage in 
the isogenic cell panel. The results showed that RB24 induced significantly higher 
levels ofDNA damage in the ErbB transfectants (EGFR, ErbB2) than in the wild-type 
(p<0.05) (Fig. 4.1 b). By contrast, TEM did not exhibit any selectivity for the 
transfectants, with equallevels of DNA damage in all three celllines (Fig. 4.1c). More 
importantly, RB24 was a 3.1 and 1.9-fold more potent DNA damaging agent than TEM 
in MDA-MB-435/EGFR and MDA-MB-435/ErbB2, respectively. 
The ability of our compound to induce superior levels of DNA damage than TEM in the 
cells and further, to selectively damage cells expressing EGFR and ErbB2, stimulated 
our interest in determining the mechanism underlying this selectivity. Having found that 
the released inhibitor RB 1 0 was fluorescent, we undertook a fluorescence microscopy 
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Figure 4.1. Effects of RB24, RB 1 0 or TEM on levels of DNA damage in the isogenic 
MDA-MB-435 cell line panel. MDA-MB-435, MDA-MB-435/EGFR and MDA-MB-
435/ErbB2 cells were preincubated for 2 h with A) RBI0 B) RB24 or C) TEM and 
levels of DNA damage were quantitated using the alkaline cornet assay. Tail moment 
(i.e., the distance between the barycenter of the head and the tail of the cornet multiplied 
by the percentage of DNA within the tail of the cornet) was used as a parameter for the 
detection of DNA damage in cells exposed to RB24, RBlO or TEM. * p-value < 0.05. 
Points, mean percentage ofuntreated cells (n=3); bars, SD. 
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analysis to observe its subcellular localization following exposure to RB24. The results 
showed that intracellular levels of RB 1 0 released by RB24 degradation were 
concentrated in the perinuclear region and interestingly, the fluorescence intensity was 
higher in the ErbB transfectants then in the wildtype (Fig. 4.2). This result was further 
confirmed by UV flow cytometric quantitation that showed significant difference (2-3 
fold) between the wildtype and the transfectants (Fig. 4.3). This is in agreement with the 
previous results showing higher levels of DNA damage in the transfectants. Thus, these 
results lead to the hypothesis that the enhanced DNA damage inflicted by RB24 may be 
due to a bystander effect, whereby RB24 anchors in its cognate sites in the perinuclear 
region from which the methyldiazonium is released (Fig. 4.4). To test this hypothesis, 
we designed a competitive experiment whereby RB 1 0 was given in combination with 
RB24 to prevent the interactions of the latter with its binding sites. 
In theory, if binding of RB24 to its cognate sites around the nucleus played a bystander 
effect, we would expect competitive binding of RB 1 0 to deplete the levels of DNA 
damage induced by RB24. Indeed, as depicted in Figure 4.5, combined treatment with 
RB 1 0 + RB24 significantly depleted the levels of DNA damage induced by RB24 in an 
MDA-MB-435 cens. More importantly, the difference was significantly enhanced in 
the cells expressing Her2 or EGFR, indicating that the latter receptors significantly 
contribute to the enhanced DNA damage observed with RB24. It should also be noted 
here that the levels of DNA damage induced by the combination of RB 1 0 + RB24 were 
similar to that of TEM and more interestingly, selectivity for the ErbB transfectants was 
completely abolished (Fig. 4.5a). This is further corroborated by the depletion 
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Figure 4.2. Intemalization of RB24 in MDA-MB-435 and MDA-MB-435/ErbB2 cells. Localization of the compound was 
determined by fluorescence microscopy. RB24 (25 /-lM) was given for 2 h prior to observation (400x magnification). 
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Figure 4.3. UV flow cytometric analysis of intracellular levels of RB 1 0 released by 
RB24 in the isogenic MDA-MB-435 cell line panel. MDA-MB-435, MDA-MB-
435/EGFR and MDA-MB-435/ErbB2 cells were treated with a dose range ofRB24 for 2 
h prior to analysis with the BD LSR flow cytometer. Columns, mean percentage of 
untreated cells (n=2); bars, SD. 
168 
Targeted 
EGFR 
Internall,~allOIm. 
I-TZ 
I-TZ 
Target perinuclear 
proteins 
No Target I-TZ 
I-TZ 
I-TZ I-TZ 
I-TZ 
Fig. 4.4. Schematic representation of the intracellular distribution of the combi-molecule 
RB24 (I-TZ) in ErbB-expressing or ErbB-null cells. 
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and delocalization of the fluorescence associated with RB24 upon co-incubation with 
JDA41 (a non fluorescent inhibitor of EGFR with ICso competitive binding within the 
same range as RB24) (Fig. 4.5b). 
4.4.3. Mechanism of selective cell-killing 
While it was obvious that RB24 could induce substantially higher levels of DNA 
damage than TEM in these cells, the translation of the latter effect into cell killing 
remained to be elucidated. Thus, the levels of JNK phosphorylation, a signaling protein 
known to be activated by DNA damage and to be involved in promoting apoptosis, were 
analyzed (Huang et al., 1999, Ohtsuka et al., 2003). The results showed that JNK was 
activated at concentrations of RB24 that induced significant DNA damage (25-100J.!M) 
(Fig. 4.6a). Conversely, at the Same concentrations, TEM did not induce significant 
DNA damage and no JNK activation was apparent. To further as certain the correlation 
between DNA damage and JNK activation, we repeated the analysis of TEM at doses at 
which equi-Ievels of DNA damage were induced (e.g. 200, 400J.!M) (Fig. 4.6a,b). 
Interestingly, like in RB24 treated cells, JNK activation was detected for TEM at its 
DNA damaging doses. Further, the pro-apoptotic role of JNK in these cells was 
corroborated by analysis of levels of apoptosis induced in the presence of its potent 
inhibitor SP600125. Indeed, Annexin V flow cytometric analysis showed that 
SP600125 reduced levels of apoptosis in cells treated with RB24 and TEM by ca 33-
35% (Fig. 4.6b). 
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Figure 4.5. Displacement ofRB24 with RBI0 and levels ofDNA strand breaks induced 
in MDA-MB-435, MDA-MB-435/EGFR or MDA-MB-435/ErbB2 cells. A) MDA-MB-
435, MDA-MB-435/EGFR and MDA-MB-435/ErbB2 cells were preincubated for 2 h 
with a dose range of RB24 in combination with RBI0 (40~M) and levels of DNA 
damage were quantitated using the alkaline cornet assay. Tail moment (i.e., the distance 
between the barycenter of the head and the tail of the cornet multiplied by the percentage 
of DNA within the tail of the cornet) was used as a parameter for the detection of DNA 
damage in cells exposed to RB24, RB 1 0 or TEM. Points, mean percentage of untreated 
cells (n=2); bars, SD. 
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(B) 
Figure 4.5. Displacement of RB24 with RB 1 0 and levels of DNA strand breaks induced 
in MDA-MB-435, MDA-MB-435/EGFR or MDA-MB-435/ErbB2 cells. B) lntracellular 
localization of RB24 in MDA-MB-435/ErbB2 cells exposed to either RB24 alone 
(25)lM) or in combination with the non-fluorescent EGFR inhibitor, JDA41 (40)lM) for 
2 h (400x magnification). 
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Figure 4.6. Effects of RB24, RB 1 0 or TEM on activation of the stress activated protein 
kinases, JNK1, 2 and apoptosis. A) JNK activation in MDA-MB-435/ErbB2 cens 
exposed to a dose range of RB24 or TEM for 4 h. B) Quantitation of phosphorylated 
JNK levels in MDA-MB-435/ErbB2 cens exposed to RB24 or TEM. Equal amount of 
cenlysate was analyzed by Western blot and probed for anti-phosphoJNK or anti-JNK 
antibodies. C) Annexin V analysis of MDA-MB-435/ErbB2 cens treated with dose 
range ofRB24 or TEM alone or in combination of the JNK inhibitor, SP600125. Levels 
of apoptotic cens were determined using Annexin V-FITC staining. * p-value < 0.05. 
Co/umns, mean percentage of Annexin-V-negative cens (n=4); bars, SD. 
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Figure 4.7. Selective inhibition of ErbB receptor activation in both MDA-MB-
435/EGFR and MDA-MB-435/ErbB2 cells. Serum-starved A) MDA-MB-435/EGFR or 
B) MDA-MB-435/ErbB2 cells exposed to the indicated concentrations of RB24 for 2 h 
and subsequently stimulated with EGF (25ng/ml) or HRGa (50ng/ml), respectively. 
Equal amount of cell lysate was analyzed by Western blotting using anti-
phosphotyrosine, anti-EGFR and anti-ErbB2 antibodies. Band intensities were measured 
using the SynGene GeneTools software package. 
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It is now known that inactivation of apoptosis is well regulated by EGFR- or ErbB2-
mediated signaling and that JNK activation promotes apoptosis in response to DNA 
damage. Therefore, we surmise that the lack of sensitivity of the ErbB transfectant cells 
to TEM may be mediated by EGFR or ErbB2. Thus, we analyzed the activation of these 
signaling pathways in response to RB24 and TEM. Activation ofEGFR (Fig. 4.7a) and 
ErbB2 (Fig. 4.7b) correlated with Bad phosphorylation in the transfectants. However, 
treatment with RB24 led to a dose-dependent inhibition of both EGFRlErbB2 and Bad 
phosphorylation in these cells, indicating an alleviation of the anti-apoptotic effects of 
ErbB receptors (Fig. 4.7a,b, Fig. 4.8a,b). In contrast, TEM was incapable of depleting 
levels of Bad phosphorylation at a concentration as high as 50J..lM, which is in agreement 
with its inability to induce neither JNK nor to block EGFR TK mediated signaling (Fig. 
4.7c,d). 
We further determined whether the ability of the combi-molecule to selectivity block 
signaling and damage DNA would translate into ErbB selective apoptosis. Interestingly, 
RB24 induced approximately 2-fold higher level of apoptosis in the ErbB transfectants 
than in the wild-type (58-73% 24 h after treatment) (Fig. 4.9). Inversely, TEM was 
only capable of inducing significant levels of apoptosis in the wild-type cells (Fig. 
4.9). RB 1 0, an inhibitor of EGFR, induced moderate levels of apoptosis in the ErbB-
expressing cells (25-30%) (Fig. 4.9c). 
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Figure 4.8. Assessment of inhibitory activity on Bad activation by RB24. Levels of 
Bad phosphorylation at Ser136 were examined in serum-starved A) MDA-MB-
435/ErbB2 or B) MDA-MB-435/EGFR cells that were preincubated for 2 h with the 
indicated concentrations of RB24 prior to stimulation with EGF (25ng/ml) or HGRa 
(50ng/ml), respectively. 
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Figure 4.8. Assessment of inhibitory activity on Bad activation by TEM. Serum-starved 
C) MDA-MB-435/ErbB2 or D)MDA-MB-435/EGFR cells were exposed to a dose range 
of TEM for 2h prior to EGF (25ng/ml) or HRGa (50ng/ml) stimulation, respectively. 
Equal amounts of cell lysates were analyzed by Western blot using anti-phosphoBad 
(Ser 136) or anti-Bad antibodies. 
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Figure 4.9. Assessment of apoptotic effects induced by RB24, RBlO and TEM. A) 
MDA-MB-435, B) MDA-MB-435/EGFR and C) MDA-MB-435/ErbB2 cens were 
treated with a dose range of RB24, TEM or RB 1 0 for 24 h. Levels of apoptotic cens 
were determined using Annexin V -FITC staining. Columns, mean percentage of 
Annexin-V-negative cens (n=3); bars, SD. 
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4.5. Discussion 
Alkylating agents are among the most potent cytotoxic drugs used in the clinic for the 
therapy of many solid tumours including breast and lung carcinomas (Evans, 2005; 
Trudeau et al., 2005). However the potency of these compounds is often mitigated by 
resistance associated with the expression ofDNA repair proteins (Garcia-Campelo et al., 
2005). Furthermore, their lack of selectivity for tumour tissues has become a major 
deterrent in their use for the therapy of solid tumours. This study was designed to 
analyze the selective potency of a novel class of combi-molecules carrying a 
methylating species. In this model, EGFR and ErbB2 transfection significantly reduced 
cell sensitivity to TEM, which is not targeted to the aforementioned receptors. 
Inversely, EGFR and ErbB2 transfection enhanced the potency of RB24, a methylating 
triazene of the same class as TEM. Thus, we hypothesize that selective and enhanced 
potency of RB24 against the transfectants is based upon mechanisms related to receptor 
targeting and cell signaling. 
The first significant observation of this study was the differential cytotoxicity and DNA 
damage induction produced by the combi-molecule in the isogenic panel. In contrast to 
TEM, levels of DNA damage induced by RB24 appeared to correlate with receptor 
levels. Correlation of DNA damage with levels of receptors suggests that their 
mechanism of intracellular distribution may differ from that of TEM. Based upon our 
results, it appears that the combi-molecule may enter the cells by passive diffusion as 
previously described for other combi-molecules (Matheson et al., 2001; Banerjee et al., 
2003; Qiu et al., 2003) and bind to its cognate sites (e.g. nascent or intemalized EGFR 
proteins or related proteins) located in the ER (Murthy et al., 1986; Offterdinger et al., 
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f 2004; Khan et al., 2006). The loss of selective delivery of DNA alkylation upon 
competitive binding with other EGFR inhibitors indicates that the entire combi-molecule 
may bind to the perinuclear region prior to degradation and release of the 
methyldiazonium ion. This model is further supported by: a) the low levels of DNA 
damage induced by RB24 in the wild-type cells line when compared with the transfected 
counterparts and b) the lower levels of DNA damage induced by TEM, a non-EGFR 
targeting molecule (Matheson et al., 2001), in all the celllines. It is also important to 
mention herein that RB24 induced slightly higher levels of DNA damage than TEM in 
wild-type cellline which may be due to unspecific binding. 
In order to elucidate the contribution of the high levels of DNA damage to cell killing, 
we examined various pathways related to the receptor and in response to DNA 
alkylation. On one hand, it is known that EGFR and ErbB2 exert anti-apoptotic effects 
through the PI3K1Akt signaling cascade, that ultimately leads to the inhibition of 
mitochondrial pore formation via Bax oligomerization (McCubrey et al., 2006). On the 
other hand, pro-apoptotic effects in response to DNA damage is mediated by the stress 
activated protein kinase, JNK (Huang et al., 1999, Ohtsuka et al., 2003). Thus, we 
analyzed key elements of these pathways (e.g. Bad and JNK activation) in the 
transfectants. Bad being downstream of EGFR or Her2 activation, its observed 
inactivation by the combi-molecule is an evidence that inhibiting the receptors alleviates 
their anti-apoptotic effects. Activation of JNK in response to DNA damage is pro-
apoptotic, therefore receptor inactivation and induction of DNA lesions are two 
cooperative events that can contribute to enhanced apoptosis. More importantly, the fact 
that activation of JNK was only seen at doses that correspond to significant levels of 
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DNA damage by both RB24 and TEM provides a direct link between levels of DNA 
damage and apoptosis in these cells. Indeed, substantially higher levels of apoptosis 
were observed in the transfectants when compared with their wild-type counterpart. 
In summary, the results presented herein can allow us to propose a model for selective 
targeting and cell killing of breast cancer cells expressing ErbB receptors by the combi-
molecular concept. As depicted in Figure 4.4, binding of a fraction of the combi-
molecules to the TK domain of the receptors at the membrane induces blockade of 
downstream signaling including the anti-apoptotic PI3K1Akt pathway. Following 
internalization, binding of a large fraction of the combi-molecules to EGFR in the 
perinuclear region plays a bystander effect that localizes the alkylating species to the 
nucleus. The elevated levels of DNA damage induced by the combi-molecule, enhances 
apoptosis through activation of JNK and other alternative pathways associated with the 
anti-apoptotic effect ofEGFRlHer2 receptor-mediated signaling. 
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4.8. Connecting text 
In Chapter 4, we investigated the mechanism underlying the selective potency of the 
cascade release combi-molecule, RB24, in an isogenic panel of breast cancer cell lines. 
We demonstrated therein, that the selectivity of RB24 is based upon its ability to induce 
enhanced DNA damage in cells transfected with EGFR or Her2. More importantly, 
enhanced DNA damage correlated with activation of the stress activated protein kinase, 
JNK, and blockade of EGFR with down-regulation of Bad-mediated anti-apoptotic 
signaling. This stimulated our interest in identifying cross-talk between signaling 
pathways that would converge to synergistic cell killing by the combi-molecule. To this 
end, we chose a cellular model wherein growth factor receptor activation correlated with 
expression of DNA repair proteins. The DU145 prostate carcinoma cells have been 
shown to express increased levels of the BER prote in, XRCC l, upon EGFR activation 
and this cell line is also known to exhibit robust resistance to methylating agents of the 
same c1ass as RB24. Thus, the following chapter is a detailed analysis of the cell 
signaling pathways and cross-talk in response to the binary stress (e.g. DNA damage, 
blockade ofEGFR) inflicted to the cells by the combi-molecule, RB24. 
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CHAPTER5 
THE COMBI-TARGETING CONCEPT: MECHANISM OF ACTION 
OF THE PLEIOTROPIC COMBI-MOLECULE RB24 (NSC 741279) 
AND DISCOVERY OF A NOVEL CELL SIGNALING-BASED 
COMBINATION PRINCIPLE 
Ranjita Banerjeel, Qiyu Qiul, James P. McNamee2 and Bertrand J. Jean-Claudel 
eCancer Drug Research Laboratory, Department of Medicine, Division of Medical 
Oncology, McGill University Health Center/Royal Victoria Hospital, 687 Pine Avenue 
West, Rm. M 7.15 Montreal, Quebec, H3A lAI Canada; 2Consumer and Clinical 
Radiation Protection Bureau, Health Canada, Ottawa, Ontario, Canada) 
5.1. Abstract 
RB24 (NSC 741279), a 3-methyltriazene termed "combi-molecule" designed to possess 
mixed epidermal growth factor receptor (EGFR) targeting and DNA methylating 
properties showed over 100-fold greater antiproliferative activity than Temodal® (TEM), 
4-fold greater potency than gefitinib and 5-fold stronger activity than an equi-effective 
combination of gefitinib+ TEM against the 0 6 -alkylguanine transferase (AGT)-proficient 
DU145 cell line that co-expresses EGFR. Investigation of the mechanisms underlying 
the unique potency of RB24 revealed that cell exposure to TEM was accompanied by 
activation of p38MAPK and concomitant elevation of the levels of X-ray repair cross-
complementing (XRCC1) protein. Levels of phospho-p38MAPK and XRCC1 were 
increased by 2-fold in EGF-stimulated cells. In contrast, EGF-stimulation did not alter 
the status of these proteins in RB24-treated cells and this translated into a 2-fold lower 
level of XRCC 1 when compared with those exposed to TEM + EGF. These effects 
correlated with significantly delayed DNA repair activity in combi-molecule-treated 
cells when compared with TEM-exposed ones. Further analysis demonstrated that in 
contrast to TEM, RB24 could block Bad phosphorylation at serine 136 in a dose-
dependent manner and induced significantly higher levels of apoptosis than the latter 
molecule. Tandem depletion of XRCC 1 and Bad activation through alternative pathways 
using the MEK1 inhibitor, PD98059, led to substantial levels of apoptosis in RB24-
treated cells. The results in toto indicate that the superior activity of the combi-molecule 
may be attributed to its ability to down-regulate DNA repair proteins such as XRCC1 
and to alleviate anti-apoptotic signaling through blockade of EGFR-mediated signaling 
while inflicting high levels of DNA lesions to the cells. 
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5.2. Introduction 
Binding of growth factors to their cognate receptor is associated with the activation of 
signaling cascades that ultimately translate into genes associated with cell proliferation 
(Modjtahedi and Dean, 1994; Moyer et al., 1997; Ciardello and De Vita, 2005). 
Tumours in which certain growth factors, such as the epidermal growth factor receptor 
(EGFR) or its closest homologue Her2 are overexpressed, show aggressive growth and 
reduced sensitivity to chemotherapeutic drugs (Slamon, 1989; Tanner et al., 1996; Yen 
et al., 1999; Hengstler et al., 1999). Recent strategies directed at blocking pathways 
activated by these receptors led to inhibition of tumour growth in vivo and gefitinib 
(ZD1839, Iressa™) is the first inhibitor of EGFR tyrosine kinase (TK) that exhibited 
antitumour activity in the clinic (Magne et al., 2002; Ranson et al., 2002; Sgambato et 
al., 2004; Bellezza et al., 2006). However, despite the significant attention given to 
EGFR-mediated signaling, little emphasis was placed on developing agents that target 
other pathways that could synergize with down-regulation of genes associated with 
depletion of EGFR autophosphorylation. Recently, within the framework of a novel 
tumour targeting strategy termed "Combi -T argeting", our laboratory has developed a 
novel class of pleiotropic inhibitors capable of not only blocking EGFR-mediated 
signaling but also inducing DNA damage, a type of insult known to subvert multiple 
signaling pathways in the ceIl, including apoptosis, stress response and cell cycle 
perturbation (Matheson et al., 2001; Brahimi et al., 2002; Matheson et al., 2003a; 
Banerjee et al., 2003; Matheson et al., 2003b; Rachid et al., 2003; Qiu et al., 2003; 
Matheson et al., 2004a; Matheson et al., 2004b; Banerjee et al., 2004; Qiu et al., 2004). 
As outlined in Figure 5.1, the combi-targeting principle is based on the premise that a 
combi-molecule 1-TZ (wherein TZ represents the alkylating function and 1 the EGFR 
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recognition moiety) will penetrate the cell by passive diffusion and bind to the ATP-
binding site of EGFR to form the TZ-I-EGFR complex. I-TZ being designed to be 
hydrolyzed under physiological conditions can break down to generate the TZ (an 
alkylating species) that damages DNA and l, a free inhibitor that can further block 
EGFR-mediated signaling. Since resistance to DNA damaging agents is often mediated 
by DNA repair enzymes, we surmised that down-regulation of DNA repair proteins 
through blockade of EGFR phosphorylation by I-TZ and l, would enhance cell-killing, 
thereby inducing more potent antitumour activity than currently available inhibitors of 
EGFR alone or individual DNA damaging agents. 
We have already demonstrated that the combi-molecule RB24 was a unique combi-
molecule with ability to block EGF-induced signaling on its own and also to be 
degraded into multiple species with EGFR TK inhibitory properties + a DNA alkylating 
methyldiazonium species (Fig. 5.1) (Banerjee et al., 2003; Banerjee et al., 2004). RB24 
belongs to the same class of methylating agents as the clinical drug Temodal® (TEM), 
which is known to induce three types of DNA adducts: N7-methylguanine (N7 -MeG), 
N3-methyladenine (N3-MeA) and 06-methylguanine (06_MeG). While the N7-MeG 
and N3 -MeA account for 85% of the total adducts and are handled by base excision 
repair (BER) enzymes, the 06_MeG adducts are repaired by a specific enzyme termed 
06-alkylguanine transferase (AGT) (Gibson et al., 1986; Tisdale, 1987; Fomace et al., 
1990; Baer et al., 1993; Mitchel and Dolan, 1993; Pegg et al., 1995). The 06_MeG 
lesions are believed to be the most cytotoxic adducts, as evidenced by the marked 
resistance of cells that express AGT. Strategies designed to enhance the potency of the 
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Figure 5.1. Stepwise release of the metabolites generated during the degradation 
cascade of the combi-molecule, RB24. The parent combi-molecule (I-TZ) hydrolyzes to 
release a series of daughter inhibitors (I-TZ', I-TZ") and at the final stage of 
degradation, a free inhibitor (I) + a DNA methylating species (TZ). 
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latter agents in resistant tumours are primarily based on the development of DNA 
repair inhibitors. 06-benzylguanine (06-BG), an inhibitor of AGT, has been shown 
to sensitize cells to TEM (Cai et al., 2000; Quinn et al., 2005). Similarly, 
methoxylamine or poly-ADP-ribose polymerase (PARP) inhibitors have been used to 
inhibit base excision repair in resistant cells (Horton et al., 2000; Liu et al., 2002; 
Miknyoczki et al., 2003; Tentori et al., 2003; Liu and Gerson, 2004). Despite the 
marked importance of BER in chemoresistance, studies designed to develop molecules 
capable of indirectly disrupting it through down-regulation of small proteins such as 
XRCC 1, a member of the BER complex, are scant. Here, we study the signaling 
pathways that contribute to the potency of one such molecule, RB24, a combi-molecule 
designed to not only down-regulate DNA repair through EGFR inhibition but also to 
methylate DNA. 
In this study, we have chosen the androgen-independent prostate cancer cellline DU145 
as a model for the following reasons: (1) it expresses AGT that repairs the cytotoxic 0 6_ 
MeG lesion, (2) EGF-stimulation in these cells significantly up-regulates nucleotide 
excision repair protein, ERCC1, and BER protein XRCCI and (3) EGF-stimulation is 
accompanied by activation of anti-apoptotic signaling that leads to Akt phosphorylation 
of Bad (Yacoub et al., 2003; Maroni et al., 2004; Fan et al., 2004; Hagan et al., 2004). 
Thus, the DU145 cells accumulate almost all the critical signaling disorders required to 
confer a robust resistance to methylating agents. In this study, we demonstrate that in 
contrast to the clinical methylating agent, TEM, these cells are exquisitely sensitive to 
the combi-molecule and investigate alternative cell signaling pathways that can be 
hammered to further sensitize them to RB24. We also demonstrate that blockade of 
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MEK1 phosphorylation exquisitely sensitizes cells to RB24, a novel type of mixed 
EGFR-DNA targeting molecule, but not to TEM. 
5.3. Materials and Methods 
5.3.1. Drug Treatment 
RB24 and RB 1 0 were synthesized in our laboratory according to known procedures 
(Banerjee et al.,2003; Rachid et al.,2003). Temodal® (TEM) was provided by Schering-
Plough Inc .. (Kenilworth, NJ, USA). Gefitinib was provided by AstraZeneca. SB203580 and 
PD98059 were purchased from Biomol (Plymouth Meeting, PA). U0126 was purchased 
from Cell Signaling Technology (Danvers, MA). In all assays, drug was dissolved in DMSO 
and subsequently diluted in RPMI-1640 containing 10% fetal bovine serum (FBS) (Wisent 
Inc., St-Bruno, QC, Canada) immediately before the treatment of cell cultures. In all assays, 
the concentration ofDMSO never exceeded 0.2% (v/v). 
5.3.2. Cell Culture 
The cellline used in this study was the human prostate carcinoma, DU145, which was 
obtained from the American Type Culture Collection (Manassas, VA). DU145 cells 
were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 
and antibiotics as described previously (Matheson et al., 2001). Cells were maintained 
at 37°C in a humidified environment of 5% C02, 95% air. The cell cultures were 
maintained in logarithmic growth by harvesting with a trypsin-EDTA solution 
(O.5mg/ml trypsin and 0.2 mg/ml EDTA) and replating before confluence. 
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5.3.3. Growth Inhibition Assay 
Growth inhibition studies were carried out with approximately 5 x 103 ceUs/weU plated 
in 96-well plates. After a 24 h incubation at 37°C in a humidified environment of 5% 
CO2, ceU monolayers were exposed to different concentrations of each drug continuously 
for 6 days. AU growth inhibitory activities were evaluated using the sulforhodamine B 
(SRB) assay (Skehan et al.,1990). The drug combinations were performed at ICso molar 
ratios. Briefly, following drug treatment, cells were fixed using 50 ,...1 of cold 
trichloroacetic acid (50%) for 60 min at 4°C, washed four times with tap water, and 
stained for 30 min at room temperature with SRB (0.4%) dissolved in acetic acid (0.5%). 
The plates were rinsed five times with 1% acetic acid and allowed to air dry. The 
resulting colored residue was dissolved in 200 ,...1 of Tris base (10 mM), and optical 
density was read for each weIl at 492 nm using a Bio-Rad microplate reader (model 
2550). Each point represents the average of at least two independent experiments run in 
triplicate. 
Antiproliferative effects that were generated by RB24 or TEM in combination with 
various inhibitory agents (e.g. SB203580, PD98059, 06-BG, U0126, gefitinib) were 
assessed by determining the combination index (CI). CI values were calculated using 
the following median effect equation (Perez et al., 1993) where CIso values >1, =1, and 
<1 demonstrated antagonistic, additive or synergistic activity, respectively: 
CIso= ICso (Compound A in combination) + ICso (Compound B in combination) 
ICso (Compound A alone) ICso (Compound B alone) 
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5.3.4. EGF -induced or Activated Pro teins 
5.3.4.1. XRCCl levels 
DU145 cells (1x106) were plated in six-well plates with 10% serum at 37°C for 
24 h and starved overnight for 18 h, after which one set was exposed to 25 JlM of RB24 
and 100J..lM ofTEM for 2 h and subsequently treated with 20 ng/ml EGF for 5 h at 37°C. 
The other set was treated with 25JlM of RB24 and 100J..lM of TEM for 2 h and 
subsequently replaced with drug- and serum-free media for 5 h at 37°C. Cells were 
washed with PBS and resuspended in cold lysis buffer [50 mM Tris-HCL PH 7.5; 150 
mM NaCI; 1% Nonidet P-40, 1mM EDTA; 5 mM NaF; 1mM Na3V04; protease 
inhibitor tablet (Roche Biochemicals, Laval, QC, Canada)]. The lysates were kept on ice 
for 30 min and collected by centrifugation at 10,000 rpm for 20 min at 4°C. The 
concentrations of prote in were determined using the Bio-Rad prote in assay Kit (Bio-Rad 
Laboratories, Hercules, CA). Equal amounts of protein were added to an 10 % SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene 
difluoride membrane (Millipore, Bedford, MA). Non-specific binding on the membranes 
were minimized with overnight incubation at 4°C with blocking buffer containing nonfat 
dry milk (5%) in PBST. Thereafter, the membranes were incubated with primary anti-
XRCC1 antibodies (Neomarkers, Fremont, CA) for 1 h for the detection of XRCC1 
levels. Membranes were stripped and re-probed with anti-actin and anti-tubulin 
(Neomarkers, Fremont, CA) for determination of corresponding receptor levels. Blots 
were incubated with HRP-goat anti-mouse antibody (1: 1000 dilution; Cell Signaling 
Research, Beverly, MA) and the bands visualized with an enhanced chemiluminescence 
system (Amersham Pharmacia Biotech, Buckinghamshire, UK) (Matheson et al., 2001). 
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DU145 cells (1 X 106) were plated in six-well plates with 10% serum at 37°C for 
24 h and starved overnight for 18 h, after which cells were exposed to 25 J...lM of RB24 
and 100J...lM of TEM for 2 h and subsequently treated with or without 20 ng/ml EGF for 
5 h at 37°C. Cells were washed with PBS and lyzed by the aforementioned method. 
Equal amounts of prote in were loaded into 1 O%SDS-P AGE and western blotting was 
performed as described. Antigens were detected with primary anti-phosphop38MAPK 
antibody or anti-phosphoJNK (Neomarkers, Fremont, CA) for 24 h for the detection of 
activated p38MAPK or JNK levels. Membranes were stripped and re-probed with anti-
p38MAPK or anti-JNK (Neomarkers, Fremont, CA) for determination of corresponding 
enzyme leve1s. Blots were incubated with HRP-goat anti-mouse antibody (1: 1000 
dilution; Cell Signaling Research, Beverly, MA, USA) and the bands visualized with an 
enhanced chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, 
UK). 
5.3.4.3. EGFR and Bad activation 
Inhibition of EGFR and Bad activation were determined by exposing serum-starved 
cells for 2 h with the indicated concentrations of RB24 or TEM prior to stimulation with 
EGF (50ng/ml and 25ng/ml, respectively). Another set of serum-starved cells were treated 
with 10J...lM ofRB24 alone or in combination with 30J...lM ofU0126 for 6 h. Equal amounts of 
cell lysates were analyzed by Western blot using anti-phosphotyrosine (Upstate USA, 
Charlottesville, VA), anti-phosphoBad (Ser136, Ser112) antibodies (Cell Signaling Tech., 
Danvers, MA). Membranes were stripped of antibody and reprobed with anti-EGFR 
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or anti-Bad antibodies (Cell Signaling Tech., Danvers, MA). 
5.3.5. Annexin V Binding 
Cells were grown in 6-well plates until confluence and then incubated with the 
compounds for 24 h. The cells were then harvested, washed twice with PBS, and 
centrifuged. Cells (105) were treated with annexin V -FITC and propidium iodide (PI) 
using the apoptosis Detection Kit (BD Bioscience Pharmingen, San Jose, CA) and the 
supplier's protocol. Annexin V-FITC and PI binding were analyzed by flow cytometry. 
Data were collected using logarithmic amplification of both the FLI (FITC) and FL2 
(PI) channels. Quadrant analysis of co-ordinate dot plots was performed with CellQuest 
software. Unstained cells were used to adjust the photomultiplier voltage and for 
compensation setting adjustment in order to eliminate spectral overlap between the FLI 
and FL2 signaIs. Statistical significance was determined using the Student t-test (n=4). 
5.3.6. Alkaline Comet Assay for Quantitation of DNA Damage 
The alkaline cornet assay was performed as previously described (Matheson et al., 
2001). The cells were exposed to a dose range of RB24 for 2h, harvested with trypsin-
EDTA, subsequently collected by centrifugation and resuspended in PBS. In DNA 
repair kinetics studies, cells were treated with RB24 or TEM for 2 h and allowed to 
recover for 2, 4, 18, 24, and 48h. Cell suspensions were diluted to approximately 106 
cells, and mixed with agarose (1 %) in PBS at 37°C in aI: 10 dilution. The gels were cast 
on Gelbond strips (Mandel Scientific, Guelph, ON, Canada) using gel casting chambers, 
as previously described (McNamee et al., 2000), and then immediately placed into a 
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lysis buffer [2.5 M NaCI, 0.1 M tetra-sodium EDTA, 10 mM Tris-base, 1% (w/v) N-
lauryl sarcosine, 10% (v/v) DMSO, and 1% (v/v) Triton X-lOO, pH 10.0]. After being 
kept on ice for 30 min, the gels were gently rinsed with distilled water and immersed in 
a second lysis buffer (2.5 M NaCI, 0.1 M tetrasodium EDTA, 10 mM Tris-base) 
containing 1 mg/ml proteinase K for 60 min at 37°C. Thereafter, the gels were rinsed 
with distilled water, incubated in alkaline electrophoresis buffer for 30 min at room 
temperature, and electrophoresed at 300 mA for 60 min. The gels were subsequently 
rinsed with distilled water and placed in 1 M ammonium acetate for 30 min. Thereafter, 
they were soaked in 100% ethanol for 2 h, dried overnight, and stained with SYBR Gold 
(1/1 0, 000 dilution of stock supplied from Molecular Probes, Eugene, OR) for 20 min. 
Cornets were visualized at 330x magnification and DNA damage was quantitated using 
the Tail Moment parameter (i.e., the distance between the barycenter of the head and the 
tail of the cornet multiplied by the percentage of DNA within the tail of the cornet). A 
minimum of 50 cell cornets were analyzed for each sample, using ALKOMET version 
3.1 image analysis software. 
5.4. Results 
5.4.1. Inhibition of EGFR activation by RB24 
We first tested the ability ofRB24 to inhibit EGF-induced EGFR phosphorylation in the 
DU145 cells. The results showed that RB24 could robustly block EGF-induced EGFR 
phosphorylation, as evidenced by 100% inhibition observed at a dose as low as 1 !lM 
without affecting the levels of the latter receptor (Fig. 5.2). 
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5.4.2. Antiproliferative potency of RB24 
As mentioned earlier, the DU145 cells possess characteristics (e.g. AGT expression) that 
confer high resistance to DNA methylating agents (Tisdale et al., 1987; Fomace et al., 
1990; Yacoub et al., 2003). Thus, its potency was compared with that of the clinically 
active methylating agent TEM in an SRB assay. RB24, despite possessing a similar 
methylating mechanism, was over 100-fold more potent than the clinical triazene TEM 
in a growth inhibitory assay (Table 5.1). Being a dual acting molecule designed to 
degrade (tl/2=42 min) to the potent EGFR inhibitor, RBlO, we also sought to determine 
whether RB24 owes its remarkable potency solely to the effects of the latter molecule. 
The results showed that RB24 was over 3-fold more potent than the free inhibitor RBlO 
against the DU145 cells (Table 5.1). This enhanced potency when compared with its 
daughter inhibitor (ICsocompetitive binding = 40nM) indicates that perhaps the DNA 
lesions that it induced also contributed to its pronounced antiproliferative activity. It is 
noteworthy that RB24 was over 4-fold more potent than gefitinib (Table 5.1) 
5.4.3. DNA damage and activation of the MAPK pathway 
DU145 cells being AGT+ and virtually insensitive to TEM exposure, 06-methylguanine 
adducts were excluded as possible cytotoxic DNA lesions induced by RB24. Thus, we 
surmised that cytotoxic DNA damage may perhaps be induced through N-alkylated 
guanine or adenine bases, the repair of which is handled by BER and that perhaps 
blockade of EGFR-mediated signaling by RB24 may down-regulate XRCCl, a key 
player of BER. To this end, we analyzed signaling associated with cell response to DNA 
damage, chiefly through the MAPK pathway. Prior to the latter analysis, we first 
confirmed the presence of DNA damage in cells exposed to a dose range of RB24 using 
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Table 5.1. Antiproliferative effects of RB24 and TEM alone or in combination with cell 
signaling inhibitors in the prostate carcinoma ceIlline, DU145 . 
Compounds Antiproliferative Combination Index 
activity (ICso, J.1M)* 
RB24 12 ± 2.6 
RBIO 38 ±2.8 
Gefitinib 49 ± 3.5 
RB24+06-BG 7 ±- 1.4 0.34 
RB24+ SB203580 30 ± 1.7 0.98 
RB24 + PD98059 0.7 ± 0.03 0.03 
RB24 + U0126 0.6 ± 0.04 0.03 
TEM 486 ± 11.6 
TEM+06-BG 55 ± 1.1 0.31 
TEM + SB203580 417±9.6 1.51 
TEM+PD98059 353 ± 5.8 1.38 
TEM + U0126 316±7.2 1.25 
TEM + gefitinib 59 ± 6.7 0.23 
TEM + gefitinib + U0126 25 ± 2.3 0.16 
RB24 + gefitinib + U0126 18 ± 0.21 0.1 
RB24 + gefitinib + U0126 2.5 ± 0.53 0.1 
* Values are means ofIC5o values and SEMsfrom three experiments. 
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Figure 5.2. Inhibition of EGFR autophosphorylation in intact cells by RB24. Serum-
starved DU145 cells were pre-incubated for 2 h with the indicated concentrations of 
RB24 prior to stimulation with EGF (50ng/ml) for 15 min. Equal amount of celllysate 
was analyzed by Western blotting using anti-phosphotyrosine and anti-EGFR antibodies. 
Band intensities were measured using the SynGene GeneTools software package. 
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the cornet assay. Marked levels of DNA strand breaks were observed at concentration as 
low as 6 /lM following a 2 h drug exposure and more importantly, levels of DNA 
damage by RB24 were approximately 3-fold higher than those by TEM (Fig. 5.3A). 
Further cornet analysis at 2-48 h post treatment showed sustained levels of DNA damage 
in cells treated with RB24 (Fig. 5.3b). In contrast, at a dose of TEM that induced 
identicallevels of DNA lesions, combined tail moment in TEM-treated cells retumed to 
controllevels as early as 18h-post-treatment, indicating rapid DNA repair (Fig. 5.3B). 
Thus, we analyzed the levels of the base excision repair protein XRCC 1 triggered by the 
presence of DNA lesions upon exposure to: (a) RB24, (b) TEM and (c) RB24+EGF in 
comparison with TEM+EGF. 
The results showed that serum-starved cells stimulated with EGF produced elevated 
levels of the XRCCI prote in. These levels were 2-fold higher in cells exposed to TEM 
+ EGF (Fig. 5.3C). In the absence of EGF stimulation, TEM induced significant levels 
of XRCCl, presumably through a stress response pathway. Similarly, induction of 
XRCCI was also observed with RB24 in the absence of EGF stimulation. However, in 
contrast to TEM, RB24 blocked induction of XRCCI through EGF-stimulation leading 
to a 2-fold lower level of the latter protein in cells exposed to RB24 when compared 
with those exposed to TEM (Fig. 5.3C). The free inhibitor RBIO that does not damage 
DNA did not trigger expression of XRCCI. However, it completely suppressed its 
expression through EGF stimulation, suggesting that the residual levels of XRCC 1 
observed following treatment with RB24 is associated with its DNA damaging 
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Figure 5.3. Effects ofRB24 or TEM on levels ofDNA damage, XRCCI and activation 
of stress response in the DU145 cellline. A, DUl45 cells were treated with RB24 (.) or 
TEM ( ... ) for 2 h and levels of DNA damage were quantitated using the alkaline cornet 
assay. Tail moment (i.e., the distance between the barycenter of the head and the tail of 
the cornet multiplied by the percentage ofDNA within the tail of the cornet) was used as 
a parameter for the detection ofDNA damage in cells exposed to RB24 or TEM. Points, 
mean percentage ofuntreated cells (n=3); bars, SD. B, cornet assay analysis of DU145 
cells pretreated with RB24 (white columns) or TEM (black columns) for 2 h followed by 
washout and replacement of drug-containing media with fresh media. Cells were 
allowed to recover for multiple timepoints. Columns, mean of three experiments; bars, 
SD. 
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Figure 5.3. EffectS ofRB24 or TEM on levels ofDNA damage, XRCCI and activation 
of stress response in the DU145 cell line. C, serum-starved DU145 cells were 
preincubated for 2 h with RB24, RB 1 0 or TEM following treatment with or without 
EGF (20ng/ml) for 5 h. Cell lysates were isolated and analyzed by Western blot for 
indicated proteins. Quantitation of XRCC 1 protein levels were measured using the 
SynGene GeneTools software package as. Columns, ratio of XRCClIactin and mean of 
three experiments; bars, SD. 
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Figure 5.3. Effects ofRB24 or TEM on levels ofDNA damage, XRCCI and activation 
of stress response in the DU145 cell Hne. D, E p38MAPK and JNK activation of 
serum-starved DU145 cells exposed for 2 h to RB24 or TEM. Following compound 
exposure, cells were treated with or without EGF (20ng/ml) for 3 h. Equal amount of 
celllysate was analyzed by Western blot and probed for anti-phosphop38MAPK, anti-
phosphoJNK, anti-JNK or anti-p38MAPK antibodies. 
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r\ component. Thus, we further characterized the path leading to XRCC 1 expression in the 
absence of EGF stimulation. 
Exposure to DNA damage of the types induced by methylating agents results in the 
activation of complex signaling pathways including the ATM and MAPK cascades 
(Mabuchi et al., 2002; Uzgare et al., 2003; Hirose et al., 2003; Stojic et al., 2004). Based 
upon studies demonstrating the involvement ofp38MAPK and JNK activation following 
DNA damage induced in cells treated with alkylating agents (Uzgare et al., 2003; Hirose 
et al., 2003; Stojic et al., 2004), we investigated the phosphorylation status of the latter 
proteins both under EGF-induced mitogenic signaling and under direct exposure to DNA 
damage. The results showed markedly elevated levels of phospho-p38MAPK both in 
cells exposed to TEM or RB24 in the absence of EGF. However, in the presence of 
EGF, the activation of p38MAPK followed the same trend as that observed for EGF-
induced XRCCI expression in response to DNA methylation. Under EGF-stimulation, 
RB24 induced approximately 2-fold less activation ofp38MAPK than TEM (Fig. 5.3D). 
Direct cell exposure to TEM or RB24 did not activate JNK, indicating that XRCC 1 
expression is not induced through the JNK pathway (Fig. 5.3E). Thus, under EGF 
stimulation and exposure to DNA damage, the DU145 cells are protected by a tandem 
induction of XRCCI expression both through EGFR-mediated mitogenic signaling and 
through DNA damage-induced stress response, culminating into a robust resistance to 
DNA lesions. 
5.4.4. Inhibition of anti-apoptotic signaling by the combi-molecule 
Following EGFR activation, numerous signaling cascades are induced that regulate not 
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r\ only cellular proliferation and growth, but can also promote cell survival. One of the 
key anti-apoptotic signaling pathways that are regulated by EGFR, is the PI3K1Akt 
pathway that ultimately lead to Bad activation (Mitsiades et al., 2004). Phosphorylation 
of Bad by Akt inhibits binding to Bel-xL, leading to a blockade of the apoptotic pathway 
(Mabuchi et al., 2002). Thus, we examined the ability of our combi-molecule, RB24, to 
inhibit phosphorylation of Bad via inhibition of EGFR activation, a process that could 
alleviate the apoptotic blockade. Western blot analyses showed that RB24 inhibited 
phosphorylation of Bad at Ser136, the target of Akt, in a dose-dependent manner (Fig. 
5.4A). It is also known that activation of Bad through phosphorylation at a different 
serine residue, SerI12, is regulated by the MAPK family. Therefore, we studied the 
ability of RB24 to inhibit phosphorylation of Bad through the MAPK cascade. The 
results showed that RB24 was capable of inhibiting Bad phosphorylation at Ser112 after 
a pulse 2 h exposure. However, when DU145 cells were treated with RB24 alone over a 
6 h period, we observed partial recovery of Bad (Fig. 5.4B). In contrast, DU145 cells 
exposed to a dose-range (3-1 OO~M) of the methylating agent TEM, resulted in no 
inhibition of Bad phosphorylation on both the aforementioned serine residues (data no 
shown). 
To determine whether the pleiotropic effects of RB24 (i.e. DNA damage, EGFR 
blockade, inhibition of Bad phosphorylation) would culminate into enhanced apoptosis, 
we examined annexin V binding to DU145 cells previously treated with RB24 or TEM. 
In contrast to TEM, RB24 induced significant levels of apoptosis (p<O.OI) after a 24 h 
drug exposure (Fig. 5.4C). 
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Figure 5.4. Assessment of the apoptotic effects of RB24 alone or in combination with 
cell signaling inhibitors in DU145 cells. A, levels of Bad phosphorylation at Ser136 
were examined in serum-starved cells that were preincubated for 2 h with the indicated 
concentrations of RB24 prior to stimulation with EGF (25ng/ml) for 15 min. In B, 
serum-starved cells were exposed to RB24 for 2h prior to EGF (25/mg/ml) stimulation 
(15 min) or treated with RB24 for 6h at the indicated doses alone or in combination with 
U0126. Equal amounts of cell lysates were analyzed by Western blot using anti-
phosphoBAD (Ser 136), anti-phosphoBAD (Ser 112), or anti-BAD antibodies. 
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Figure 5.4. Assessment of the apoptotic effects of RB24 or TEM alone or in 
combination with cen signaling inhibitors in DU145 cens. C, DU145 cens were treated 
with 25 /-LM RB24 or TEM alone or in combination with 8B203580, PD98059, U0126 
for 48 h. Levels of apoptotic cens were determined using Annexin V -FITC staining. 
Columns, mean percentage of Annexin-V-negative cens (n=4); bars, 8D. 
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5.4.5. Enhancing the potency of the combi-molecule 
In addition to being a masked form of a two-drug combination, the combi-molecule is a 
single molecule. Therefore, it can be combined with other antitumour agents. Studies on 
the multiple signaling pathways indicated that blockade of EGFR-mediated signaling did 
not suffice to completely suppress XRCC1 expression in these cells. Thus, p38MAPK, 
the activation of which does not require EGFR phosphorylation, was pointed as a logical 
target to enhance the potency of the DNA damaging component of RB24. The results 
showed that blockade of p38MAPK with SB203580 at an equi-effective dose induced an 
additive effect (Table 5.1). 
Having found that inhibition of MEK1-related phosphorylation of Bad was restored 
rapidly and with CUITent knowledge of its significant involvement in cross-talk between 
mitogenic, apoptotic and stress signaling, MEK1 appeared as a critical target for 
enhancement of the potency of the combi-molecule. The results showed that while the 
combination of a p38MAPK inhibitor with RB24 yielded minimal inhibition of XRCC 1 
expression, inhibition of its upstream MEK kinase with PD98059 induced significant 
depletion of the latter protein in the cells and significant depletion of Bad 
phosphorylation when combined with U0126 (Fig. 5.4B, 5.5A). This translated into 
substantiallevels of apoptosis (Fig. 5.4C) and a unique combination synergy (CIso=O.03) 
in the SRB antiproliferative assay (Table 5.1, Fig 5.5B). In contrast, the potency of the 
triazene TEM could only be moderately enhanced by the MEK inhibitors, PD98059 and 
U0126 (Table 5.1, Fig. 5.5C). 
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Figure 5.5. Characterization of the enhancement in growth inhibitory activity of RB24 
or TEM when in combined with SB203580 or PD98059. A, serum-starved DU145 cells 
were exposed to RB24 or TEM alone or in combination with either SB203580 or 
PD98059 for 2h followed by a 5 h exposure to EGF (20ng/ml). Levels of the BER 
protein, XRCCl, were analyzed by Western blot using anti-XRCCI or anti-a-tubulin 
antibodies. B, antiproliferative activity studies were carried in DU145 cells exposed to 
RB24 (e) or the MEKI inhibitor, PD98059 (À), alone or in combination (.) for a 
continuous 6 days. C, cell growth inhibition studies in DU145 cells treated for 6 days 
continuously with TEM (e) or PD98059 (+), alone or in combination (T). 
Antiproliferative activity was determined using the SRB assay. Points, mean of three 
experiments run in triplicate; bars, SD. 
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5.4.6. Deconvolution of the potency of the combi-molecule and discovery of a novel 
combination formula 
Since RB24 possesses both EGFR inhibitory and DNA damaging properties, we sought 
to determine whether a triple combination of TEM (clinical DNA damaging)+gefitinib 
(clinical EGFR inhibitor) +U0126 (potent MEK1 inhibitor) would prove synergistic or 
more efficacious than the 2-drug combination RB24+MEK1 inhibitor. Although the 
combination of TEM+gefitinib+U0126 did result in a synergistic activity, that of 
RB24+U0126 was more than 20-fold more potent than the latter formula at equi-
effective doses (Table 5.1). When using RB24 in a triple drug combination with either 
TEM+U0126 or gefitinib+U0126, the results indicated that both triple combinations 
were synergistic, but still remained approximately 30- or 4-fold less advantageous than 
the two-drug combination of RB24 + U0126 (or PD59068) at equi-effective doses, 
respectively (Table 5.1). 
5.5. Discussion 
The potency ofDNA alkylating agents is significantly limited by the expression ofDNA 
repair enzymes that process the DNA adducts in resistant tumour cells (Pegg et al., 
1995; Miknyoczki et al., 2003; Yacoub et al., 2003). To circumvent this problem, 
numerous investigations have been directed at sensitizing cells using DNA repair 
inhibitors (Cai et al., 2000; Horton et al., 2000; Miknyoczki et al., 2003). Despite the 
significant advances on the molecular biology of stress response, strategies designed to 
sensitize the cells using relevant signal transduction pathways are scant. As an example, 
the potency of TEM is enhanced by the use of 06-benzylguanine, a direct inhibitor of 
AGT (Cai et al., 2000; Quinn et al., 2005), or by inhibitors of PARP (Miknyoczki et al., 
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2003; Tentori et al., 2003). More recent studies have used methoxylamine to indirectly 
deplete BER and sensitize cells to TEM (Liu and Gerson, 2004). Here we exploited the 
relationship between DNA repair and EGFR-mediated signaling to design a single 
molecule capable of inducing a tandem damage of DNA and blocking of signal 
transduction. Indeed, the results presented herein showed that RB24 could block XRCC 1 
expression through the depletion of EGFR phosphorylation while being capable of 
damaging DNA. Unfortunately, being a DNA damaging agent, it also induced XRCCI 
presumably through activation of the stress response pathway. The ability of RB24 to 
down-regulate XRCCI through EGFR inhibition led to an overall two-fold lower level 
of EGF-stimulated XRCCI in DU145 cells when compared with TEM-treated ones. 
Indeed, cell exposure to TEM induced elevation of XRCC 1 through both the stress 
response pathway and EGF stimulation, leading to an additive augmentation of the latter 
DNA repair protein. The implication of the stress response pathway in the induction of 
XRCCI in the absence of EGF-stimulation was ascertained by the marked upregulation 
ofphospho-p38MAPK in these cells when RB24 or TEM were directly administered to 
the cells alone. Thus, this study led to the discovery that additive induction of XRCC 1, 
through EGFR activation and alternative pathways, may be at least partly responsible for 
resistance to DNA methylating agents. TEM, being a simple alkylating agent, was 
incapable of blocking the elevation of XRCC 1 levels associated with EGFR TK 
activation. In contrast, by strongly blocking EGFR, the combi-molecule was able to 
deplete the base excision repair protein and more importantly, we demonstrated that this 
was associated with a remarkable delay in DNA strand break repair in these cells. It is 
important to note herein that taking into account the ability of the combi-molecules to 
induce 3-fold higher levels DNA damage than TEM, the analysis was performed at 
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concentrations that inflict equi-Ievel of DNA strand breaks by these two agents. 
Therefore the observed delay is truly dependent upon biological factors and not to levels 
of DNA damage. Thus, the complex combi-molecule RB24 is the first example of a 
DNA damaging molecule capable of both inducing DNA lesions while capable of 
preventing the repair of the latter damage. 
Furthermore, despite the fact that DU145 cells are protected by anti-apoptotic 
mechanisms driven by EGFR-mediated activation of the Akt-Bad cascade as weIl as 
overexpression of Bel-2 (Eisenmann et al., 2003; Mitsiades et al., 2004; Xiao and Singh, 
2006), the combi-molecule was capable of inducing marked levels of apoptosis in these 
cells. This again can be rationalized in light of its ability to block EGFR activation as 
confirmed by the significant inhibition of Bad phosphorylation at serine 136, which is a 
target of Akt (Mabuchi et al., 2002). It is now weIl known that Bad phosphorylation 
prevents its heterodimerization with Bel-xL, thereby allowing it to sequester Bax and 
subsequently interrupt mitochondrial pore formation. In contrast to the combi-molecule, 
TEM, that was deprived of anti-signaling properties, could only induce a barely 
detectable level of apoptosis in these cells. This is in agreement with the constant 
activation of Bad observed in TEM-exposed cells even at supralethal doses. 
Increase in levels of XRCC 1 produced through the activation of the stress response 
pathway was not completely abolished by the combi-molecule. Thus, we surmised that 
strategies designed to enhance the potency of RB24 should be directed at blocking key 
players of the stress response pathway that may be activated upon induction of DNA 
damage. It is now known that DNA lesions trigger activation of ATM or c-abl, which in 
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turn lead to further activation of members of the MAPK pathway (Stojic et al., 2004). 
Thereafter, the repair of certain types of DNA lesions can be mediated either through 
JNK activation (e.g. cisplatin adducts) or through p38MAPK phosphorylation (e.g. 
methylating agents) which is then followed by induction of early response genes 
(Uzgare et al., 2003; Hirose et al., 2003; Stojic et al., 2004). Since JNK was not 
activated upon exposure to RB24 and TEM, response to DNA damage induced by the 
latter drugs may be mediated primarily through p38MAPK activation. lndeed blockade 
ofp38MAPK enhanced the potency ofRB24 producing an additive effect which may be 
associated with partial depletion of XRCC 1. 
MEK1 is known to be involved in cross-talk between various cascades including growth 
factor stimulation and antiapoptotic signaling (Yacoub et al., 2003; Maroni et al., 2004; 
Stojic et al., 2004). Further, previous studies by Yacoub et al. (2003) demonstrated that 
blockade of MEK1 by PD98059 led to significant depletion of XRCC1 in y-irradiated 
DU145 cells. Similarly, marked reduction ofXRCC1 levels was seen when PD98059 or 
U0126 were co-administered with RB24 or TEM. However, in RB24-treated cells, 
levels of apoptosis induced by the latter treatment were remarkably higher than any 
treatment that depleted XRCC1 in this study. This unique synergy can be explained by 
the blockade of reactivation of Bad by MEK1 signaling. lndeed inhibition of MEK1 
through EGFR was reversible, being recovered as early as 6 h after treatment. It is 
noteworthy that in the cell growth inhibitory assay, the potency of RB24+PD98059 or 
U0126 combinations were superior to that of classical combinations involving 
RB24+06-BG, TEM+06-BG or 3-drug combination principles 
219 
TEM+gefitinib+PD98059 or U0126, at equi-effective concentrations. This new 
discovery demonstrates that while the combi-molecule principle can produce superior 
antiproliferative activity with a single molecule in lieu of two, it can also produce a 
similar effect with two- instead of three-way combinations. It is now known that the 
reduction of the number of drugs in a combination may decrease the risk of additive 
toxicity (Powis, 1991). 
This study conclusively demonstrates that the combi-molecular strategy can be applied 
to significantly modify the biological activity of classical pharmacophores. Here, it has 
offered the opportunity to study two DNA methylating agents with the same DNA 
damage pharmacophore (an alkyltriazene function) but with substantially different 
antiproliferative activity profiles: one of them being virtually inactive and the other 
exquisitely potent against a resistant prostate tumour cellline. We also demonstrated that 
this difference is imputed to the additional growth factor receptor TK inhibitory property 
imprinted in the molecule that induced a tandem depletion of DNA repair protein and 
inactivation of anti-apoptotic signaling while high level cytocidal DNA lesions were 
being inflicted. Further, we outlined herein that in addition to being a combi-molecule, 
RB24 can exert additive and synergistic effects in combination with cell signaling 
inhibitors that disrupt alternative pathways in the cells. This novel strategy sets premise 
for exploring new avenues in the development of novel types of alkylating agents for the 
therapy of growth factor receptor-expressing refractory tumours. 
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,--, 5. 8. Connecting text 
In the preceding chapter, we demonstrated that the binary targeting properties of the 
cascade release combi-molecule could induce significant antiproliferative activity 
through a co-operative and multi-targeting mechanism in a cell line known to express 
various survival characteristics (e.g. autocrine expression of EGF and EGFR, expression 
of AGT, overexpression of Bcl-2). In the following chapter, we will determine whether 
this translates into anti-tumour activity in vivo using the more water-soluble 3' -chloro 
analogue of RB24, RBI07. We will also demonstrate that in vivo, RB24 can fragment 
into the predicted sub-components of the cascade. 
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• CHAPTER6 
DEGRADATION, CYTOKINETICS AND PHARMACOANALYSIS 
OF ACETOXYMETHYLTRIAZENES TERMED CASCADE 
RELEASE COMBI-MOLECULES DESIGNED TO INHIBIT THE 
EPIDERMAL GROWTH FACTOR RECEPTOR WHILE 
DAMAGING DNA 
Ranjita BanerjeeI, James P. McNamee2 and Bertrand J. Jean-Claudel 
eCancer Drug Research Laboratory, Department of Medicine, Mc Gill University Health 
Center/Royal Victoria Hospital, Montreal, Quebec, Canada! 2 Consumer and Clinical 
Radiation Protection Bureau, Health Canada, 
Ottawa, Ontario, Canada) 
6.1. Abstract 
Within the context of a new strategy termed "Combi-Targeting", one class of molecule 
containing an acetoxymethyltriazene was designed to degrade into multiple inhibitors of 
EGFR TK + a methyldiazonium species. Although sustained antiproliferative activity 
was induced in vitro by the lead combi-molecule, RB24, also known as a "cascade 
release" combi-molecule, the characterization of its in vivo degradation as weIl as its 
antitumour activity in mice models remain to be demonstrated. Here we report the first 
evidence for the formation of the diverse metabolites in vivo following i.v. injection of 
RB24, using LC-MS analysis. The potency of the cascade release approach in vivo was 
demonstrated with a more water-soluble analogue of RB24, RB 1 07, in alkylating-agent-
resistant DU145 human prostate carcinoma xenograft mode!. In vitro, RB 107 was 
shown to induce the same cell response profile as RB24, with significant EGFRIDNA 
targeting potential and almost identical effect on cell cycle progression. They induced 
significant cell cycle arrest in GIat low doses and mild G2/M arrest at higher doses. 
RB 1 07 was tolerated at doses as high as 200 mg/kg and induced significant antitumour 
activity at 15 days post-treatment (100 mg/kg, i.p. injection, once every other day). Its 
activity was superior to that of the clinical EGFR TK inhibitor, gefitinib, and the 
triazene, Temodal™ (TEM) administered alone at equi-doses (100 mg/kg). The combi-
molecule also showed superior potency when compared with classical combination of 
TEM+gefitinib at equi-doses (50 mg/kg). The results in toto indicate that the cascade 
release approach leads to the stepwise release of multiple bioactive species in plasma 
and translates into significant antiproliferative activity in vivo. 
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6.2. Introduction 
The epidermal growth factor receptor (EGFR) is often overexpressed in breast, ovarian 
and prostate carcinomas (Hu and Xing, 2003; Shelton et al., 2005; Baszley and Gullick, 
2005). Aberrant expression of EGFR is associated with tumour invasiveness, enhanced 
anti-apoptotic signaling and reduced drug sensitivity (Modjtahedi and Dean, 1994; 
Baszley and Gullick, 2005). In search for new strategies to sensitize EGFR-expressing 
tumour cells to cancer therapeutics, we recently developed a strategy termed "combi-
targeting"(Matheson et al., 2001; Brahimi et al., 2002; Qiu et al., 2003; Matheson et al., 
2003; Rachid et al., 2003; Banerjee et al., 2003; Qiu et al., 2004; Banerjee et al., 2004, 
Matheson et al., 2004a; Matheson et al., 2004b). This strategy was based on the premise 
that blockade of EGFR would down-regulate anti-apoptotic signaling, as weIl as DNA 
repair enzymes responsible for tumour cell resistance to cytotoxic DNA alkylating 
agents. Thus, we designed a novel class of pleiotropic drugs containing a quinazoline 
moiety to block the tyrosine kinase (TK) activity of EGFR + a triazene chain 
"programmed" to release a DNA damaging species upon hydrolysis. This new class of 
molecule termed "combi-molecule" has now been shown to induce significant 
antiproliferative activity in EGFR-expressing cells that are resistant to Temodal® (TEM), 
a c1inical DNA damaging agent of the same c1ass (Matheson et al., 2001; Qiu et al., 
2003; Matheson et al., 2003; Banerjee et al., 2003; Banerjee et al., 2004, Matheson et 
al., 2004a). Combi-molecules of the triazene class are particularly useful probes for the 
combi-targeting concept due to their small size and their reasonable rate of hydrolysis 
under physiological conditions. SMA41, the first combi-molecule or combi-triazene 
used to prove the feasibility of this concept, induced DNA damage and blocked EGFR 
autophosphorylation in the human TEM-resistant, A431 carcinoma of the vulva cellline 
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(Matheson et al., 2001). It aIso induced significant antiproliferative activity in vivo at 
high doses (Matheson et al., 2004b). However, the rather moderate EGFR TK inhibitory 
of its released inhibitor SMA52 (ICso=lf.lM) and its poor water solubility prec1uded its 
further development. To cÏrcumvent these problems, we designed a new c1ass of 
molecule with two major features: a) replacement of the methyl by a less bulky chloro-
or bromo-group to enhance interaction with the hydrophobie pocket and b) appendage of 
an acetoxymethyl to the N3 position of the triazene chain to promote water solubility. 
These novel compounds termed "cascade release" combi-molecules, that owe their 
names to their ability to be hydrolyzed into multiple inhibitors of EGFR TK, were 
designed to generate more potent monoalkyltriazene analogues of SMA41 (e.g. BJ2000, 
ICso=O.1f.lM; ZR08, ICso=0.039f.lM) (Brahimi et al., 2002; Rachid et al., 2003; Banerjee 
et al., 2003). The ability of the metabolites generated during the degradation cascade to 
block EGFR was proven by independent synthesis of each of the degradation products 
and their testing in an ELISA for isolated EGFR and whole cell assay involving EGF-
induced EGFR autophosphorylation. Because of the rapid conversion of the entire 
combi-molecule into the final steps of the cascade, the formation of each of the transient 
metabolites in vivo remained hypothetical. Thus, in this study we sought to anaIyze the 
~ X~NH 
Scheme 6.1 
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X=Br,RB24 
X=CI,RBI07 
cascade using LC-MS analysis of plasma samples collected immediately or 5 min 
following i.v. injection. RB24, the most studied cascade release combi-molecule 
(BaneIjee et al., 2003; Banerjee et al., 2004; BaneIjee et al., 2006), was used for 
analysis of the cascade in vivo and its chloro-analogue, RB 1 07, being more water-
soluble, was used for efficacy studies (see Scheme 6.1). We show herein that its cellular 
response profiles parallel that of RB24 and examine its antiproliferative potency in a 
DU145 prostate cancer xenograft mode!. 
6.3. Materials and Methods 
6.3.1. Drug Treatment 
RB24, RB 107, RBI05, BJ2000, RBIO and FD105 were synthesized in our laboratory 
;'"" .. according to known procedures (Banerjee et al., 2003; Rachid et al., 2003). Temodal® 
(TEM) was provided by Schering-Plough Inc. (Kenilworth, NJ, USA). Gefitinib was 
provided by AstraZeneca. In aIl assays, drug was dissolved in DMSO and subsequently 
diluted in RPMI-1640 containing 10% fetal bovine serum (FBS) (Wisent Inc., St-Bruno, QC, 
Canada) immediately before the treatment of cell cultures and the concentration of DMSO 
never exceeded 0.2% (v/v). 
6.3.2. Cell Culture 
The cell line used in this study was the human prostate carcinoma, DU145, obtained 
from the American Type Culture Collection (Manassas, VA). The cell line was 
maintained in RPMI 1640 medium supplemented with 10% FBS and antibiotics as 
described previously (Matheson et al., 2001; Banerjee et al., 2004). Cells were 
maintained in a monolayer at 37 oC in a humidified environment of 5% C02, 95% air. 
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(' The cultures were maintained in logarithmic growth by harvesting with a trypsin-EDTA 
(0.5 mg/mL trypsin and 0.2 mg/mL EDTA) and replating before confluence. 
6.3.3. EGFR Kinase Enzyme Assay 
The EGFR kinase assay is similar to the one previously described (Matheson et al., 
2001; Banerjee et al., 2003). MaxiSorp 96-well plates (Nalge Nunc international, 
Naperville, IL) were incubated overnight at 37°C with 100 ,...,Llwell of 0.25 ng/mL poly 
[L-glutamic acid -L-tyrosine, 4: 1] (PGT) in PBS. Excess PGT was removed and the 
plate was washed three times with wash buffer (0.1 % Tween 20 in PBS). The kinase 
reaction was performed using 4.5 ng/well EGFR affinity-purified from A431 cells 
(Matheson et al., 2001; Banerjee et al., 2003). The compound was added and 
phosphorylation initiated by the addition of ATP (20 ,...,M). After 8 min at room 
temperature, the reaction was terminated by aspiration of the reaction mixture and 
rinsing the plate four times with wash buffer. Phosphorylated PGT was detected after a 
25 min incubation with 50 ,...,Llwell of horseradish peroxidase-conjugated PY20 anti-
phosphotyrosine antibody (Santa Cruz Biotechnology, Santa Cruz, CA) diluted to 0.2 
,...,g/mL in blocking buffer (3% bovine serum albumin and 0.05% Tween 20 in PBS). 
Antibody was removed by aspiration and the plate washed four times with wash buffer. 
The signals were developed by the addition of 50 IlLlwell 3,3' ,5,5' -tetramethylbenzidine 
peroxidase substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD) and after 
blue color development, 50 ilL of H2S04 (0.09 M) was added per well to stop the 
reaction. The plates were read at 450 nm using a Bio-Rad ELISA reader (model 2550; 
Bio-Rad, Hercules, CA). 
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(, 6.3.4. In vitro Growth Inhibition Assay 
To study the effect of our compounds on cellular proliferation, cells were grown in 96-well 
plates and exposed to a dose range of each drug for 6 days. Cell growth was measured using 
the sulforhodamine B (SRB) assay (Skehan et al., 1990). Briefly, following drug treatment, 
cells were fixed using 50 ~L of cold trichloroacetic acid (50%) for 60 min at 4°C, washed 
five times with tap water, and stained for 30 min at room temperature with SRB (0.4%) 
dissolved in acetic acid (0.5%). The plates were rinsed five times with 1% acetic acid and 
allowed to air dry. The resulting colored residue was dissolved in 200 ~L of Tris base (10 
mM), and optical density read for each well at 492 nm using a Bio-Rad microplate reader 
(model 2550). Each point represents the average of at least two independent experiments run 
in triplicate. 
6.3.5. Autophosphorylation Assay 
DU145 cells (lx106) were preincubated in a six-well plate with 10% serum at 37°C for 
24 h and starved ovemight for 18 h, after which they were exposed to a dose range of 
RB107 for 2 h and subsequently treated with 50 ng/mL EGF for 15 min at 37°C. Cells 
were washed with PBS and resuspended in cold lysis buffer [50 mM Tris-HCL pH 7.5; 
150 mM NaCI; 1% Nonidet P-40, 1 mM EDTA; 5 mM NaF; 1 mM Na3V04; protease 
inhibitor tablet (Roche Biochemicals, Laval, QC, Canada)]. The lysates were kept on ice 
for 30 min and collected by centrifugation at 10,000 rpm for 20 min at 4°C. The 
concentrations of prote in were determined using the Bio-Rad Protein Assay Kit (Bio-
Rad Laboratories, Hercules, CA). Equal amounts of prote in were added to a 10% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene 
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difluoride membrane (Millipore, Bedford, MA). Non-specifie binding on the membranes 
were minimized with a blocking buffer containing nonfat dry milk (5%) in PBST. 
Thereafter, the membranes were incubated with primary anti-phosphotyrosine antibody 
(Upstate Biotechnology, Lake Placid, NY) for the detection of phosphotyrosine. 
Membranes were stripped and re-probed with anti-EGFR (Neomarkers, Fremont, CA) 
for determination of corresponding receptor levels. Blots were incubated with HRP-goat 
anti-mouse antibody (1:1000 dilution; Cell Signaling Research, Beverly, MA) and the 
bands visualized with an enhanced chemiluminescence system (Amersham Pharmacia 
Biotech, Buckinghamshire, UK) (Matheson et al., 2001). 
6.3.6. Alkaline Cornet Assay 
The alkaline cornet assay technique was used to quantitate DNA strand breaks induced 
by RB107 and TEM in DU145 cells. The cells were exposed to drugs for 2 h and 
harvested with trypsin-EDTA. They were subsequently collected by centrifugation and 
re-suspended in PBS. The resulting cell suspensions were diluted to 3x105 cell/mL, and 
mixed with 0.75% agarose in PBS at 37°C in a 1:9 dilution. The gels were cast on 
Gelband strips (Mandel Scientific, Guelph, ON, Canada) using gel casting chambers, as 
previously described, then immediately placed into a lysis buffer (2.5 M NaCl, 0.1 M 
tetrasodium EDTA, 10 mM Tris-base, 1% w/v N-lauryl sarcosine, 10% v/v DMSO and 
1% v/v Triton X-IOO). After being kept on ice for 30 min, the gels were gently rinsed 
with distilled water and immersed in a second lysis buffer (2.5 M NaCl, 0.1 M 
tetrasodium EDT A, 10 mM Tris-base) containing 1 mg/mL proteinase K for 60 min at 
37°C. Thereafter, they were rinsed with distilled water, incubated in alkaline 
electrophoresis buffer for 30 min at 37°C, and electrophoresed at 300 mA for 60 min. 
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The gels were subsequently rinsed with distilled water and placed into 1 M ammonium 
acetate for 30 min. They were further soaked in 100% ethanol for 2 h, dried ovemight 
and subsequently stained with SYBR Gold (1: 1 0,000 dilution of stock supplied by 
Molecular Probes, Eugene, OR) for 20 min. For evaluation of cornets, DNA damage was 
assessed using the tail moment parameter (i.e. the product of the distance between the 
barycenters of the head and the tail of the cornet multiplied by the percentage DNA in 
the tail region). A minimum of 50 cells/comet were analyzed for each sample, using 
ALKOMET v3.1 software, and the values presented are average tail moments for the 
entire cell population (McNamee et al., 2000) 
6.3.7. Flow Cytometric Analysis of Cell Cycle Progression 
DU145 cells (1xl06) were preincubated in six-well plates with 10% serum at 37°C for 
24 h. Thereafter, cells were treated with the indicated dose range of RB24, RBI07, 
RB10, FD105 and TEM for 24 h. The cells were harvested with trypsin-EDTA, 
centrifuged and re-suspended in PBS. Vinde1ov's solution [O.OlM Tris-base, 10mM 
NaCI, 700 U RNase, 7.5x10-s M propidium iodide, 0.1 % NP-40] was added (400111) for 
10min at 37°C, and the fluorescence (FL2) detected DNA content was measured using a 
Becton Dickinson Flow Cytometer. 
6.3.8. Pharmacoanalysis 
The drug, RB24, was administered Lv. to CD-l male mi ce (3/group/time point) (Charles 
River, Saint-Constant, QC, Canada) at 100 mg/kg dose in 004 mL of a Tween 80 
(6%)/ethanol (10%) saline solution. Blood samples were collected in heparinized tubes 
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either immediately or 5 min post-injection administration and centrifuged for 8 min at 
3000 rpm and plasma separated with a micropipette and stored at - 80 oC. Plasma 
aliquots (50/-lL) were mixed with acetonitrile (100 /-lL) to precipitate the proteins and the 
mixture centrifuged for 5 min at 6000 rpm. Samples were analyzed by LC-MS using a 
Discovery C18 (15cmx3mm, 5mm) colurnn at pH=9 to identify the peaks corresponding 
to the expected metabolites. 
6.3.9. Mouse Xenograft Studies (DU145) 
CD-1 nude male mi ce (River, Saint-Constant, QC, Canada) were maintained as per 
Mc Gill animal safety protocols. Dose finding was performed with 2 CD-1 nude 
mi ce/group and the maximum tolerated dose defined as dose that does not induce more 
than 15% weight loss over a period of at least 14 days. For xenograft studies, mice were 
treated with 1x106 cells suspended in 0.2 mL PBS injected subcutaneously into the flank 
of each mouse. Treatments began when tumors became palpable. The animaIs were 
placed into treatment groups of 6 mice each and one control group that received the 
vehicle for RB107(Tween 80 (6%)/ethanol (10%) in saline), TEM (10% DMSO in 
saline) and gefitinib (10% Tween 80 in saline). The treatment groups were given RB 107 
(e.g. 100mg/kg), TEM (100 mg/kg) or gefitinib (100 mg/kg) in 0.4 mL volume i.p. every 
other day. Tumor burdens were measured before each injection and tumor volume was 
calculated using the formula TV = [(tumor width + tumorlength)/4]3 x 4/3 x 3.14159. 
Statistical significance was determined using a two-tailed Student t-test (n=6). 
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/.--..., 6.4. Results 
6.4.1. In vitro analyses 
6.4.1.1. Binary EGFRIDNA targeting properties 
The dual EGFRIDNA targeting properties of RB 1 07 were characterized by 
Western blotting of EGF-stimulated DU145 cells and the single-cell 
microelectrophoresis (cornet) assay. Using an ELISA, we first demonstrated that 
RB 1 07 was capable of blocking activation of isolated EGFR in a dose-dependent 
manner with an 1Cso of 0.28J.lM (Table 6.1). Likewise, Western blotting results showed 
a dose-dependent blockade of EGF-induced EGFR phosphorylation (ICso=4J.lM) 
(Fig.6.1 a). 
On the other hand, cornet analysis following a 2 hour drug treatment, a time period that 
allows maximal intracellular decomposition of RB 1 07, demonstrated that the drug 
induced significant levels of DNA damage (Fig. 6.2b). More importantly, these levels 
were approximately 1.5-fold higher than that inflicted by the clinical drug, TemodafM 
(TEM) (Fig.6.2b). 
6.4.1.2. Antiproliferative activity 
Having demonstrated the binary targeting properties of RB 1 07, we examined its 
antiproliferative activity in the DU145 cell line that has already been shown to be 
sensitive to EGFR inhibitors in vitro (Vicentini et al., 2003; Sgambato et al., 2004). 
More importantly, DU145 cells also express the DNA repair enzyme 06-alkylguanine 
transferase (AGT) that is known to confer resistance to methylating agents of the same 
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Table 6.1. Inhibition of EGFR TK activation and antiproliferative activity in DU145 
cells by RB24, RBI07, RB 105, BJ2000, FDI05, TEM and gefitinib. 
Compound 
RB24 
RBI07 
RBI05 
BJ2000 
FDI05 
TEM 
Gefitinib 
ICso competitive binding 
(JlM) 
0.28 
0.23 
0.1 
>10 
a Banerjee et al., J Med Chem 2003; 46:5546-51. 
b J Pharmacol Exp Ther 2002;303:238-46. 
cMoulder et al., Cancer Res 2001 ;61: 8887-95 
dBanerjee et al., 2006 (Chapter 5) 
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Antiproliferative activity 
(ICso,JlM) 
12 ± 2.6d 
24 ± 1.3 
21 ± 1.1 
26 ± 1.3 
36 ±2.4 
470 ± 5.6 
47 ± 1.2 
(A) 
+EGF 
+EGF -EGF 50 10 1 0.1 (!lM) 
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EGFR 
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----.- TEM 
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Figure 6.1. Binary targeting properties of the combi-molecule, RBI07. A, inhibition of 
EGFR TK autophosphorylation by RB107 in DU145 cells. Serum-starved cells were 
pre-incubated for 2 h with the indicated concentrations of RBI07 prior to stimulation 
with EGF (50 ng/mL) for 15 min. Equal amounts of cell lysates were analyzed by 
western blotting using anti-phosphotyrosine antibodies. Membranes were stripped of 
anti-phosphotyrosine and re-probed with anti-EGFR antibodies as a loading control. B, 
In vitro DNA damage analysis was carried out after a 2 h exposure to RB 1 07 and TEM. 
Tail moment parameters were measured with ALKOMET image analysis software for at 
least 50 cells/dose. Each point represents at least two independent experiments. 
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class as RBI07 (e.g. TEM) (Pegg et al., 1995a; Pegg et al., 1995b). The results showed 
that the combi-molecule, RBI07, was greater than 33-fold more potent than TEM and 
approximately 4-fold more potent than gefitinib, indicating that the binary targeting 
strategy leads to more potent molecules (Table 6.1). These results suggest that the dual 
targeting combi-molecules are more potent than their single targeted counterparts. 
6.4.1.3. Cell cycle effects 
DNA alkylators are known to block the cell cycle in S and G2/M phases in 
sensitive tumour cells (D'Atri et al., 1998; Hirose et al., 2001; Hirose et al., 2003). On 
the other hand, inhibitors of EGFR TK block the cell in the G 1 phase (Lebeau et al., 
2003; Chang et al., 2004; Gonzales and Fry, 2005). RB107 and RB24, being a 
combination of both classes of drugs, it was important to determine the effect of their 
combined properties on the cell cycle in DU145 cells. Interestingly, the results showed 
that both RB 1 07 and RB24 predominantly blocked the cells in Gland this cell cycle 
profile paraIle1s that induced by their reversible inhibitory counterparts, FD 1 05 and 
RB 1 0, respectively (Fig 6.2). In contrast, the DNA damaging agent, TEM, did not 
induce any significant cell cycle perturbation (Fig 6.2). 
6.4.2. Pharmacoanalysis 
Following direct Lv. administration (lOOmg/kg), LC-MS characterization of compound 
re1eased, at either 0 min or 5min post-injection, from RB24 confirmed the presence of 
RBI0 (mlz 315), ZR08 (mlz 357), and RB14 (mlz 387) in plasma (Fig. 6.3a,b). Weight 
loss monitoring analysis showed that RB 1 07 was weIl tolerated with no noticeable 
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o 50uM 
Fig. 6.2. Cell cycle effects on DU145 cells. Cell cycle profile following exposure to a 
dose-range of RB 107, FDI05 and TEM for 24 h in the DU145 cellline. 
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Figure 6.3. Pharmacokinetic analysis of the complex combi-molecule, RB24 in CD-I 
nude mice. LC-MS analysis of the metabolites present at either A) 0 min or B) 5 min 
following Lv. administration ofRB24 (lOOmglkg). 
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Figure 6.4.Weight loss monitoring study in CD-l nude mice. Dose finding was 
performed with 2 CD-l nude mi ce/group administered RB107 at A, 50 mg/kg, B, 100 
mglkg or C, 200 mglkg. RB107 was administered i.p. every other day, for a total of 9 
injections over a two week period. 
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weight loss 21 days after an every other day treatment schedule at doses as high as 200 
mg/kg (Fig. 6.4). 
6.4.3. In vivo efficacy 
To determine whether the binary targeting properties and the in vitro antiproliferative 
activity of the compound would translate into in vivo activity, we analyzed the effect of 
RB 1 07 on DU145 prostate tumours grafted on immunocompromised mice. The results 
showed significant antitumour activity 15 days post-treatment (p<0.05) (Fig. 6.5a). In 
contrast, at the same dose TEM demonstrated no significant activity (Fig. 6.5b). 
Similarly, under the aforementioned schedule, both gefitinib and an equi-dose 
combination of TEM (50 mg/kg) + gefitinib (50 mg/kg) showed no significant 
antitumour activity at any time point (p>0.05) (Fig. 6.5c,d). 
6.5. Discussion 
Previous studies demonstrated that RB24 could induce sustained antiproliferative 
activity and this was imputed to its ability to generate multiple species with EGFR TK 
inhibitory activity + a methyldiazonium species. Although the fluorescence property of 
the ultimately released metabolite RB 1 0 permitted its identification, the short life of the 
other metabolites of the cascade precluded their characterization. Thus, we designed an 
experiment wherein RB24 was injected i.v. to CD-I mice and the plasma collected either 
immediately or 5 min after injection. The rapid process permitted the detection of aIl 
predicted species, the predominant one being the monoalkyltriazene, ZR08. It should be 
remembered that the small difference between the half-life of RB24 (tll2=42 min) and 
RB14 (t1l2=40 min), as weIl as between RBl4 and ZR08 (t1l2=38 min), indicated a rapid 
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Figure 6.5. Antitumour activity of RB107 and TEM in a DU145 xenograft model. 
Comparison of tumour growth inhibition two weeks following i.p. administration 
between vehic1e and A, RB107 (100 mg/kg) or B, TEM (100mg/kg) every other day in 
CD-1 nude male mice. Statistical analysis was performed with a two-tailed t-test. Star 
indicates statistical significance p< 0.05 (n=6)~ bars, SD. 
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Figure 6.5. Antitumour activity of gefitinib and gefitinib + TEM in a DU145 xenograft 
model. Comparison of tumour growth inhibition two weeks following i.p. 
administration between vehicle and C, gefitinib (100 mglkg) or D, gefitinib + TEM 
(50mg/kg) every other day in CD-1 nude male mice. Statistical analysis was performed 
with a two-tailed t-test. Star indicates statistical significance p< 0.05; bars, SD. 
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transition between these elements of the cascade (Banerjee et al., 2003). The stability of 
ZR08 is in the same range as analogous naked triazenes (e.g. SMA41, t1l2=30 min; 
BJ2000, t1l2=34 min) (Fig. 6.6). Therefore, conversion of ZR08 into RBIO at the last 
step of the cascade should be considered rate-limiting and RB24 or RB14, "prodrugs" of 
ZR08. This is further corroborated by both the appearance of a higher titer of ZR08 in 
the plasma immediately after RB24 injection and 5 min after administration. This 
indicates that indeed, ZR08 is the most stable of the transient metabolites. It should be 
noted that the most stable metabolite of the entire cascade is RB 1 0, Thus, following the 
disappearance of all metastable metabolites, EGFR inhibition is sustained by RB 1 0, 
which is a strong inhibitor ofEGFR (ICso=0.04J.lM). 
Interestingly, despite the generation of these multiple speCles the cascade release 
molecule analogue, RBI07, used in the in vivo studies, was well tolerated 
(MTD=200mg/kg). Their tolerance paralleled that of the cyclic methylating triazene, 
TEM (Brada et al., 1999; Rudek et al., 2004; Jones et al., 2005), that is known to have 
an MTD > 200 mg/kg. This good tolerance also indicates that dual targeting of EGFR 
and DNA methylation by an alkylating agent is a non-toxic event. 
Methylating agents like TEM are, in general, inactive against AGT-expressing cells in 
vitro and in vivo (Pegg et al., 1995a; Pegg et al., 1995b). In this study the combi-
molecule (a methylating agent) induced superior antiproliferative potency when 
compared with TEM and its equi-dose combination of TEM + gefitinib. The significant 
potency observed with RB107, in a once every other day schedule in an AGT+ DU145 
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model is rather unique and may be imputed to its ability to simultaneously damage DNA 
and block EGFR. Indeed, previous studies with its analogue RB24, demonstrated that 
inhibition of EGFR activation in the DU145 cells is concomitant with down-regulation 
ofphosphorylation of the anti-apoptotic protein Bad (Banerjee et al., 2006b). In contrast 
to TEM, the latter molecule was capable of inducing high levels of apoptosis in the 
DU145 cell line. These results suggest that the single combi-molecule is a superior 
mimic of a two-drug combination when compared at equi-doses. 
Flow cytometric analysis and fluorescence microscopy in previous studies have shown 
that DNA damage induced by the RB 1 07 analogue, RB24, is consistently higher in 
isogenic cells that express high levels of EGFR or Her2 and that the released inhibitor 
RBIO (the bromo-analogue of FD105) was preferentially distributed in the perinuclear 
region (Banerjee et al., 2006a). Further, co-administration of RB24 with its metabolite 
RB 1 0 depleted levels of DNA damage and abolished EGFR targeting, indicating that the 
combi-molecule primarily anchors into perinuclear binding sites prior to releasing the 
methyldiazonium that intensively damages the DNA (Banerjee et al., 2006a). Therefore, 
the enhanced potency of the combi-molecule when compared with combination of 
individual drugs, may not only be due to their binary EGFRIDNA targeting functions, 
but also to their ability to induce discrete distribution of the bioactive species within the 
various subcellular compartments (e.g. cytoplasm, perinuclear region). Qiu et al. (2006) 
have recently shown that JDA35, a fluorescent inhibitor released by the combi-molecule, 
JDA58, is distributed in the perinuclear region in DU145 cells analysed in vitro and in 
vivo, indicating that the perinuclear distribution of the cascade release combi-molecule is 
common to other combi-molecules. 
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It is important to note herein that in contrast to TEM, the cascade release molecules, 
RB 1 07 and RB24, being designed to block EGFR and damage DNA, preferentially 
blocks the cells in G 1, indicating that blockade of EGFR is playing a significant role in 
their antiproliferative activity. lndeed, it has already been shown that inhibitors of 
EGFR block the cell cycle in G 1 (Lebeau et al., 2003; Chang et al., 2004; Gonzales and 
Fry, 2005). However, the combined effect of the combi-molecule on the cell cycle is 
seen at the highest dose (e.g. 50~M) where in addition to a strong arrest in GI (84 %) a 
significant block in G2/M was also observed (i.e. 43% increase in cell number). This 
indicates that cells that escape the G liS arrest may be arrested later in G2/M due to the 
DNA lesions inflicted by the combi-molecule. 
This study conclusively demonstrated that the binary targeting property of combi-
molecules capable of releasing multiple EGFR inhibitory species and DNA damaging 
methylating agent, translate into significant antitumour activity in vivo. 
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CHAPTER7 
DISCUSSION 
AND 
CONTRIBUTION TO KNOWLEDGE 
7.1. Discussion and contribution to knowledge 
Depending on the progression or stage, current cancer therapy involves the combination 
of multiple modalities including surgery, radiation and chemotherapy. Although 
conventional chemotherapy with cytotoxic agents have proven to be effective in many 
sol id tumours, their toxicity still remain a major deterrent for their clinical use. Current 
advances in cancer chemotherapy involve the development of therapeutics that are 
capable of targeting overexpressed or dysfunctional proteins implicated in the malignant 
phenotype (e.g. EGFR, Her2, bcr-abl). 
Recent studies have shown that inhibition of EGFR or its closest homologue, Her2 
(ErbB2), receptor tyrosine kinases involved in aggressive tumour progression and 
chemoresistance, resulted in significant anitproliferative activity in tumour cells (Lebeau 
et al., 2003; Shelton et al., 2005). Her2 is overexpressed in 20-25% of invasive breast 
cancers and occurs primarily through gene amplification (Slamon et al., 1987; Lebeau et 
al., 2003). Overexpression of Her2 is associated with poor disease-free survival and 
chemoresistance (Press et al., 1997; Paik et al., 1998). Therefore, Her2 has become an 
important therapeutic target in breast cancer (Luftner et al." 2005). Herceptin ™ 
(trastuzumab), a recombinant humanized monoclonal antibody directed towards the 
extracellular domain of the Her2 receptor, has proven highly effective against breast 
cancer. Currently, Herceptin™ is the only Her2-targeted therapy approved by the US 
Food and Drug Administration for the treatment of metastatic breast cancer and is 
administered in combination with chemotherapies such as paclitaxel and docetaxel 
(Luftner et al., 2005; Robert et al., 2006). 
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Numerous small molecule inhibitors targeting the EGFR TK have been developed and 
have shown promising anti-tumour activity in the clinic (Baselga and A verbuch, 2000; 
Moulder et al., 2001; Sgambato et al., 2004; Martin et al., 2006). However, the clinical 
response to this drug remains weak and in many cases, they only induce disease 
stabilization (Baselga and A verbuch, 2000; Moulder et al., 2001; Marshall, 2006). 
Although these compounds have been found to be well-tolerated, they are unable to 
induce significant cell-killing, a characteristic that is usually associated with cytotoxic 
chemotherapeutic agents such as DNA alkylators and antitumour antibiotics (Ciardello 
et al., 2000). The primary contribution of this thesis is to demonstrate that cytotoxicity 
can be conferred to these agents by designing compounds termed cascade release combi-
molecules, "programmed" to not only release an alkylator, but also multiple inhibitors of 
EGFR TK. More specifically, we demonstrated that these molecules could be masked 
with latent functions that do not hamper EGFR inhibitory effects and rather increase the 
water-solubility of the designed agents, leading to a more suitable formulation. Thus, 
the development ofthis thesis can be summarized into three major discoveries: 1) design 
and development of cascade release molecule, 2) discovery of a novel model of EGFR 
and Her2 targeting by small molecules and 3) discovery of a synergistic cross-talk 
between MAPK, anti-apoptotic signaling and DNA repair pathways that contribute to 
enhanced potency. 
Discovery 1: Cascade release molecules 
The observation that the putative degradation products from the parent cascade combi-
molecule have different biological response profiles (e.g. RB24 inducing more 
protracted inhibition of EGFR autophosphorylation than RB 14 and ZR08) indicate that 
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each member of the cascade may contribute to EGFR inhibition in ceIls, thereby 
hammering the receptor to prevent its reactivation (Banerjee et al., 2003, Banerjee et al., 
2004). More importantly, the potent and stable EGFR inhibitor released at the last step 
of the cascade further prolongs the EGFR inhibition and sustains antiproliferative 
activity. Further, the masking acetoxymethyl group of RB24, being able to promote 
water solubility, give the molecule the property of a water soluble envelope containing 
multiple species. Indeed, ZR08 that is released by the parent combi-molecule, is so 
insoluble in water that it is not suitable for in vivo studies. The fact that none of these 
molecules, when tested individuaIly, showed any significant loss ofEGFR TK inhibitory 
activity indicates that the signaling inhibitory properties of these molecules are weIl 
preserved during and after decomposition (Banerjee et al., 2003). This finding can 
inspire the design of molecules to target other types of disease-related kinases by 
programming them to maintain their activity while being hydrolytically activated to 
generate another target-directed species. This princip le is summarized by the model 
derived from this study and is depicted in Figure 7.1. The complex combi-molecule 
exemplified as I-TZ, can be designed to bind to the target 1 (e.g. EGFR, Her2) , to 
decompose to I-TZ' directed at target 1, while being allowed to be converted to I-TZ" 
pointed at target 1. The latter combi-molecule can release l directed at target 1 + a 
species aimed at target 2. If the rate of conversion of each of the elements in the 
cascade can be optimized, or if conversion can lead to molecules directed at different 
targets (e.g. target 2, target 3, target 4), this model will provide a me ans to significantly 
ameliorate multi-targeting and sustained inhibition of kinases. Cancer being a disease 
arising from a complex network of interrelated biological processes within a single 
ceIl, it is critical that cancer drug development progress towards the development of 
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single agents capable of interfering with multiple pathways. In this context, the novel 
model pioneered by this thesis is a demonstration of the feasibility of such agents. 
Discovery 2: Discovery of a novel model of EGFR and Her2 targeting by small 
mole cules 
The literature is punctuated with molecules designed with a recognition head and DNA 
damaging function. As an example, estramustine was designed to contain an estradiol 
warhead linked to a nitrogen mustard moiety (Petrow and Padilla, 1986). Although this 
molecule could bind to the estrogen receptor, the compound did not damage DNA 
directly (von Schoultz et al., 1991). Small molecule-based targeting has long been 
based on creating covalent linkage between the recognition head and the cytotoxic tail. 
Another example is the peripheral benzodiazepine receptor (PBR)-targeting agent 
containing a benzodiazepine moiety and a melphalan tail that did not show selectivity 
for tumours overexpressing PBR (Kupczyk-Subotkowska et al., 1997). Here we 
discovered that molecules termed combi-molecules that contain a hydrolysable linkage 
between the recognition head and the DNA damaging tail could indeed target the DNA 
damage to cells expressing a specific receptor (Banerjee et al., 2006a). More 
importantly, this is the first time that intracellular localization of the target receptor has 
been shown to direct the delivery of the DNA damaging agent. We believe that the 
combi-molecule owes this advantage to its hydrolyzable linkage. Indeed, the molecule 
can rapidly bind to the receptor and slowly hydrolyze to the alkylating species, allowing 
a bystander effect that leads to abundant release of alkylators towards the nucleus. It has 
now been demonstrated that EGFR is intemalized following activation and is distributed 
in the perinuclear region (Murthy et al., 1986; Khan et al., 2006). Thus, this model (see 
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figure 4.4, p. 167) suggests that if many receptors are proven to be relocalized in the 
same manner, we will have discovered a mean to selectively damage DNA in cells with 
various receptors involved in aberrant signaling in refractory tumours. 
Discovcry 3: Discovcry of a syncrgistic cross-talk bctwccn MAPK and anti-
apoptotic signaling or DNA rcpair pathways 
In principle, when growth signaling is activated in a cell, all survival pathways are 
alerted. This is mediated through activation of anti-apoptotic pathways, DNA repair 
pathways and cell cycle factors (Rowinsky et al., 1999; de Thonel and Eriksson, 2005). 
On the other hand, when the cells are exposed to various stressors, including radiation 
induced DNA damage, reactive oxygen species and DNA alkylation, many pathways 
leading to their rescue and those that induce their death by apoptosis are activated. The 
combi-molecules, RB24, described in this thesis, are capable of both blocking growth 
factor-mediated signaling and inducing stress through DNA damage. We have 
presented herein the first characterization of the multiple signaling pathways activated in 
response to a single drug that behaves as a binary stressor. As depicted in Figure 7.2, 
where the combi-molecule is exemplified by 1-TZ, it appears that both the 1-TZ itself, 
and the inhibitors that it releases, can exert blockade of two major signaling pathways: 
1) the Ras/Raf/MAPK cascade and 2) the PI3K1Akt pathway. Through this mechanism, 
the molecule blocks growth factor-mediated signaling while down-regulating anti-
apoptotic pathways (Banerjee et al., 2006b). The DNA damaging component, TZ, 
triggers stress response mediated by the MAPK family, an event that leads to 
expression of the DNA repair protein, XRCCI (Banerjee et al., 2006b). The latter BER 
protein is also induced by receptor activation. We have discovered that concomitant 
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induction of XRCCI through DNA damage response and EGFR activation causes an 
elevation of the latter protein in the presence of the alkylator, TEM. This elevation of 
XRCCI can only augment resistance to the latter alkylator. Conversely, the combi-
molecule is capable of down-regulating the latter DNA repair protein through EGFR 
activation, but not through stress response. In toto, in contrast to TEM, by shutting 
down aIl growth factor-related signaling, the combi-molecule was capable of partially 
depleting XRCC 1 and committing the cells to apoptosis. 
On the other hand, MEKI being at the interface ofvarious signaling pathways, including 
the one that leads to induction of XRCC 1, we found that its blockade could not only 
deplete the levels of the latter protein, but also significantly enhance apoptosis in these 
ceIls. This has led to a new formula for synergistic combination in cancer therapy. The 
following combinations were found markedly synergistic: 1) combi-molecule+MEKI 
inhibitor and 2) clinical TKI + TEM + MEKI (Banerjee et al., 2006b). It should be 
noted herein that combination formulas discovered within this context of this thesis have 
been submitted for patent protection by McGill University Office of Technology 
Transfer (OTT) (Jean-Claude and Banerjee, 2005). Thus, by exploring multiple 
signaling pathways in response to the mixed targeted combi-molecule, we discovered a 
novel combination model that may not only ameliorate the potency of the combi-
molecule itself, but also that of the currently used clinical drugs from both the triazene 
and clinical TKI classes. 
In summary, we have developed novel complex combi-molecules capable ofnot only 
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interfering with multiple signaling pathways in the ceIl, but also selectively targeting 
cells with aberrant expression of the ErbB 1 and ErbB2 gene products. The work 
performed for this thesis was deployed from the design and synthesis ofthe probe drugs, 
to the demonstration of in vivo potency of a novel tumour-targeting approach. 
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The synthesis of a novel acetoxymethyltriazene designed to be a prodrug of multiple inhibitors 
of the epidermal growth factor receptor (EGFR) and a methyldiazonium species is described. 
Studies with each of the expected metabolites demonstrated significant EGFR tyrosine kinase 
inhibitory activities and the released methyldiazonium was trapped with p-nitrobenzylpyridine. 
Their ability to damage genomic DNA in whole ceUs was demonstrated by using the single cell 
microelectrophoresis (cornet) assay. The results suggest that this approach may weU represent 
a novel drug combination strategy involving single molecules masking multiple bioactive agents. 
Introduction 
The altered protein expression and activity of receptor 
tyrosine kinases (TK) are implicated in the progression 
of various types of cancers. One such dysfunction is the 
overexpression of the epidermal growth factor receptor 
(EGFR) and its closest homologue HER2 (erbB2) that 
correlates with aggressive tumor progression and poor 
prognosis.! Recently, we developed a novel strategy that 
seeks to combine DNA-damaging properties and EGFR 
TK inhibitory activities into single molecules termed 
"combi-molecules" designed to kill EGFR-expressing 
tumor cells.2- s To enhance the EGFR inhibitory potency 
and stability of these compounds, we designed a novel 
strategy termed "cascade release" (CR) that seeks to 
mask the combi-molecule into a prodrug "programmed" 
to release the antitumor species by hydrolytic activation. 
Since these molecules, henceforth referred to as "cascade 
release molecules" (CRM), are also designed to retain 
significant EGFR affinity on theii own, this principle 
leads to conditions under which three generations of 
inhibitors can be derived from the parent CRM. 
To test the CRM principle, we initially designed 
structure 2 (Scheme 1) with the hope that it would not 
only retain affinity for EGFR but also hydrolyze to 
generate monoalkyltriazene 1 which, as previously 
demonstrated, heterolyzes into the corresponding 6-
amino-4-anilinoquinazoline (an inhibitor of EGFR) + a 
methyldiazonium species.2,3 Thus, CRM 2 was designed 
to be the prodrug of two known inhibitors of EGFR. Its 
synthesis proceeded according to Scheme 1. Structure 
1, obtained as described earlier,6 was treated with acetyl 
chloride in methylene chloride at 0 oC to give 2 in an 
18% yield. Studies of the hydrolysis of 2 under physi-
ological conditions (Le. incubation in serum containing 
media at 37 oC) demonstrated little degradation after 
24 h. Further exposure for an additional 24 h led to 
minor degradation. Therefore, it was concluded that this 
* Corresponding author. Tel: (514) 842-1231. ext 35841. Fax: (514) 
843-1475. E-mail: jacquesJeanc1aude@mcgill.ca. 
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molecule was not a suitable probe for the demonstration 
of the CRM principle. 
We subsequently designed structure 6 (Scheme 2), 
which would not only offer the opportunity to further 
mask the CRM but also to degrade according to known 
kinetics and mechanisms.1·8 It has already been dem-
onstrated that acetoxymethyltriazenes rapidly degrade 
to the corresponding hydroxymethyl triazene, which in 
turn is converted to a monoalkyltriazene of type 1.6 
Further, heterolysis of triazene is known to generate 
an aromatic amine and an alkylating agent. 8 Thus, we 
surmised that these mechanisms of degradation might 
lend themselves to the demonstration of the CRM 
principle. 
1O,10211jm030423m CCC: $25.00 © 2003 American Chemical Society 
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Table 1. EGFR TK Inhibition. Alkylating Activity. and 
Half-Lives of Compounds 1-3. 5. 6. and 8 
half-life ((1/2).' min 
compds 
1 
2 
3 
5 
6 
8 
TEM 
inhibn of EGFR 
IC5o.,uMa 
0.2 
0.578 
0.04 
0.11 
0.13 
0.07 
NIA 
alkylating activity (10-3 min-I)b 
9.1 
1.5 
0.05. 
6.6 
5.8 
8.9 
11.3 
RPMI 
35 
>200 
NIA 
40 
42 
38 
NIA 
PBS 
69 
>200 
NIA 
70 
84 
68 
NIA 
a EGFR TK values are means of two experiments. Alkylating 
activity and half-lives values were obtained from single experi-
ments. b Measured as a rate of alkylation of NBP at pH 7.5. 
C Measured by UV absorbance at 290 nm. 
Results and Discussion 
Chemistry. The synthesis of 6 proceeded according 
to Scheme 2. Briefly. compound 3 was treated in 
acetonitrile with NOBF4 to generate intermediate 4. 
which was treated in situ with a 10: 1 mixture of 
formaldehyde/methylamine. Alkalinization with aque-
ous KZC03 led to precipitation of compound 5. in high 
yield. However. this compound coprecipitated with solid 
KZC03, which was removed by resuspension in THF 
followed by collection and evaporation of the filtrate. 
Hydroxymethyltriazene 5 was obtained in a pure state 
(70% yield) without requirement for further purification. 
Treatment of 5 with acetic anhydride in pyridine gave 
6 as a pure solid. We have already reported the 
synthesis of 8.9 
The stability of 6 and that of each of its putative 
metabolites were studied by allowing them to degrade 
in both phosphate-buffered saline (PBS) and serum-
containing media using UV spectrophotometric analysis. 
Compound 6 was much less stable than 2. with a half-
life of 42 min in serum-containing media (Table 1). 
Interestingly, its putative metabolite 5 (Scheme 3) 
showed a half-life of 40 min, suggesting that conversion 
of 6 to 5 may be a rapid event. Indeed, it has already 
been reported that acetoxymethyltriazenes are rapidly 
converted to the corresponding hydroxymethyltriazene 
in PBS.IO-1Z 
Attempts to monitor the formation of 5 by HPLC 
failed due to its instability under the separation condi-
tions. However, when 6 was allowed to degrade over-
Journal of Medicinal Chemistry. 2003. Vol. 46. No. 25 5547 
night under physiological conditions. we could success-
fully detect amine 3 (Schemes 2 and 3) as the sole 
product. suggesting that the putative intermediary 
metabolites may have been formed according to the 
mechanism outlined in Scheme 3. This mechanism has 
already been proposed for similar triazenes.11,1Z Addition 
ofwater to iminium ion 7 may generate the methylol5, 
which may self-deformylate to give the monoalkyltria-
zene 8. To circumvent problems associated with on-
column degradation of 6 and that of its metabolite 5, 
we designed a fluorescence detection assay in order to 
monitor the formation of 3, the ultimately generated 
stable metabolite. Absorption-emission spectra of the 
latter showed absorption at 290 nm and emission at 450 
nm. Thus, we could unambiguously analyze the kinetics 
of formation of 3 by spectrofluorimetry. Interestingly, 
the rate of conversion of 5 to 3 was slower than that of 
8 to 3. These data support a stepwise degradatlon of 
the CRM in the sequence proposed in Scheme 3. More 
importantly, the symmetrically inversed relationship 
between the degradation of the diverse metabolites and 
the formation of 3 suggest a near stoichiometric conver-
sion of 6 to 3 (Figure 1). A similar result was reported 
for triazenoquinazolines of types 1 and 8.3 
Biology. Our objective being to generate multiple 
inhibitors from a parent one, we tested the EGFR TK 
inhibitory activity of each of the putative metabolites 
alone in a short 8-min exposure ELISA. The assay was 
based on the inhibition of phosphorylation of poly(L-
glutamic acid-L-tyrosine, 4:1) (PGT) by EGFR tyrosine 
kinase. Structure-activity relationships (SAR) in the 
quinazoline series have already demonstrated tolerance 
of bulky substituents at the 6- and 7 -positions. 13- 15 
Indeed, the triazene appendage to the 6-position of this 
series did not significantly alter the EGFR binding 
affinities wh en compared with 3. As an example, the 
IC50 values for 3 and 8 were in the same range le.g., 8 
(IC50 = 0.07 .uM), 3 (IC5o = 0.04 .uM)] (Table 1). More 
importantly, previous studies have demonstrated the 
strong dependence of the SAR of quinazolines on the 
electronic character of the substituents at the 6-posi-
tion. 14.15 Electron-donating groups at the 6-position 
enhance activity. whereas electron-withdrawing ones 
are deleterious to affinity. In this study, it was found 
that acylation of 1 decreased the affinity of the resulting 
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Figure 1. Formation (.) of 3 du ring the de gradation ( .... ) of 
(a) 6. (b) 5, and (c) 8 in RPMI supplemented with FBS 10% at 
37 oC. Degrada.tion experiments were carried out by UV 
spectrophotometric analysis. The analyses were performed at 
25 ,uM. Drugs were added to RPMI -1640 with 10% FBS (2 mL) 
and incubated at 37 oC. 
compound 2 by 3-fold (Table 1). This may be due to the 
decrease in the electron-donating character of the tri-
azene, whieh may deplete the partial charges on the 
nitrogens in the quinazoline ring. lndeed, when acyla-
tion was performed in a manner that did not affect the 
p-extended system of 1,2,3-triazene (as in 6), there was 
little change in binding affinity when compared with 
the parental monomethyl triazene 8. A significant 
decrease in the electron density at NI was already 
demonstrated by 15N spectroscopy when N3 in cyelie and 
acyelic triazenes are acylated. 16.17 
Previous studies demonstrated that serum stimula-
tion of isogenie cells transfected with EGFR or the 
HER2 gene product represent good models for the 
determination of tumor selectivity of combi-molecules, 4 
since they offer the advantage of growth-stimulating the 
two celllines with a common growth factor. When this 
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Table 2. Inhibition of Serum-stimulated Growth in NIH3T3, 
NIH3T3/HER14. and NIH3T3/neu Cell Unes by Compounds 
1-3. 5. 6. 8. TEM, Ag1478 and Combination of TEM + 
AG1478 
ICso, ,liMa 
compds NIH3T3 NIH3T3/HER14 NIH3T3/neu 
1 125 ± 1.7 28.9 ± 5.5 16.5 ± 2.3 
2 200 ± 6.3 '149 ± 14.2 60.6 ± 6.9 
3 14.5 ± 1.9 10.4 ± 0.5 0.42 ± 0.03 
5 12.8 ± 0.45 2.1 ±0.3 0.09 ± 0.03 
6 15.4 ± 0.55 3.4 ± 1.2 0.21 ± 0.05 
8 150.5 ± 1.9 8.8 ± 0.6 0.09 ± 0.03 
TEM 214.0 ± 11.1 207.2 ± 12.7 210.0 ± 16 
AG1478 28.6 ± 3.6 9.8 ± 0.3 4.0 ± 0.2 
TEM+AG1478 39.4 ± 5.4 6.2 ± 0.5 1.1 ± 0.06 
aValues are means of ICso values and SEMs from three 
experiments. 
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Figure 2. Effect of 6 on serum stimulated-proliferation in 
NIH3T3 (.) and NIH3T3/neu ( .... ) cells. Cells were starved for 
24 h and exposed to each drug + serum for 72 h and growth 
inhibition was measured using SRB assay. Each point repre-
sents at least two inde pendent experiments run in triplicate. 
model was used, ail compounds possessing EGFR TK 
inhibitory activities selectively blocked serum-stimu-
lated growth of NIH 3T3 ce Ils transfected with EGFR 
(NIH3T3/HER14) or HER2 (NIH3T3/neu), indicating 
translation of the EGFR TK inhibition into blockade of 
growth-factor-mediated proliferation (Table 2). A typieal 
NIH3T3/NIH3T3neu differential growth response pro-
file is shown in Figure 2. Moreovèr, it is noteworthy that 
the cascade release molecule 6 is significantly more 
potent than its metabolite 8 (p < 0.001) in the EGFR 
transfected cellline NIH3T3/Herl4. However, the order 
of potency of these two molecules was inverted in the 
NIH3T3/neu cell line, indieating that perhaps 6 is less 
selective for HER2/neu than 8 and therefore may not 
serve as an efficiently targeted prodrug of 8 in these 
cells. 
To further demonstrate the efficacy of the cascade 
combi-molecular approach, the effects of 6 were com-
pared with those of elassieal combination of temozolo-
mide (TEM) and AG1478, a known in vivo active EGFR 
TK inhibitor. 18 The combinations were performed at 
IC50(TEM)IIC50(AG1478) molar ratios. The results showed 
that 6 was 2.5- and 5-fold more potent than equieffective 
doses ofTEM + AG1478 in NIH3T3/Her14 and NIH3T3/ 
neu cells, respectively. Superior activity (e.g. lü-fold) 
when compared with the TEM + AG478 combinations 
was observed for 8 only in the NIH3T3/neu cells, whieh 
is in agreement with its strong activity in the latter cell 
line. These results support the significant antiprolif-
Prodrug Ta Release Multiple lnhibitors of EGFR 
TBf 
AGl478 
erative potency of our combi-targeting and combi-
molecular CRM approaches. 
The hydrolysis of our CRM is expected to generate 
multiple inhibitors of EGFR and, at the final stage of 
degradation, the methyldiazonium species. Since the 
latter is known to be the cytotoxic DNA-alkylating 
metabolite of triazenes,3-5.l9 we studied the alkylating 
potency of the different agents using the 4-(p-nitroben-
zyl)pyridine (NBP) test.20 In this colorimetrie assay, the 
alkylating species is trapped by NBP and a purple color 
is developed following addition ofbase. As a control, we 
compared the alkylating capacity of our compounds with 
that of a clinical DNA-methylating cyclic triazene, 
temozolomide (TEM). The NBP assay indicated that the 
parent compound 6 had a slower rate of alkylation when 
compared with the putative metabolite 5, 8, and TEM 
(Table 1). As expected, the naked inhibitor 3 demon-
strated no alkylating activity, and the stable acylated 
compound 2 was found to have the slowest rate of 
alkylation in the entire triazene series. 
The translation of the alkylating activity of 5 and 6 
into DNA damage in human tumor cells was tested 
using the single cell microelectrophoresis (cornet) assay 
in mouse fibroblast isogenic cell !ines NIH 3T3 and 
NIH3T3/neu. In contrast to the naked inhibitor 3, the 
acetoxymethyltriazene 6 was found to induce a dose-
dependent increase in DNA strand breaks in both NIH 
3T3 and its transfected counterpart, NIH 3T3/neu 
(Figure 3) confirming the binary targeting properties 
of the CRM. 
This study conclusively demonstrates the feasibility 
of a molecule that may degrade in a stepwise mecha-
nism into intermediary structures that when tested 
independently showed EGFR TK inhibitory activities. 
Although it was not possible to monitor the kinetics of 
formation of ail the degradation products (e.g. the 
methylol intermediate 5 or the monoalkyltriazene 8), 
their ultimate conversion to the stable metabolite 3 
suggests that they may have been formed according to 
the mechanism out!ined in Scheme 3. Further, in 
addition to the ability of the CRMs to release inhibitors 
of EGFR. their alkylating activity and their DNA-
damaging potential suggest the formation of the puta-
tive methyldiazonium species. Thus, the combi-targeting 
and CRM principles mimic the effects of complex mul-
tidrug combinations involving modern inhibitors of 
EGFR TK and a classical DNA-damaging agent. More 
importantly, the results presented herein suggest that 
these effects may be selectively targeted to cells ex-
pressing the HER2 or EGFR oncogenes. 
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Figure 3. Quantitation of DNA damage using the alkaline 
cornet assay. DNA damage induced by RB24 and RBIO in (a) 
NIH 3T3 and (b) NIH 3T3/neu cell !ines. Tai! moment was 
used as a parameter for the detection of DNA damage in NIH 
3T3 and NIH 3T3/neu cells exposed to RB24 or RBIO for 30 
min. 
Experimental Section 
Chemistry. lH NMR spectra and l3C NMR spectra were 
recorded on a Varian 400 or 300 spectrometer. Mass spectros-
copy was performed by the McGill University Mass Spectros-
copy Center. ESI and APCI spectra were performed on a 
Finnigan LC QDUO spectrometer. Data are reported as mJz 
(intensity relative to base peak = 100). Melting points were 
determined in open capillary tubes on a Meltemp melting point 
apparatus and were uncorrected. 
6-(3-Acetyl-3-methyltriazenyI)-4-(m-toluidyI)quinazo-
Une (2). To a solution of 6-(3-methyltriazenyl)-4 anilino-
quinazoline 1 (100 mg, 0.400 mmoI) in methylene chloride (5 
mL) was added triethylamine (0.1 mL). The mixture was 
stirred for 15 min at 0 oC and acetyl chloride (0.05 mL, 0.920 
mmol) was added dropwise. Thereafter, the solution was 
evaporated under vacuum and the resulting brown residue 
purified on a silica gel column (40% ethyl acetate in hexane) 
to give 2 as a brown powder (18 mg, 16%): mp 188 oC; FABS 
m/z 335.2 (MH+) , 235 (M - 3-acetyl-3-methyltriazene) mJz 
335.162034 (MH+), ClsHlsN60l requires 335.16190; lH NMR 
(300 MHz, DMSO-d6) à 8.84 (s, IH, NH), 8.58 (s, IH), 8.14 (d, 
IH, J= 2.1 Hz), 8.12 (d, IH, J= 2.1 Hz), 7.83 (d, IH, J= 8.7 
Hz), 7.68 (s, lH), 7.66 (s, IH), 7.26 (t, lH, J= 7.8 Hz), 6.95 (d, 
IH, J= 8.1 Hz), 3.39 (s, 3H, CH3), 2.57 (s, 3H, CH3) , 2.34 (s, 
3H, CH3); l3C NMR (75 MHz, DMSO-d6) à 173.3, 158.6, 155.7, 
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150.7, 146.6, 139.5, 138.2, 130.0, 128.9, 125.3, 124.5, 123.6, 
120.6, 120.4, 116.0, 28.4, 22.8, 22.0. 
6-(3-Hydroxymethyl-3-methyltriazenyl)-4-(3'-bromophe-
nylamino)quinazoline (5). To a solution of 4-(3'-bromophe-
nylamino)-6-aminoquinazoline 3 (100 mg, 0.318 mmol) in 
acetonitrile (20 mL) kept at 0 oC on an ice bath was added 
nitrosonium tetrafluoroborate (74.3 mg, 0.637 mmol) dropwise. 
The solution was stirred for 20 min and 0.9 mL of a mixture 
of 40% methylamine (0.075 mL, 0.954 mmol), 37% formai de-
hyde (0.75 mL, 9.54 mmol), concentrated HCl (0.1 mL) was 
added ail at once. The diazonium solution was subsequently 
alkalinized with potassium carbonate (400 mg, 2.86 mmol) and 
the precipitate was filtered to give a white solid contaminated 
with excess potassium carbonate. The precipitate was therefore 
resuspended in THF and the resulting solution filtered. The 
organic solvent was further evaporated to give 4 asa pure 
brown solid (90 mg, 73%): mp 150 oC; FABS m/z 387 (MH+ 
with 79Br) , 389 (MH+ with 81Br), 359 (M - N2) m/z387.056 895 
(MH+) , ClsHISNsOIBr requires 387.056 70; IH NMR (400 MHz, 
DMSO-ds) (} 9.91 (s, IH, NH), 8.57 (s, IH). 8.50 (s, IH). 8.25 
(s, IH), 7.99 (d, IH, J= 8.8 Hz), 7.92 (d, IH, J= 7.6 Hz), 7.76 
(d, IH, J= 8.8 Hz), 7.34-7.25 (m, 2H), 6.37 (s, IH, OH), 5.17 
(s, 2H, CH2), 3.19 (s, 3H, CH3); l3C NMR (75 MHz, DMSO-ds) 
(} 164.3, 158.0, 154.0, 148.9, 149.8, 130.9, 129.5, 126.3, 125.2, 
124.7,121.8,121.2,116.4,116.1,78.8.34.0. 
6-(3-Acetoxymethyl-3-methyltriazenyl)-4-(3'-bromophe-
nylamino )quinazoline (6). 6- (3-H ydroxymethyl-3-methy 1-
triazenyl)-4-(3'-bromophenylamino)quinazoline 5 (100 mg, 0.258 
mmol) was dissolved in pyridine (2.mL), after which acetic 
anhydride (0.055 mL. 0.516 mmol) was slowly added. The 
solution was further kept on ice for 1.5 h and the pyridine 
evaporated as an azeotrope with toluene to give 6 as a pure 
brown residue (105 mg, 95%): mp 140 oC; FABS m/z429 (MH+ 
with 79Br) , 431 (MH+ with 81Br), 298 [M - (3-acetoxymethyl-
3-methyltriazene)], 401 (M - N2) m/z 429.067460 (MH+) , 
CI8H17Ns02Br requires 429.067 28; IH NMR (400 MHz, DMSO-
ds) (} 10.02 (s, IH, NH), 8.61 (s, 2H). 8.25 (s, IH). 7.99 (d, IH, 
J= 8.4 Hz), 7.93 (d, IH, J= 7.6 Hz). 7.79 (d, IH, J= 9.2 Hz), 
7.35-7.26 (m, 2H). 5.86 (s, 2H, CH2), 3.26 (s, 3H, CH3), 2.07 
(s, 3H, CH3); 13C NMR (100 MHz, DMSO-ds) (} 170.8, 158.1, 
154.4 149.5, 147.7, 141.8, 130.9, 129.7, 126.5, 125.1, 124.8, 
121.8, 121.3, 117.3, 116.2,79.4,35.5,21.6. 
Drug Treatment. Compounds l, 2, 3, 5, 6, and 8 were 
synthesized in our laboratories according to known procedures. 
Temozolomide (TEM) was provided by Shering-Plough Inc. 
(Kenilworth, NJ). In ail assays, drugs Wère dissolved in DMSO 
and subsequently diluted in RPMI-1640 containing 10% fetal 
bovine serum (FBS) (Wisent Inc., St-Bruno, Canada) or in 
DMEM containing 10% bovine calf serum (GIBCO BRL, 
Burlington, Canada) immediately before the treatment of cell 
cultures. In ail assays, the concentration of DMSO never 
exceeded 0.2% (v/v). 
Purity of Compounds. Purity analyses were performed 
by high performance liquid chromatography (HPLC) using a 
Spectrasystem (Thermoquest) and a Waters C4 15-,um 300 x 
3.9-mm column (reverse phase). The operating mode was 
isocratic and two different systems of sol vents were used: the 
first one was 100% acetonitrile with a 0.35 mL/min flow rate 
at 254 nm and the second system was 80% 2-propanol and 
20% dioxane with a 0.5 mL/min flow rate at 254 nm. 
Cell Culture. The celilines used in this study, the mouse 
fibroblasts NIH3T3, NIH3T3/HERI4 (NIH3T3 cells stably 
transfected with the EGFR gene) , and NIH3T3/neu (NIH3T3 
cells stably transfected with HER2) were generous gifts from 
Dr. Moulay Aloui-Jamali of the Montreal Jewish General 
Hospital. NIH3T3, NIH3T3/HERI4, and NIH3T3/neu cells 
were maintained in DMEM supplemented with 10% FBS and 
antibiotics. Ali cells were maintained in an atmosphere of 5% 
CO2• 
Degradation. The half-lives of 6, 5, and 8 under physi-
ological conditions were studied by a UV spectrophotometer. 
The compounds were dissolved in a minimum volume ofDMSO 
and diluted with RPMI-1640 supplemented with 10% FBS, and 
absorbances were read at 240 nm in a UV cell maintained at 
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37 oC with a circulating water bath. The half-life was esti-
mated by a one-phase exponential decay curve-fit method 
using the GraphPad software package (GraphPad software, 
Inc., San Diego. CA). 
The study of the conversion of the compounds (6, 5, and 8) 
to their corresponding free inhibitor (3) was performed by 
spectroCuorometry, as the latter amine is fluorescent (absorp-
tion 290 nm, emission 450 nm). Briefly, 125,uM of the drug 
conjugates was added to RPMI-1640 with 10% FBS and 
incubated for 4 h at 37 oC in a microplate spectrofluorometer 
(SpectraMax Gemini flourescence reader, Molecular Deviee, 
CA). The data were acquired and analyzed by SoftMaxPro 
(Molecular Device, CA). 
HPLC analysis was performed to study the degradation of 
compounds 2, 5, and 6. The compounds were dissolved in a 
minimum volume of DMSO, diluted with RPMI-1640 supple-
mented with 10% FBS, using a Spectrasystem (Thermoquest) 
and a Waters C4 15-,um 300 x 3.9-mm column (reverse phase). 
The operating mode was isocratic using a 60% acetonitrile and 
40% water solvent system with a 0.5 mL/min flow rate at 254 
nm. 
EGFR Kinase Assay. Nunc Maxisorp 96-well plates were 
incubated overnight at 37 oC with 100 ,uL/weIl of 25 ng/mL 
PGT in PBS. Excess PGT was removed and the plate was 
washed three times with wash buffer (Tween 20 (0.1 %) in 
PBS). The kinase reaction was performed by using 4.5 ng!well 
EGFR affinity-purified from A431 cells. The compounds were 
added and phosphorylation was initiated by the addition of 
ATP (20 ,uM). After 8 min at room temperature with constant 
shaking, the reaction was terminated by aspiration mixture 
and by rinsing the plate four times with wash buffer. Phos-
phorylated PGT was detected following a 25 min incubation 
with 50 ,uL/weli ofHRP-conjugated PY20 anti-phosphotyrosine 
antibody (Santa Cruz Biotechnology, CA) diluted to 0.2 mg! 
mL in blocking buffer (3% bovine serum aIbumin, 0.05% Tween 
20 in PBS). Antibody was removed by aspiration and the plate 
washed four times with wash buffer. The signaIs were devel-
oped by the addition of 50 ,uL/weli of 3,3',5,5'-tetramethylben-
zidine peroxidase substrate (Kirkegaard and Perry Laborato-
ries, Gaithersberg, MD) and following blue color development. 
50 ,uL of H2S04 (0.09 M) was added per weil, and plates were 
read at 450 nm using a Bio-Rad ELISA reader (model 2550). 
In Vitro Growth Inhibition Assay. To study the effect 
of our compounds on serum-stimulated proliferation, cells were 
grown to 70% of confluence in 96-well plates and washed twiee 
with PBS, after whieh they were exposed to serum-free media 
for 24 h. Cells were exposed to each drug + serum for 72 h, 
and cell growth was measured using the sulforhodamine B 
(SRB) assay. Briefly, following drug treatment, cells were fixed 
using 50 ,uL of cold trichloroacetic acid (50%) for 60 min at 4 
oC, washed five times with tap water, and stained for 30 min 
at room temperature with SRB (0.4%) dissolved in acetic acid 
(0.5%). The plates were rinsed five times with 1 % acetie acid 
and allowed to air-dry. The resulting colored residue was 
dissolved in 200 ,uL of Tris base (10 mM), and the optieal 
density was read for each weil at 492 nm using a Bio-Rad 
microplate reader (model 2550). Each point represents the 
average of at least two independent experiments run in 
triplicate. 
Alkylating Activity Assay. For each time point. IO,uL of 
compound 50 mM was added to 2% p-nitrobenzylpyridine 
(NBP)-ethylene glycol (100,uL) mixed with Tris pH 7.5 (27% 
ethanol) (70 ,uL) and incubated at 37 oC. The color was 
developed with a solution of acetone-triethylamine (50/50, 
v/v). Optieal density was read for each weil at 540 nm using a 
Bio-Rad microplate reader (model 2550). 
Cornet Assay for Quantitative Analysis of DNA Dam-
age. A modified alkaline cornet assay technique was used to 
quanti ta te DNA damage induced by 6 and 5 in NIH3T3 and 
NIH3T3/neu cells. The cells were exposed to drugs for 24 h 
and harvested with trypsin-EDTA. They were subsequently 
collected by centrifugation and resuspended in PBS. The 
resulting cell suspensions were diluted to 3 x 105 cell/ mL, 
and mixed with 0.75% agarose in PBS at 37 oC in a 1:9 
Prodrug Ta Release Multiple Inhibitors of ECFR 
dilution. The gels were cast on Gelband strips (Mandel 
Scientific, Guelph, Canada) using gel casting chambers, as 
previously described, and then immediately placed into a lysis 
buffer (2.5 M NaCI, 0.1 M tetrasodium EDTA, 10 mM Tris-
base, 1 % w/v N-lauryl sarcosine, 10% v/v DMSO, and 1% v/v 
Triton X-100). After being kept on ice for 30 min, the gels were 
gently rinsedwith distilled water and immersed in a second 
lysis buffer (2.5 M NaCl, 0.1 M tetrasodium EDTA, 10 mM 
Tris base) containing 1 mg/ml proteinase K for 60 min at 37 
oC. Thereafter, they were rinsed with distilled water, incubated 
in alkaline electrophoresis .buffer for 30 min at 37 oC, and 
electrophoresed at 300 mA for 60 min. The gels were subse-
quently rinsed with distilled water and placed into 1 M 
ammonium acetate for 30 min. They were further soaked in 
100% ethanol for 2 h, dried overnight, and subsequently 
stained with SYBR Gold (1:10000 dilution of stock supplied 
by Molecular Probes, Eugene, Ore.) for 20 min. For evaluation 
of cornets, DNA damage was assessed using the tail moment 
parameter (Le., the product of the distance between the 
barycenters of the head and the tail of the cornet multiplied 
by the percentage DNA in the tail region). A minimum of 50 
cells/comet were analyzed for each sample, using AlKOMET 
v3.1 software, and the values presented are average tail 
moments for the entire cell population. 
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Sustained antiproliferative mechanisms by RB24, a targeted 
precursor of multiple inhibitors of epidermal growth factor 
receptor and a DNA alkylating agent in the A43 1 epidermal 
carcinoma of the vulva cell line 
R 8anerjee', Z Rachid', Q Qiu', JP McNamee2, AM Tari3 and 8J Jean-Claude*" 
1 Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University Health Center/Royal Victoria Hospital, 687 
Pine Avenue West, Rm. M 7.15, Montreal, Quebec, Canada H3A 1 AI; 2Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, 
Ontario, Canada KIA 1 CI; 3The University of Texas MD Anderson Cancer Center. Houston, TX 77030, USA 
Recently, with the purpose of enhancing the potency of epidermal growth factor receptor (EGFR)-based therapies, we designed a 
novel strategy termed 'Cascade-release targeting' that seeks to develop molecules capable of degrading to multiple tyrosine kinase 
(TK) inhibitors and highly reactive electrophiles, in a stepwise fashion. Here we report on the tirst prototype of this mode!, RB24, a 
masked methyltriazene, that in addition to being an inhibitor on its own was designed to degrade to RB 14, ZR08, RB 1 0 + a DNA 
alkylating methyldiazonium species. The cascade degradation of RB24 requires the generation of two reactive electrophiles: (a) an 
iminium ion and (b) a methyldiazonium ion. Thus, we surmise that these species could alkylate the active site of EGFR, thereby 
inreversibly blocking its action and that DNA damage could be induced b> the methyldiazonium. Using the EGFR-overexpressing 
human epidermoid carcinoma of the vulva cell line, A431, we demonstrate herein that (a) RB24 and its derived species (e.g. RB 14, 
ZR08) inreversibly inhibit EGFR autophosphorylation, (b) RB24 induced signiticant levels of DNA strand breaks, (c) sustained 
inhibition of EGFR by RB24 was associated with blockade of MAPK activation and c-fos gene expression, (d) RB24 induced 
irreversible cell growth inhibition with a 1 OO-fold greater potency than TemodaIT", a clinical methyltriazene. The pronounced growth 
inhibitory potency of RB24 was attributed to its ability to simultaneously damage DNA and inreversibly block EGFR TK activity. 
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Overexpression of the epidermal growth factor receptor (EGFR) 
family and its cognate ligand has been correlated with aggressive-
ness and poor prognosis in various tumours such as breast, 
ovarian and prostate cancer (Modjtahedi and Dean, 1994; Xie et al, 
1995; Turner et al, 1996; Meden and Kuhn, 1997; Chen et al, 2000). 
The implication of these receptors in cancer progression has 
garnered significant attention and agents capable of b!ocking 
disordered growth signalling mediated by these proteins are now 
in a significant number of clinical trials against many cancers. One 
such agent, Iressa, a trademark of the AstraZeneca group of 
companies, exhibits a broad spectrum of antitumour activity 
against many human solid tumour xenografts of various origins 
including breast, lung, colorectal and head and neck (Ciardiello 
et al, 2001a; Moulder et al,2001; Heimberger et al, 2002; Magné 
et al, 2002; Ranson et al, 2002). However, despite the significant 
activity of this compound in preclinical models, in Phase II clinical 
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trial, it only induced a response rate of approximately 10% in a 
cohort of patients with non-small-cell lung cancer (NSCLC) 
(Magné et al, 2002; Dancey and Freidlin, 2003). Severa! possible 
explanations have been put forth to explain the failure to 
demonstrate a benefit: inadequate dosing, reduced drug delivery 
to tumour, lack of sustained potency and failure to select patients 
on the basis of having tumours in which EGFR presents a growth 
advantage (Dancey and Freidlin, 2003). 
The Jack of sustainability of the antitumour action of reversible 
inhibitors has stimu!ated the design of new irreversible inhibitors 
of EGFR tyrosine kinase (TK). One such compound, PD183805, 
bearing a 6-acrylamido group designed to alkylate cysteine 773 in 
the active site of the ATP-binding pocket irreversibly blocks EGFR 
TK and is now in Phase 1 development in patients with head and 
neck, breast and non-small cell lung carcinoma (Ciardiello and 
Tortora, 2001b). Other approaches to enhance the potency of 
EGFR inhibitor-based therapy include combinations of inhibitors 
with several cytotoxic agents including taxol, cytoxan and 
adriamycin (Ciardiello et al, 1999, 2001a; Magné et al, 2002; 
Danceyand Freidlin, 2003). Within the same line of idea, with the 
purpose of developing more potent and targeted therapies, we 
developed a novel strategy termed 'Combi-targeting' that seeks to 
synthesise single molecules that are capable ofboth blocking EGFR 
TK and inducing cytotoxicity by damaging DNA (Brahimi et al, 
2002; Matheson et al, 2001, 2003a, 2004a; Qiu et al, 2003, 2004; 
Rachid et al, 2003). Two such compounds, SMA41 (Matheson et al, 
2003a, 2004b) and BJ2000 (Brahimi et al, 2002), the first models 
designed to demonstrate the feasibility of this principle, showed 
significant DNA-damaging ability and irreversible block of EGFR 
autophosphorylation in A431 cells. More importantly, these agents 
induced a more sustained antiproliferative activity when compared 
with a reversible inhibitor of EGFR (Matheson et al, 2001, 2004b; 
Brahimi et al, 2002). In addition, these molecules, also termed 
'Combi-molecules,' selectively induced antiproliferative activity 
against EGFR transfectants in isogenic models (Brahimi et al, 2002; 
Matheson et al, 2003a). 
In order to further augment the potency of the Combi-targeting 
approach, we recently designed RB24 (an acetoxymethyltriazene) 
to generate three inhibitors of EGFR and at the final stage of 
degradation a methyldiazonium species capable of damaging DNA 
(Banerjee et al, 2003). This masked cluster of molecules was 
expected to produce more sustained antitumour effects with the 
prospect of inducing activities similar or superior to that of 
classical combinations involving a reversible EGFR inhibitor + a 
cytotoxic drug. Here we study the mechanism of action of RB24, 
the first prototype of this strategy termed 'cascade release', and 
demonstrate the sustainability of its antitumour activity in A431 
cells, which overexpress EGFR and its cognate ligand, TGF-()( 
(Lanzi et al, 1997). The ability of this cell line to aggressively 
proliferate by a TGF-()(-mediated autocrine induction has made it 
an ideal model for studying the mechanism of action of EGFR TK 
inhibitors. In addition, these cells express 06-alkylguanine 
transferase (06-AGT), a DNA repair enzyme that by repairing 
the 06-alkylguanine DNA adduct confers significant resistance to 
AGT + cells (Lee et al, 1991; Mitchel and Dolan, 1993; Pegg et al, 
1995; Cai et al, 2000; Yingna et al, 2000; Matheson et al, 2003b). 
MATERIALS AND METHODS 
Drug treatment 
RB24, RBI4, ZR08 and RBI0 were reported elsewhere (Banerjee 
et al, 2003). TemodaPM was provided by Shering-Plough Inc. 
(Kenilworth, NJ, USA). In ail assays, the urug was dissolved in 
DMSO and subsequently diluted in RPMI-1640 containing 10% 
fetal bovine serum (FBS) (Wisent Inc., St-Bruno, Canada) 
immediately before the treatment of cell cultures. In ail assays, 
the concentration of DMSO never exceeded 0.2% (v/v). 
CelI culture 
The cellline used in this study, the human epidermoid carcinoma 
of the vulva, A431, was obtained from the American Type Culture 
Collection (Manassas, VA, USA). The A431 cell line was 
maintained in RPMI-I640 supplemented with 10% FBS and 
antibiotics as described previously (Matheson et al, 2001). Ali 
cells were maintained in an atmosphere of 5% CO2• 
In vitro cytokinetic growth inhibition assay 
To study the irreversible effects of our compounds on cell 
proliferation, 200cellswell- 1 were plated in 96-well plates with 
serum-containing media. Cells were exposed to each drug + serum 
for either 2, 8, 12,24 or 48h. After each time point, the drug was 
removed and cells were washed 2 x with PBS and allowed to 
recover with fresh serum-containing media for a total of 96 h. Cell 
growth was measured using the sulphorhodamine B (SRB) assay. 
Briefly, following drug treatment and recovery, cells were fixed 
using 50,u1 of cold trichloroacetic acid (50%) for 60 min at 4°C, 
© 2004 Cancer Research UK 
Mechanism of irreversible antiproliferative activity of RB24 • 
R Bane~ee et 0/ 
washed five times with tap water and stained for 30 min at room 
temperature with SRB (004%) dissolved in acetic acid (0.5%). The 
plates were rinsed five times with 1 % acetic acid and allowed to air 
dry. The resulting coloured residue was dissolved in 200,u1 of Tris 
base (10 mM), and optical density was read for each weil at 492 nm 
using a Bio-Rad microplate reader (model 2550). Each point 
represents the average of at least two independent experiments run 
in triplicate. 
Autophosphorylation assay 
A431 cells (l x 106) were preincubated in a six-weil plate with 10% 
serum at 37°C for 48 h and starved overnight for 24 h, after which 
they were exposed to a dose ranye of each drug for 2 h and 
subsequently treated with 50 ng ml- EGF for 15 min at 37°C. Cells 
were washed with PBS and resuspended in cold lysis buffer (50 mM 
Tris-HCl pH 7.5, 150mM NaCI, 1% Nonidet P-40, 1 mM EDTA, 
5 mM NaF, 1 mM Na3 V04, protease inhibitor tablet (Roche 
Biochemicals, Laval, Canada». The lysates were kept on ice for 
30 min and collected by centrifugation at 10000 rpm for 20 min at 
4 oC. The concentrations of protein were determined using the Bio-
Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). 
Equal amounts of protein were added to a 10% SDS-polyacryla-
mide gel electrophoresis (SDS - PAGE) and transferred to a 
polyvinylidene difluoride membrane (Millipore, Bedford, MA, 
USA). Nonspecific binding on the membrane was minimised with 
a blocking buffer containing nonfat dry milk (5%) in PBST. 
Thereafter, the membranes were incubated with primary anti-
bodies (either antiphosphotyrosine antibody (Upstate Biotechnol-
ogy, Lake Placid, NY, USA) for the detection of phosphotyrosine, 
or anti-EGFR (Neomarkers, Fremont, CA, USA» for determination 
of corresponding receptor levels. Blots were incubated with HRP-
goat anti-mouse antibody (Bio-Rad Laboratories) and the bands 
visualised with an enhanced chemiluminescence system (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK). Band intensities 
were measured using the SynGene GeneTools software package. 
To study the effects of RB24 on the activation of extraceullular 
signal-regulated kinases 1,2 (Erkl,2), protein Iysates were obtained 
as described above and Western blot was performed as previously 
reported (Tari and Lopez-Berestein, 2000). The membrane was 
incubated with antiphosphorylated Erkl,2 antibodies or antibodies 
specific for Erkl,2 (Cell Signaling, Beverly, MA, USA). 
Reverse EGFR autophosphorylation 
This assay was performed as previously described (Fry et al, 1998). 
A431 cells were grown to confluence in six-weil plates and then 
incubated in serum-free medium for 24 h. Duplicate sets of cells 
were then treated with 30,uM of each compound for 90 min. One set 
of cells was th en stimulated with EGF (SOngml- 1) for ISmin and 
extracts were made as described under the Western blotting 
procedure ab ove. The other set of cells was washed free of the 
compound with warm serum-free media and incubated for 2 h. 
Thereafter, the cells were washed, incubated for another 2 h, 
washed again and then incubated for a further 4 h. This set of cells 
was then stimulated with EGF and extracts were prepared as for the 
first set. 
RT - pCR for c-fos. expression 
A431 cells were grown to confluence in six-weil plates and then 
incubated in serum-free medium for 24h. Cells were exposed to 
the indicated concentrations of the drug prior to stimulation with 
EGF (50ngml- 1 ) for 30min. Total RNA was isolated using the 
High Pure RNA Isolation Kit of Roche Molecular Bochemicals 
(Germany), following the manufacturer's instructions. Quantita-
tive analysis of c-fos mRNA and G3PDH mRNA (2,ug of RNA for 
each sample) was preformed by Titan One Tube RT-PCR Kit 
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(Roche Molecular Bochemicals), following the manufacturer's 
instructions and using the following primers: S'ATGATGTTCTC 
GGGCTTC3' (sense), 5'CTCCTGCCAATGCT CTGC3' (antisense) 
for c-fos and S'CCATGGAGAAGGCTGGGG3' (sense), S'CAAA 
GTTGTCATGGATGACC3' (antisense) for G3PDH. 
Alkaline cornet assay for quantitation of DNA damage 
The alkaline cornet assay was performed as previously described 
(Matheson et al, 2001). The cells were exposed to drugs (RB24, 
RB14 or RB10) for 30 min, harvested with trypsin-EDTA, 
subsequently collected by centrifugation and resuspended in 
PBS. Cell suspensions were diluted to approximately 106 cells 
and mixed with agarose (1%) in PBS at 37°C in al: 10 dilution. 
The gels were cast on Gelbond strips (Mandel Scientific, Guelph, 
Canada) using gel-casting chambers, as previously described 
(McNamee et al" 2000), and then immediately placed into a lysis 
buffer (2.5 M NaCI, 0.1 M tetrasodium EDTA, 10 mM Tris-base, 1% 
(w/v) N-Iauryl sarcosine, 10% (v/v) DMSO and 1% (v/v) Triton X-
100, pH 10.0). After being kept on ice for 30 min, the gels were 
gently rinsed with distilled water and immersed in a second Iysis 
buffer (2.5M NaCI, 0.1 M tetrasodium EDTA, 10mM Tris-base) 
containing 1 mgml- l proteinase K for 60 min at 37°C. Thereafter, 
they were rinsed with distilled water, incubated in alkaline 
electrophoresis buffer for 30 min at 37°C and electrophoresed at 
300 mA for 20 min. The gels were subsequently rinsed with distilled 
water and placed in 1 M ammonium acetate for 30 min. Thereafter, 
they were soaked in 100% ethanol for 2 h, dried overnight and 
stained with SYBR Gold (1 : 10000 dilution of stock supplied from 
Molecular Probes, Eugene, OR, USA) for 20 min. Cornets were 
visualised at x 330 magnification and DNA damage was quanti-
tated using the Tail Moment parameter (i.e. the distance between 
the barycentre of the head and the tail of the cornet multiplied by 
the percentage ofDNA within the tail of the cornet). A minimum of 
50 cell cornets were analysed for each sample, using ALKOMET 
version 3.1 image analysis software. 
RESULTS 
Inhibition of EGFR autophosphorylation 
Western blot analysis demonstrated that RB24 blocked EGF-
induced EGFR autophosphorylation in A431 cells in a dose-
dependent manner with an ICso ::::: 2 /lM without affecting the levels 
of EGFR (Figure 1). RB24 is a degradable molecule capable of 
generating an extremely reactive iminium ion intermediate that 
may alkylate the receptor and irreversibly inhibit EGFR activity. To 
test this hypothesis, we used the reversibility assay previously 
described (Fry et al, 1998; Smaill et al, 2000) according to which 
the cells were treated with the drug for 90 min and the culture 
medium repeatedly removed and replaced three times after 
treatment, after which EGFR autophosphorylation was measured. 
+ EGF 
As expected, RB24 at 30/lM completely suppressed EGF-dependent 
EGFR autophosphorylation in A431 cells immediately after drug 
exposure (Figure 2A). However, at 8 h post-treatment following 
repeated washouts in drug-free medium, EGFR autophosphoryla-
tion activity was completely inhibited in cells treated with RB24, 
indicating that the latter is capable of inducing irreversible 
inhibition of EGFR autophosphorylation. Similarly, irreversible 
inhibition was observed in cells exposed to the daughter molecules, 
RB14 and ZR08, however with a 20% recovery of the total activity 
(Figure 2B). In contrast, the naked inhibitor, RB10, was shown to 
have completely reversible inhibition of EGFR autophosphoryla-
tion (Figure 2A). 
Inhibition of EGFR-mediated signalling 
Antiproliferative activity induced by RB24 requires the translation 
of inhibition of EGFR autophosphorylation into inhibition of 
downstream signalling. To determine wh ether blockade of EGFR 
autophosphorylation translates into inhibition of downstream 
signalling, we analysed the effect of the parent compound, RB24, 
on EGF-induced phosphorylation ofErk1,2 and c-fos expression in 
A431 cells. The results showed that RB24 induced complete 
inhibition of Erk1,2 phosphorylation at concentrations as low as 
S/lM without affecting the levels of Erk1,2 (Figure 3). Similarly, 
RT - PCR analysis showed that RB24 induced nearly 100% 
inhibition of EGF-mediated c-fos gene expression' at low concen-
trations (1 /lM) (Figure 4), indicating that inhibition of EGFR 
phosphorylation by RB24 is accompanied by a significant blockade 
of EGFR-dependent downstream signalling. 
Quantitation of DNA damage 
Using the alkaline cornet assay, we demonstrated that like TEM 
(Matheson et al, 2001), RB24 and RBl4 induced a dose-dependent 
DNA damage in A431 cells after a 30 min drug exposure (Figure 5). 
Interestingly, RB24 and RB14 induced identical levels of DNA 
damage, which is in agreement with the fact that the former is a 
prodrug of the latter. As expected, the reversible inhibitor, RBlO, 
did not demonstrate any DNA-damaging activity. 
Irreversible growth inhibitory activity 
SRB assays demonstrated that RB24 and RB14 retained significant 
antiproliferative activity after a short 2 h exposure and a 4-day 
recovery (Figure 6A and B). In contras t, the free inhibitor, RB10, 
lost at least 95% of its activity under the same conditions 
(Figure 6D). The monoalkyltriazene, ZR08, showed partially 
reversible activity with an 85% retention of activity following 2 h 
drug exposure (Figure 6C). In contrast to the antiproliferative 
effects of RB24, increasing exposure time was associated with a 
significant increase in potency for ail other molecules of the 
degradation cascade (RB14, ZR08, RB10). Despite being a potent 
.. l1li1---- Phosphotyrosine 
EGFR 
Figure 1 Selective inhibition of EGFR autophosphorylation in intact cells by RB24. Serum-starved A43 1 cells were preincubated for 2 h with the indicated 
concentrations of RB24 prior to stimulation with EGF for 15 min. An equal amount of cell Iysates was analysed by Westem blotting using 
antiphosphotyroslne antibodies. Membranes were stripped of antiphosphotyroslne and reprobed with anti-EGFR antibodies as a loading control. Band 
intensities wene measured using the SynGene GeneT ools software package. 
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Figure 2 Reverse EGFR autophosphorylation in the presence of RB24, RB 14, ZR08 and RB lOin A43 1 cells. (A) Duplicate sets of cells were treated with 
30llM of deslgnated compound to be tested as a reversible EGFR inhibitor for 90 min. One set of cells was then stimulated with EGF for 15 min, and extracts 
were made as described underthe Western blotting procedure. The other set of cells was washed free ofthe compound with serum-free media, incubated 
for 2 h, and further washed twice and incubated for 4 h, This set of cells was then stimulated with EGF, and extracts were made similar to the first set (B) 
Comparison between the inhibition of autophosphorylatlon activity induced by RB24, RB 14, ZR08 and RB 1 O. The film was scanned and band intensities 
were quantified uSlng Synge ne GeneT ools software. Values are percentage of control of phosphotyrosine/EGFR 
+ EGF 
-EGF +EGF 0.1 i.M 11lM SIIM 10liM 100IlM 
...... f-___ Phosphorylated Erk1 ,2 
--... _ .. -. ...... .... --- Erk1,2 
Figure 3 Effect of RB24 on Erk 1,2 activation in A431 cells. Serum-starved cells were preincubated for 2 h with the rndlcated concentrations of RB24 prior 
to stimulation wlth EGF for 15 min. Protein Iysates were obtained and Western blot was perfonmed as descnbed by Tan and Lopez-Berestein (2000). 
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Figure 4 Effect of RB24 on c-fos gene expression in A431 cells. Serum-
starved cells were preincubated for 2 h with the indicated concentrations of 
RB24 prior to stimulation with EGF for 30 min. Quantitative analysis of c-fos 
and G3PDH was prefonmed by RT -PCR as descnbed in Materials and 
methods. 
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alkylating agent, the clinical triazene, Temodal™, demonstrated no 
significant activity at any of the exposure times in the A431 cells 
(Figure 6E), In summary, the strength of the retention of potency 
was in the following order: RB24 > RB 14> ZR08 ~ RB 1 0, 
DISCUSSION 
Mechanisms of EGFR TK inhibition 
The design of our combi-molecule, RB24, was based on the 
premise tlIat acetoxymethyltriazenes are known to be hydrolysed 
to a hydroxymethyltriazene intermediate that rapidly degrades 
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Figure 5 Quantitation of DNA damage using the alkaline comet assay. 
Tail moment was used as a parameter for the detection of DNA damage in 
A431 cells exposed to RB24, RB 14 and RB 1 0 for 30 min. Each pOint 
represents at least two independent experiments. 
into the corresponding monoalkyltriazene (Remens et al, 1984; 
Cameron et al, 1985; Remens and Vaughan, 1986). The latter 
further heterolyses to an aromatic amine + a DNA-damaging 
species. In a recent publication (Banerjee et al, 2003), we 
demonstrated that indeed RB24 was capable of generating the 
ultimate amino compound RB 1 0, in a symmetrically inversed 
relationship. As depicted in Scheme 1, decomposition through the 
intermediates, RB14 and ZR08, is the sole mechanism by which 
RB24 can be converted to RBI0. Thus, the significant EGFR 
inhibitory potency of the putative intermediates RBI4, ZR08 and 
EGFR 
Scheme 1 
Scheme 2 
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RBI0 indicates that RB24 would maintain its TK inhibitory 
potency throughout the multistep degradation cascade. More 
importanùy, RB24 and its two derivatives (RBI4, ZR08) induced 
irreversible inhibition of EGFR TK when tested alone, a protracted 
inhibition that may be rationalised in the light of recent data on 
the mechanism of irreversible acrylamide-based inhibitors. It is 
now known that 4-anilinoquinazolines bearing a 6-acrylamido 
group react with the cysteine 773 of EGFR, thereby irreversibly 
blocking the receptor (Fry et al, 1998; Smaill et al, 1999, 2000). 
Based on the mechanism of decomposition of RB24 (Banerjee et al, 
2003), we did not expect a direct reaction between the cysteine 
thiol group and the acetoxy moiety. Perhaps, if the iminium ion is 
formed in the active site of EGFR, it may react with the cysteine as 
depicted in Scheme 2. Addition of thiol group to the iminium ions 
of acetoxymethyltriazene has already been reported by lIey et al 
(1991) who developed this type of triazenes as lyase inhibitors. 
Moreover, the ultimate triazene metabolite of RB24, ZR08, may 
also direcùy alkylate the cysteine residue. Quinazolinotriazenes of 
the same class, BJ2000 and SMA41, have already been demon-
strated to induce irreversible inhibition (Brahimi et al, 2002; 
Matheson et al, 2003b, 2004b). 
Although it was not the focus of this study to identify the site of 
alkylation of the receptor, the irreversible nature of TK inhibition 
by RB24 indicates that it may have inflicted covalent damage at a 
site of EGFR that is critical for its TK activity. In corroboration, 
RBIO that does not possess a reactive triazene tai! induced 
reversible EGFR TK inhibitory activity. 
DNA damage 
The iminium ion is a stable cation that may not be reactive enough 
to account for the strong DNA-damaging potential of RB24. 
Despite the significant body of results that confirm its formation 
DNA 
RB10 Methyldiazonium 
EGFR 
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Figure 6 Irreversible grQ\,vth inhibition for RB24, RB 14, ZR08, RB 1 0 and TEM in A431 cells. Cells were exposed to (A) RB24, (B) RB 14, (C) ZR08, (D) 
RB 1 0 or (E) TEM for 2, 8, 12, 24 or 48 h following recovery for a total of 96 h. Cell growth was measured using SRB assay. Each point represents at least two 
independent experiments run in triplicate. 
during the process of hydrolysis of acetoxymethyltriazenes 
(Hemens et al, 1984; Hemens and Vaughan, 1986; Iley, 1987; 
Vaughan and Manning, 1988; Merrin and Hooper, 1992), its 
implication in the DNA-damaging properties of the latter elass of 
compounds is yet 10 be demonstrated. In contrast, it is now 
common knowledge that the methyldiazonium is capable of 
inducing significantly high levels of DNA alkylation partieularly 
at N7 and 06 positions of guanine, thereby inducing DNA damage 
and lethal mutations in tumour ceils (Bodeil et al, 1985; Tisdale, 
1987; Baer et al, 1993). The promutagenic 06-alkylguanine adduct 
is considered to be the primary cytotoxic lesion induced by 
triazenes. Ceils, like A431, that express high levels of AGT, a DNA 
repair enzyme that repairs the 06-alkylguanine adduct, are known 
© 2004 Cancer Research UK 
to be resistant to alkyltriazenes. In corroboration, the A431 ceUs 
used in the study were markedly insensitive to TemodaPM, a cyelie 
triazene known to release the methyldiazonium species upon 
hydrolysis (Cameron et al, 1985; Gibson et al, 1986; Baig and 
Stevens, 1987). 
Irreversible growth inhibition 
The ability of RB24 to degrade into several species with significant 
EGFR inhibitory activities and to damage DNA may perhaps be 
responsible for its sustained potency in A431 ceUs. More 
importantly, white its antiproliferative effect was maintained even 
4 days after a 2 h drug exposure, under the same conditions, ZR08 
British Joumal of Cancer (2004) 91 (6), 1066- 1073 
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induced a partially reversible growth inhibitory activity. We have 
already reported similar results in A431 cells for analogous 
quinazolinotriazenes (e.g. SMA41 and BJ2000)". Thus, the marked 
irreversibility of the action of RB24 may be partially imputed to 
additive antiproliferative contribution of species generated during 
the degradation steps that precede the formation of ZR08. This 
antiproliferative contribution may result from their ability to block 
EGFR-mediated growth signalling, since as previously mentioned 
the transient iminium ion species generated during these 
degradation steps may not damage DNA. The partially reversible 
growth inhibitory potency of ZR08 (third step of the cascade) may 
perhaps be due to the dependence of its antiproliferative activity 
on the ultimately released reversible inhibitor RBIO, the concen-
trations of which might have been drastically depleted by multiple 
washouts. This indicates that the ultimate antiproliferative effect of 
ZR08 is mediated by a combination of DNA damage inflicted by 
the methyldiazonium species and EGFR TK inhibitory activity 
induced by RBIO. 
A synergistic interaction between the strong EGFR TK inhibitory 
potency and the marked DNA-damaging potential of RB24 may 
also partly account for its remarkable potency against the A431 
cells. Indeed, blockade of EGFR in these cells was accompanied by 
potent inactivation of Erkl,2 kinase and inhibition of c-fos gene 
expression. We now know, based on previous experiments, that 
blockade of EGFR-mediated signalling may not affect the levels or 
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function of the AGT enzymes. However, Yacoub et al (2003) 
recently demonstrated that EGF upregulates the DNA repair genes 
XRCCI and ERCCI in prostate celllines through Erkl,2 signalling. 
Thus, blockade of EGFR-mediated signalling may downregulate 
the DNA repair enzymes that are involved in the repair of DNA 
strand breaks, thereby exacerbating the cytotoxic effect of the 
latter lesions. 
In conclusion, we have demonstrated that a molecule engineered 
to possess complex' EGFR inhibitory properties and capable of 
further releasing DNA-damaging species could induce significantly 
more sustained antiproliferative activity than a reversible inhibitor 
of the same class (e.g. RBlO). Moreover, its multiple properties 
have conferred antiproliferative activity in a cell line in which a 
classical methylating agent of the same class does not show any 
detectable activity. Thus this mode! may well represent a new 
strategy to ameliorate the chemotherapy of EGF-dependent 
refractory tumours. Further studies are ongoing to demonstrate 
the pot.::ncy of this novel drug in vivo. 
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